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 The implications for glycan and glycoprotein presentation from a biomaterial 
surface in mediating immune cell interactions and responses are incompletely 
understood. The goal of this dissertation was to obtain critically needed data in glycomics 
relevant to the next generation of biomaterials and combination products. To do this 
required a deeper understanding of how human immune cells interact with glycans and 
glycoproteins presented from material surfaces. Dendritic cells (DCs) are the most potent 
antigen presenting cells (APCs) and provide a bridge between the innate, non-specific, 
immune response toward external signals such as foreign pathogens and the adaptive 
immune response directed toward specific antigens. C-type lectin receptors (CLRs) are a 
class of pattern recognition receptors (PRRs) found on DCs and their recognition of 
glycans have been shown to have immunomodulatory (both tolerogenic and pro-
inflammatory) effects.1–3 CLRs have been shown to be key regulators of pathogen-
induced innate immunity, antigen processing for adaptive immune responses, immune 
system evasion by pathogens and tumors, and in recognition of self-proteins.3–7 Given 
that DCs use CLRs to recognize characteristic pathogen and tumor glycan structures, and 
that this recognition leads to functional immunomodulatory effects, we hypothesized that 
DCs use these CLRs to recognize and respond to biomaterials, through glycan structures 
in the adsorbed protein layer (or inherent in the biomaterial structure) to direct immune 
responses. Thus, with an understanding of this interaction, immunomodulatory 
combination products could be designed to direct the DC response toward a pro-
inflammatory vaccine delivery system or induction of tolerogenic phenotype for tissue 
engineered constructs.  
 The primary objectives of this dissertation were to (1) analyze and optimize 
molecular factors of importance in recognition of surface presented glycans for 
recognition and promotion of both pro- and anti-inflammatory DC phenotypes and (2) to 
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elucidate the effect of presentation modality (i.e. soluble, phagocytosable, and non-
phagocytosable delivery of glycans) on DC phenotype.  The overall hypothesis was that 
distinct molecular presentations of glycans/glycoproteins to DCs are able to controllably 
modulate their phenotype with functional immunological consequences. Specific Aim 1 
was to develop a carrier for glycans that was able to show a differential DC phenotype 
across similar glycan structures and that had optimal molecular characteristics i.e. charge 
and ligand valency, for maximal modulation of DC phenotype from a non-
phagocytosable display. Specific Aim 2 was to identify how glycan presentation 
modality alters DC phenotype and how these display strategies can be harnessed to drive 
DCs toward a desired phenotype.  Throughout both of these aims multivariate linear 
regression was used to quantify claims made and to provide predictive results that could 
possibly be applied to systems other than those developed herein.  .   
 To accomplish Aim 1 a suitable carrier for glycans that could modulate DC 
phenotype when displaying glycans from a non-phagocytosable surface had to be 
identified.  To do this, five different carriers were assessed for their efficacy.  Cationized 
bovine serum albumin (BSA) modified with polymannose structures and adsorbed to a 
tissue culture polystyrene (TCPS) well was found to modulate DC phenotype to the 
greatest extent.  Thus, further optimization of cationized BSA, was performed to help 
optimize the DC response to surface adsorbed glycans.  
  The charge and number of glycans covalently bound to BSA was varied and the 
subsequent DC phenotype to these adsorbed conjugates was determined.  It was found 
that highly cationized (pI above 9.75) BSA with an average of more than 20 
carbohydrates per protein modulated DC phenotype to the greatest extent in response to 
the presented glycan.  Furthermore, this presentation context was shown to be able to 
modulate DC phenotype across multiple glycan structures indicating its use as a platform 
for surface presentation of glycans to DCs.  The results from these studies were then 
modeled and it was found that the most important factors for a pro-inflammatory DC 
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response were having a high density (>20 glycans/BSA) and then to a lesser extent 
having a pI above 9.75.  No significant trends were found for the tolerogenic reporter 
from DCs when doing this modeling, however, an inverse trend in density and charge 
was shown for the tolerogenic reporter than for that of the pro-inflammatory response.  
 The interaction of the DCs with the carbohydrates was confirmed to be via 
receptors that utilize calcium or manganese, thus implicating CLRs in their use, by 
treating DCs with EDTA and looking at internalization of beads by DCs and subsequent 
DC phenotype in response to these adsorbed conjugates in the presence of EDTA. 
Finally, the modulation of DC phenotype was found to also be carbohydrate structure-
dependent, even when comparing similar structures, and thus the conjugates were further 
validated as a platform for use in presenting carbohydrates from a non-phagocytosable 
surface to DCs.  The results from the comparison between sugar structures were then 
analyzed in a model and it was found that distinct terminal structures of glycans were 
able to be predicative of DC phenotype. 
 The optimization studies from Aim I discovered that single mannose presented in 
a high density (>20 sugars per BSA) from highly cationized BSA (isoelectric point>9.75) 
was able to modulate DC phenotype to an equal extent as other more complex glycan 
structures.  Thus, for the determination of presentation modalities’ effect on DC 
phenotype only the monosaccharides mannose and glucose were used.  Glucose was 
chosen as a control for mannose because of its structural similarity to mannose and 
because, in its monosaccharide form, no known CLR on DCs binds to glucose.  The high 
density and cationic glycoconjugates were then adsorbed to the wells of 384 well plates, 
delivered in a range of soluble concentrations, or adsorbed to 1 µm and 50 µm of 
polystyrene beads and delivered to DCs to examine modality of display effects.  The 
subsequent DC phenotype was then assessed.  However, prior to assessment of DC 
phenotype an indicator of which receptors DCs were using to respond to these conjugates 
was desired.  Thus, enzyme linked lectin assays were performed with recombinant human 
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lectins, Dectin-1 and DC-SIGN, on the adsorbed conjugates.  It was found that DC-SIGN 
bound the mannose conjugates with high affinity and that the glucose conjugates were 
not bound by Dectin-1 to a greater extent than that of the negative control.   
 Mannose glycoconjugates adsorbed to a non-phagocytosable surface modulated 
DC phenotype to the greatest extent.  Interestingly, glycoconjugates delivered in a soluble 
form to DCs did not alter DC phenotype to a statistically significant level over untreated 
cells, even at high (100 µg/ml) concentrations, and conjugates adsorbed to 
phagocytosable polystyrene beads produced an effect that is in between those two 
extremes.  The results from these studies were then run in a multivariate general linear 
model and it was found that the presentation modalities were statistically different from 
each other, even when controlling for ligand and donor variances.  Also, using an 
interaction model between modalities and ligands it was found that adsorbed and soluble 
mannose conjugates were statistically different from each other, indicating a receptor 
specific response from the cells toward these conjugates.  Thus, antibody blocking and 
EDTA treatment of DCs was performed and phagocytosis of coated microbeads in the 
presence of these inhibitors was assessed via flow cytometry.  It was found that for the 
mannose conjugates anti-DC-SIGN and anti-Dectin-1 both statistically decreased 
phagocytosis of the beads by DCs.  Additionally, EDTA also statistically decreased the 
amount of internalization of beads by DCs.  This provided further evidence for CLR 
mediated response to the adsorbed conjugates.  Finally, an indication of what the fate of 
the adsorbed conjugates was upon interaction with the DCs was desired.  Thus, 
conjugates were fluorescently modified and adsorbed to wells, DCs were then incubated 
with the adsorbed fluorescent conjugates for 24 hours and the subsequent DC 
fluorescence was measured.  It was found that DCs were removing glycans from the 
surface of the wells and that this removal was increased for the mannose conjugates.  
Again, indicating a specific receptor mediated response to the adsorbed mannose 
conjugates.   
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 In summary, this report identifies molecular factors of importance for non-
phagocytosable display of glycans to DCs.  It uses modeling to statistically prove these 
associations and provides indications for future researchers in the design of glycan 
microarrays.  Furthermore, this study statistically shows that glycan presentation to DCs 
is dependent upon the modality of the display and that this differential response is at least 
in part due to CLRs and more specifically DC-SIGN and Dectin-1.   
 However, this research has led to additional new questions that require study.  
Why is the response to the cationized adsorbed conjugates by DCs so much higher than 
that of the non-cationized conjugates?  What signaling and specific receptors are 
mediating this response?  How do the cells treated with these adsorbed conjugates affect 
the systemic immune system, i.e. Th1, Th2, Treg proliferation, cytokine production, MHC 
presentation of co-delivered antigen, etc.?  Is an analogous response to other disparate 
glycan structures not tested herein similar to those found here?  Are models used here 
able to be used with other classes of glycan or CLRs?  What other molecular factors are 
of importance for phenotypic modulation of DCs by adsorbed conjugates that were not 
tested or varied herein, i.e. ligand length and lability?  What molecular signaling 
mechanism is involved in the differential response to different display modalities?  What 
is the mechanism of recognition and activation of DCs to adsorbed high density glucose 
presented from highly cationic BSA conjugates which should not be recognized by a 
specific CLR?  Finally, the results showed that adsorbed conjugates were being 
internalized by DCs.  Whether this internalization is necessary for DC activation and to 
what extent the internalization of conjugates plays in the phenotype modulation of DCs is 
an important and unanswered question.   All of these are future directions for the work 
proposed herein and could each provide valuable insight for the understanding of DC 
interaction with glycans and more importantly how to harness that interaction to exploit 




CHAPTER 1  INTRODUCTION 
 Dendritic cells are seen as the link between innate and adaptive immunity. They 
have an array of pattern recognition receptors that can see and respond to pathogen, 
danger, and self-associated molecular patterns.8  One class of these receptors, known as 
CLRs, can bind to and recognize glycan structures.  These receptors have only recently 
begun to be studied on DCs and thus many of their signaling mechanisms, ligand 
specificities, and downstream ligation effects are not known.  These receptors have not 
been as intensively studied as other receptor classes in large part due to the limited supply 
of glycan structures that are able to be obtained via natural or synthetic means.  
Glycosylation of proteins is not template driven like DNA and protein synthesis and thus 
obtaining large amounts of homogenous glycan structures from cells or bacteria is not 
challenging.  Additionally, using carbohydrate chemistries currently available to create 
large arrays of diverse structures is not economically feasible.  Thus, glycan microarrays 
have been created to determine ligands for recombinantly expressed CLRs.  Many 
different approaches for these arrays have been created but all are generally non-
phagocytosable display of glycans.  Few studies have been conducted with whole cells 
and these arrays because only adhesion and cell death can be easily assessed from these 
arrays.  Furthermore, DC response to any of the arrays has not yielded positive results in 
the past due to the “loosely” adherent nature of DCs and because of the complex surface 
marker and soluble factor release that constitutes different DC phenotypes.  Thus, two 
fronts for improving the current state of the field for DCs were studied herein.  The first 
was to design an optimized carrier for non-phagocytosable surface display of glycans to 
DCs for use as an indicator of properties necessary for DC response to glycan 
microarrays.  The second was to determine if the cell response to these adsorbed 
conjugates was relatable across display modalities.  This is of interest because if cell 
response to the adsorbed conjugates was identical to that of the cell response when 
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delivered in a microbead or in a soluble form then cell response to microarrays should 
become an area of intensive research for all glycobiology.  If, however, cell response was 
not relatable between these display modalities then more diverse efforts would be needed 
on the part of glycobiologists to assess cell response to a variety of carbohydrates in a 
variety of display modalities.   
1.1 Research Significance 
 Fibrous encapsulation is pervasive and has been shown to have deleterious effects 
in orthopedic prostheses, biosensors, electrodes, and cardiovascular implants.9–13 For 
example, in the United States alone, dental implants fail in ~50,000 people/year and 
~15% of all total knee arthroplasties fail due to fibrous encapsulation.14,15  To limit this 
effect, a tolerogenic, anti-inflammatory, wound healing immune response to the implant 
is critically needed.7,16–18  Conversely vaccines require a pro-inflammatory and/or 
immunostimulatory response.3,5,19  However, few clinically approved combination 
products, biologics, or materials have shown an ability to elicit a large and controllable 
effect that changes the ultimate fate of implants or increases efficacy of vaccines over 
that of current clinical adjuvants.   
 Dendritic cells and their interaction with carbohydrates through CLRs have been 
shown to play critical roles in both immune acceptance and activation and thus are seen 
as an ideal target for modulating the responses discussed above.  However, carbohydrates 
can only be exploited with a more complete understanding of host immune interaction 
with carbohydrates and glycoproteins.  This dissertation builds part of the carbohydrate 
foundation onto which future implanted devices and vaccine conjugates can be designed. 
The information uncovered has direct implications in development of glycan-based 
surfaces/biomaterials which stimulate DC maturation as effective adjuvants for vaccines 
or inhibit DC maturation to minimize immune responses in tissue engineering and 
implanted medical devices.  Additionally, the work herein shows that glycan display 
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modality is an important factor for consideration of DC response to glycoconjugates 
which has implications across the field of glycobiology.  Modality of display, has not 
been accessed across the field and thus, while not studied in this report, it is possible that 
other immune cells and indeed any cells, respond differentially to different modalities of 
display of glycan.  Furthermore, this dissertation lays the groundwork for creating a 
template for modeling of immune interaction with glycans.  Modeling has the potential to 
play an instrumental role in the elucidation of cell response to glycan structures because 
extremely limited amounts of purified complex carbohydrate sugars are capable of being 
synthesized.  Due to this shortcoming, extensive cellular studies cannot easily be 
performed and modeling can be used to overcome this limitation.  It is hypothesized that 
the information obtained from modeling will offer new avenues and approaches in 
immune modulation and potentially lead to new types of combination products utilizing 
CLR ligands. These could have the potential to modulate the immune response toward 
clinically efficacious vaccines and implants/coatings and thus improve clinical outcomes. 
1.2 Innovation:   
 Soluble and phagocytosable glycan presentation to APCs has been studied but 
little direct comparative data between the two and no comparison to well surface 
displayed glycans has been seen.20,21  Furthermore, due to the extremely limited supply of 
well-defined oligosaccharides capable of being obtained via synthetic or biological means 
surface interaction with recombinant CLRs or other lectins to glycan microarrays has 
been used as a proxy for direct cellular response for glyco-conjugate creation and 
therapeutic approaches.22,23  Additionally, the non-phagocytosable surface display of 
glycans to cells has not undergone a thorough analysis.  Thus, the critical molecular 
factors for display of glycans to DCs so that the cells can respond to the glycans with 
high efficacy from biomaterial surfaces are unknown. The experiments herein addressed 
these issues by use of a novel high throughput (HTP) methodology.  This method allowed 
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for an order of magnitude less glycan to be used than previous functional assays, evaluate 
both pro- and anti-inflammatory immune responses from DCs, and allowed for the testing 
of multiple surface display modalities simultaneously. The work completed herein 
challenged the conventional view in the literature that it is glycan structure, density, and 
context of presentation alone that determine phenotypic modulation of DCs and cells in 
general. This was done by first optimizing single molecular factors and combinations of 
factors in concert to obtain a foundation of non-phagocytosable display parameters that 
were then used to show quantitative difference in DC response across display modalities. 
Finally, the creation and validation of predictive models for DC activation in response to 
CLR stimulation via adsorbed synthetic glycoproteins was performed. It is hypothesized 
that this modeling approach can now be used as a template for future glycan studies 
performed across multiple classes of glycan ligands.  This has not been seen in the 
literature previously and has a large value to the field of glycobiology because modeling 
has the ability to isolate and predict factors of importance to glycan display which 
ultimately means that less glycan will be needed to complete the necessary studies for 
clinically efficacious treatments. 
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CHAPTER 2  SPECIFIC AIMS AND HYPOTHESES 
 The role that glycans play in systemic immune response is still largely unexplored 
and the DC response to diverse glycan motifs across various presentation contexts has not 
been assessed.  Because of the critical role that DCs play in the coordination of both 
innate and adaptive immune responses to foreign pathogens, this is a major limitation for 
the intelligent design of biomaterials, coatings, and combination products that utilize 
glycans.  Elucidation of the fundamentals factors of glycan display important for the 
immune response to these conjugates will be critical for determining how to overcome 
fibrous encapsulation of implants, impotent vaccine conjugates, and to develop 
therapeutics targeting cancers and parasitic infections. Furthermore, understanding 
optimal presentation modalities for glycans to engineer immune response toward a 
desired outcome is critical for the design of future therapeutics.  Due to the extremely 
rare nature of complex glycan structures, this understanding can currently only be had if 
computational models are employed to predict the DC response to glycans.  These 
models have not been seen in the literature and thus must be developed in order to move 
to the next phase of therapeutic development. 
  
  
Aim 1:  Identify molecular factors in the non-phagocytosable display of glycans to 
dendritic cells that are important for phenotypic modulation.  Hypothesis:  Molecular 
characteristics (density, charge, and glycan structure) of both the carrier and glycan can 
significantly modulate DCs toward a pro- or anti-inflammatory phenotype.  The purpose 
of this Aim was to permutate molecular factors of the carrier and glycan to determine 
which factors lead to altered DC phenotypes when the DC is cultured with glycans 
displayed from a non-phagocytosable surfaces.  Molecular characteristics of vaccine and 
biomaterial conjugates have been shown to drastically alter the immunogenicity of 
conjugates.24–28 However, this has not been shown in relation to DCs and non-
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phagocytosable glycan presentation.  Assessment of DC phenotype modulation by 
glycans via a thorough analysis of carrier charge, density of presentation, and glycan 
structure as well as combinations therein were performed.  We examined the effect on 
DC phenotype of two monosaccharides at multiple densities, four levels of carrier charge, 
and six distinct mannose structures.  Assessment of DC phenotype was performed via the 
High throughput (HTP) technique developed in house.  After assessment of charge and 
density multivariate modeling was used to statistically isolate and predict which 
molecular factors carried the most weight in phenotypic modulation.  These factors were 
then used to create an optimized carrier that was used with more complex glycan 
structures. The DC phenotype was then assessed in response to the conjugates and the 
structural motifs necessary for DC phenotype modulation were uncovered via 
multivariate modeling. 
 Aim 2: Identify how glycan presentation modality alters DC phenotype and how 
these display strategies can be harnessed to drive DCs toward a desired phenotype.  
Hypothesis:  Displaying carbohydrates to dendritic cells in a soluble, phagocytosable, 
and non-phagocytosable form will cause a differential DC phenotype.  The purpose of 
this Aim is to determine how DC phenotype is modulated by a limited set of simple 
proteoglycan conjugates displayed in three presentation modalities.  The immune 
response to non-phagocytosable glycans has been implicated in the body’s innate 
response to implanted materials and biofilms. However, a correlative relationship 
between the two has not been established. Furthermore, a comprehensive study of the DC 
response to non-phagocytosable glycans versus other display modalities has not been 
performed.  In this aim we measured the DC response to simple proteoglycan conjugates 
displayed in a soluble form, from a phagocytosable bead, and from a well surface to 
explicitly define this relationship. The optimized proteoglycan conjugates from Aim 1 
were used so that maximal DC response could be seen and to better mimic the display of 
glycans found in nature. Assessment of DC phenotype in response to these structures was 
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performed via the same HTP technique as in Aim 1.  The DC phenotype in response to 
the altered modality of display for identical conjugates was then modeled using a 
multivariate linear model to show that different display modalities had differential effects 
on DC phenotype.  Proof that DCs were interacting with the conjugates from these 
studies via CLRs was desired.  Thus, antibody blocking studies were performed with 
conjugates adsorbed onto 1 µm beads to determine if blocking antibodies were able to 
inhibit phagocytosis of the beads by DCs.  Finally, an indication of what the fate of the 
adsorbed conjugates was upon interaction with the DCs was desired.  Thus, conjugates 
were fluorescently modified and adsorbed to wells, and DC internalization of the 
fluorescent conjugates was assessed.   
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CHAPTER 3  LITERATURE REVIEW 
3.1  Dendritic Cells in Immunology 
 Dendritic cells play a pivotal role in the host immune response to a variety of 
foreign entities.29,30. Dendritic cells are distributed in almost every tissue and organ in the 
body and are considered APCs.  Dendritic Cells are of hematopoietic origin and are 
specialized for the non-specific uptake, transport, processing and presentation of antigens 
to T cells.31–33  While several other cell types are defined as APCs, macrophages and B 
cells, only DCs are able to efficiently stimulate naïve T cells.34  DCs are derived from 
monocytes in vivo and are differentiated form monocytes using ganulocyte-macrophage 
colony stimulating factor (GM-CSF) and interluken-4 (IL-4).35,36.  However, 
differentiation of monocytes into DCs is not guaranteed as monocytes have been shown 
to differentiate into macrophages, osteoblasts and osteoclasts.37  Interestingly, in the 
presence of IL-6 secreting fibroblasts, monocytes will not differentiate into DCs even 
when cultured with GM-CSF and IL-4.38 
 Dendritic cells are the most potent APCs of the immune system.  These cells have 
evolved to have a myriad of pattern recognition receptors that can distinguish 
characteristic pathogenic structures and signal the cell to respond.  Dendritic cells reside 
in almost every tissue in the body and their primary function is to sample the local 
microenvironment for pathogenic or foreign molecules, uptake these structures, and 
present them to other leukocytes.  How the antigen is processed, the extent of activation 
of the DC, the phenotypic outcome of that stimulation, and the extent of the downstream 
immune response can all be regulated by the context in which the DC encounters the 
antigen and the subsequent response to that antigen.    The DC constantly samples the 
surrounding environment with its PRRs.  Once a pathogen is detected the pathogen is 
phagocytized, killed, processed, and its peptides displayed on the Major 
histocompatibility complex (MHC) of the DC.  If the pathogen has infected the DC 
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(viruses or mycobacteria) the DC has no need to capture the pathogen but instead process 
the pathogens’ peptides and present them on the MHC.  While the antigen is being 
processed the DC is also going through a process known as maturation.  During 
maturation the DC up regulates co stimulatory molecules, increases cytokine production, 
and down regulates phagocytosis receptors and begins to migrate toward the lymph node.  
Once the antigen is processed, displayed, and the DC has up-regulated all costimulatory 
molecules the DC is said to be a mature DC (mDC).  When the mDC reaches the lymph 
node it encounters naïve T cells which sample the peptides displayed on the DC surface.  
If the T-cell receptor (TCR) is specific for the peptide the T cell matures and begins to 
clonally expand.   
 The maturation process is key in the development of an immune response not 
only because it signals the DC to migrate to the lymph where it will encounter naïve T 
cells but because it enables the DC to activate those T cells and cause them to clonally 
expand.  This process is not necessarily linked to a pro-inflammatory response as DC 
maturation can lead to proliferation of tolerogenic T cells (Tregs).
39,40  The exact 
mechanism of DC recognition and processing after initial contact with the pathogen or 
foreign material is heavily dependent upon what receptors are activated.  For instance if 
the CLR, Dectin-1, is stimulated via the delivery of β-glucans to DCs  the DC is able to 
prime Th1 and Th17 responses as well as cytotoxic T-lymphocyte (CTL) responses.41  In 
a study done by Leibundgut-Landmann et al. Dectin-1 stimulation was also shown to be 
an adjuvant for CTL cross-priming in vivo.  This ability to promote cross-priming of 
antigen led to potent CTL responses that protected the treated mice from developing 
tumors.41  In contrast stimulation of the CLR Dec205, DC‑SIGN, or macrophage 
mannose receptor (MMR) by antibodies without co-stimulation of toll-like receptors 
(TLRs) efficiently induces a tolerogenic state in DCs.42–44  Thus, elucidating which PRRs 
stimulate the desired response from DCs can be of enormous benefit in not just vaccine 
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delivery but also in implantation of tissue engineered constructs and other medical 
devices. 
3.1.1 Mechnisms by which DCs respond to biomaterials 
 Dendritic cells have been shown by the Babensee lab to undergo maturation upon 
biomaterial contact depending on the biomaterial used.45–47 The form of the biomaterial 
microparticles, scaffold or film48  has been shown to influence the DC response as well as 
the effect of surface contact and area.45,49    Thus, that DC interaction with biomaterials is 
an important factor in tissue engineering is clear.  However, in combination products, 
materials that utilize both a synthetic and biological component, the effect of the 
biomaterial adjuvant effect has been demonstrated to influence downstream effectors of 
DC maturation such as humoral IgG production and .50,51 Thus, elucidating how the 
presence of biomaterials alters the host immune response to co-delivered biologics and 
discovering the optimal ways in which to tailor those biomaterials shows great promise  
for the improved modulation of host response against combination products.   
 Biomaterials have been shown to have an adjuvant effect that enhances the 
immunogenicity of ovalbumin (OVA).  OVA adsorbed to phagocytosable microparticles, 
co-delivered in poly(lactic-co-glycolic acid) (PLGA) microparticles, or delivered in 
PLGA scaffolds, was found to support a moderate humoral immune response that was 
able to be maintained for over four months and was seen to be primarily a Th2 response 
as indicated by IgG1 antibody titers.50  Interestingly, the PLGA scaffold delivery induced 
a larger and longer lasting humoral response than did the two microparticle 
counterparts.52  Such enhanced immune response was hypothesized to be due to the 
danger signals released from tissue damage at the implant site due to the fact that 
HMGB1 a potent danger signal, was found in  higher concentrations in exudates from 
subcutaneously implanted PLGA scaffolds in comparison to naïve control.53 This result 
suggested the possible role of danger signal biomaterial-induced adjuvant effect.   
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   Furthermore, different biomaterials have been found to induce differential DC 
maturation.  PLGA and chitosan films were shown to induce DC maturation with alginate 
and agarose did not.54    Mixed lymphocyte reactions showed that DCs treated with 
PLGA and chitosan films supported higher levels of T-cell proliferation as compared to 
that of untreated DCs, and DCs treated with hyaluronic acid films induced lower levels of 
T-cell proliferation.  Additionally, agarose and alginate showed no change in T cell 
proliferation as compared to that untreated cells.  Furthermore, surface processing of 
titanium surfaces has been shown to drastically alter DC phenotype as measured by both 
cytokine secretion and surface marker expression of costimulatory molecules by DCs.46  
Specifically that hydrophobic surface modification in combination with high roughness 
increases activation marker CD86 in DCs.46  A complex cytokine release profile was 
determined in which DC surface marker expression did not couple with historically 
expected cytokines, thus implicating a new hybrid phenotype for the DCs.  Principle 
Component Analysis (PCA) was performed on the data to draw more clear correlations 
between the soluble factors and DC phenotype and it was found that pure titanium and 
SLA modification of titanium surface pushed DCs toward a pro-inflammatory phenotype, 
while modified SLA surface treatment was associated with non-inflammatory DC 
response.46 Additionally, it was found that for titanium surfaces hydrophobicity/philicity 
was heavily associated with IL10 production in DCs.  Interestingly, from this work it was 
also shown that increased DC adhesion was not sufficient to induce DC maturation as 
surfaces that showed statistically different CD86 expression showed equivalent adhesion 
to surfaces.46     
 The study above clearly indicates the importance of biomaterial surface properties 
and DC maturation however, material properties for the tested biomaterials were not 
completely controlled.  Thus, very controlled surface presentation of defined surface 
chemistries has also been studied using self-assembled monolayers and with distinct 
terminal groups (CH3, OH, COOH, and NH2).
55  Based on cell morphology, 
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allostimulatory capacity, and expression of maturation markers each SAM surface 
elicited modest DC maturation in comparison to untreated DCs.  Methylated surfaces 
were found to be the least activating in terms of surface marker expression but released 
the largest amounts of pro-inflammatory cytokines TNF-α an IL-6.  It was found that this 
was due to the fact that cell viability on the methylated surfaces was lower than that of 
the other SAMs. 
 Further study was given to DC response to controlled polymeric surfaces in a 
recent study that looked at a library of polymethacrylates (pMAs).47 It was found that 
pMAs induced differential DC responses.  Specifically that several of the the pMAs 
increased the maturation factor of DCs to a greater extent than that of the positive control 
LPS, and each of the pMA treatments produced a unique cytokine profile from the DCs 
with HEMA showing strong anti-inflamamtory response and nbutyl-cyclohexyl-undecyl 
methacrylate and isobutyl-benzyl-THFF methacrylate producing the most inflammatory 
phenotype.  Also of interest was that when these factors were modeled alongside the 
material properties it was found that based off of polymer composition one could predict 
DC phenotype using a PCA model.  Furthermore, it was found that DCs were 
morphologically distinct on different polymer surfaces and that pHEMA and not 
pIBTMA was able to induce a significant amount of DC apoptosis.  pIBTMA was 
consistently shown to low levels of inflammatory cytokines and chemokines as compared 
to untreated cells and rounded cell morphologies.   
 Finally, the exact mechanisms by which DCs recognize and respond to 
biomaterials remains to be elucidated.  Complement and adsorption of danger signals 
from plasma proteins have both been implicated in the response.56 However, recent 
research using MyD88 and TLR knockout mice demonstrated that DCs use TLR2, TLR4, 
and TLR6 for the responses to a diverse set of biomaterials.57 Also recently, β integrins 
were shown to play a role in mediating DC adhesion and response to biomaterials.58 
These studies implicate extracellular matrix (ECM) proteins adsorbed to biomaterial 
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surfaces as being integral to DC response to these proteins.  DCs cultured on collagen or 
vitronectin substrates released higher levels of IL-12p40 while DCs cultured on albumin 
or serum coated plates generated higher amounts of IL10.59  Based off of these results, 
intelligently engineered biomaterials may guide the presentation, orientation, or 
conformation of adsorbed proteins in such a way that these combination products will 
either induce DC tolerance or activation to co-delivered antigen.  The utility of using 
biomaterials over natural, heterogeneous, ligands is that biomaterials can induce a 
controllable and tunable response from the immune system that can be tailored for any 
level or phenotype desired.  The experiments listed above begin to uncover the factors 
necessary for this control and it is expected that future works will further uncover novel 
factors for modulation of DC response to biomaterials.  
3.2 Pattern Recognition Receptors 
 The two most heavily studied and diverse PRR classes on DCs are TLRs and 
CLRs (CLRs).  Toll-like receptors, the most characterized of the PRRs, are membrane 
bound proteins containing varying amounts of leucine-rich repeats in their extracellular 
domains that are involved in the ligand-recognition.60 Currently, twelve TLR receptors 
have been discovered in humans.60  These TLRs recognize a variety of bacterial and viral 
pathogen associated molecular patterns PAMPs and several injury molecular motifs, 
danger associated molecular patterns (DAMPS).60–62 Examples of microbial or viral 
ligands for TLRs include lipopolysaccharide (LPS) (TLR4), lipopeptides and lipoproteins 
(TLR2), double-stranded viral RNA (TLR3), and bacterial flagellin (TLR5). 60,63–68.  
Most TLR’s signaling propagation occurs through MyD88, a cytoplasmic adapter protein 
common for all TLRs (except TLR3). TLR4 is also able to signal in a MyD88 
independent manner 69.  Upon ligation TLRs can stimulate three independent signaling 
pathways: the IKK complex (inhibitor of nuclear factor-B), mitogen-activated protein 
kinase (MAPK), and toll/IL-1R domain-containing adapter molecule (Trif).  Activation 
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of the IKK pathway results in the release and activation of nuclear factor- B (NF-B) 
transcription factor family (p65, p50, p52, RelB, and cRel).  Activation of the MAPK 
family (c-Jun N-terminal kinase, JNK; p38, and extracellular-signal-regulated kinase, 
ERK) results in the subsequent phosphorylation/activation of activator protein (AP)-1 
transcription factor family (cJun, cFos, FosB, Fra-1, Fra-2, JunB, JunD).  Activation of 
the Toll/IL-1R domain-containing adapter molecule (Trif), a MyD88 independent 
pathway, leads to the activation of interferon regulatory factor 3 (IRF3) transcription 
factor to induce interferon production 60. The above pathways can be stimulated singly or 
in an overlapping fashion depending on the availability of ligand for a particular TLR.  
Co stimulation through NF-B and AP-1 has been shown to yield a more potent 
inflammatory response 70. The up-regulation of the transcription factors above can have 
diverse effects on DC maturation and phenotypic outcome of the DC.  However, most of 
the above transcription factors when activated via the TLR pathway lead to pro-
inflammatory mediators.   
3.2.1 C-Type Lectin Receptors on Dendritic Cells 
 C-type lectin receptors are calcium dependent carbohydrate binding receptors that 
represent a unique class of signaling receptors that has only begun to be studied.   In DCs 
these receptors are conically thought to recognize carbohydrate moieties present on 
pathogens but they have also been found to bind to altered carbohydrate structures found 
on apoptotic, cancerous and necrotic cells.1,42,71–74 Table 1 shows all of the currently 
known lectins present on DCs.  Of note is that for many of the lectins many ligand 
specificities are unknown or signaling pathway have not been uncovered.42  What Table 1 
makes apparent is that while CLRs have not been as well characterized as TLRs they do 
play an important role in the DC interaction with a variety of intercellular mediators and 
pathogens.1,40,42,74–78  Also of note from Table 1 is the redundancy of these receptors; 
seven CLRs have been shown to bind to mannosylated structures while ten sialic acid 
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binding proteins are found on DCs.  This redundancy can be explained in part by the fact 
that in vivo CLRs are often expressed on specific subsets of DCs.  For instance, MR is 
highly expressed on myeloid DCs, whereas Langerin expression is restricted to 
Langerhans cells.42 Another good example is DC-SIGN which is widely expressed on 
dermal DCs, as well as DCs in lymph nodes and mucosal tissues but MGL is only seen in 
a subset of dermal DCs.79,63 Thus, multiple lectins are needed to produce distinct 
outcomes in each subset depending on the DC microenvironment and function.  It has 
also been postulated that the redundancy of CLRs on specific DC subsets could be 
present to create diverse, highly regulatable, and specific phenotypic responses from 
DCs.4,5,42,80 This is supported by comparing the adapter protein each receptor signals 
through, seen in Table 1, which shows that drastically different outcomes would be 




Table 1:  List of lectins on DCs.  For each CLR signaling motifs and pathways, 
functional effects of ligation, ligand specificity, endocytic activity, calcium 
dependence and reference if known is listed.    
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3.2.1.1 Signaling by CLRs on Dendritic Cells 
 Based on cytoplasmic signaling motifs and signaling potential, shown in Table 1 
myeloid CLRs can be grouped independently of structure into the following broad 
categories: Syk-coupled CLRs, CLRs with immunoreceptor tyrosine-based inhibitory 
motif (ITIM) domains, and CLRs without a clear immunoreceptor tyrosine-based 
activating motif (ITAM) or ITIM motif.  Each of these groups can then be further divided 
into receptor classes based on calcium dependence, seen in Table 1, and by glycan ligand 
able to be bound.   
 Syk has emerged as a major tyrosine kinase involved in the early signaling by a 
subset of CLRs. CLR coupling to Syk can be indirect, often occurring through the Fc 
receptor γ chain (FcRγ) or DAP12, which are classical Syk-recruiting ITAM motifs.82 
However, lectins in Table 1 with a hemITAM signaling molecule possess the ability to 
directly signal Syk through a single tyrosine-based motif found in the cytoplasmic 
domain.83 For these receptors phosphorylation of the tyrosine in the ITAM or hemITAM 
motifs generates docking sites for the SH2 domains of Syk, which undergoes a 
conformational change that allows auto-phosphorylation and activation of the Syk 
pathway.82 Active Syk can then signals through a variety of intermediaries to PI3K or 
PLCγ, which in turn coordinates many downstream signaling pathways that lead to 
myeloid cell activation.42 This class of receptors is most easily divided by the hemITAM-
based CLRs (Dectin-1, CLEC-2, DNGR-1, and SIGN-R3) and the ITAM-coupled CLRs 
(Dectin-2, BDCA-2, Mincle, and MDL-1).  Though functional downstream activation 
effects of stimulation of both of these classes are similar ultimate phenotypes have been 
found to be disparate depending on stimulation.82,84 
 Lectins with ITIM domains are a distinct group of CLRs that express ITIM motifs 
that recruit phosphatases and thereby negatively regulate signaling through kinase-
associated receptors, notably the Syk-coupled CLRs and TLRs.84 ITIM-bearing CLRs 
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modulate myeloid cell activation when they are triggered together with receptors known 
to stimulate pro-inflammatory responses from DCs such as TLRs and compliment 
receptors. Myeloid CLRs included in this group are DCIR, MICL and the Siglecs. Of 
these receptors the Siglecs are the most heavily studied and well understood.  Within the 
Siglecs there are generally three groups based on features of the transmembrane and 
cytoplasmic tails of individual Siglecs that reflect the major mechanisms by which they 
mediate their biological functions. The first group is made up of Siglec-1 and Siglec-4 
lectins that lack inhibitory signaling cytosolic motifs and possess neutral transmembrane 
domains.84 These Siglecs have been shown to primarily mediate adhesion events between 
immune cells and endothelium and are known to be critical in the arrest of cell rolling on 
the endothelium wall.84    
 The second group of Siglecs in this type of functional classification is the largest 
and includes members in which the major biological function is immune-inhibitory, 
mediated by cytosolic ITIMs.  In this family of Siglecs, ligand recognition results in 
phosphorylation of the ITIM tyrosine and the ITIM-like tyrosine to Src family kinases 
such as Lyn. These kinases can phosphorylate cytosolic ITIM tyrosines, which then in 
turn recruit tyrosine phosphatases such as SHP-1 or SHP-2 that can attenuate signal 
transduction.85,86  Human Siglecs that contain ITIM motifs include Siglec-2, -3, and -5 
through 12.  A general view of ITIM-containing Siglecs is that they maintain a 
constitutive inhibitory signal when bound to their cognate sialoglycoconjugates in the 
same cell in which they are expressed.87 Exposure of the host to a pathogen, even if the 
pathogen lacks surface sialoglycans, may either alter Siglec expression or alter cellular 
levels of Siglec ligands.84  Pathogens that do express surface sialic acid may engage 
cognate Siglecs to attenuate inflammation as part of immune evasion, but innate immune 
cell activation may also be modulated in order for the host to generate specific protective 
responses.87  
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 The third category of Siglecs, members contain a positively charged residue in the 
transmembrane anchor region. These Siglecs associate with a disulfide-linked homodimer 
of DAP12 which contains an aspartate transmembrane residue and a cytosolic ITAM 
motif. On the basis of data from other DAP12-containing receptors whose ligands are 
known, it is hypothesized that ligation of these ITAM-linked Siglecs leads to a 
conformational change that results in enhanced accessibility of the cytosolic tyrosine 
containing motifs of either DAP12 or DAP10 to non-receptor tyrosine kinases.84  This 
enhanced accessibility further results either in tyrosine phosphorylation of the ITAM of 
DAP12 to facilitate Syk family tyrosine kinase recruitment and activation or in 
phosphorylation of DAP10, resulting in phosphatidylinositol-3 kinase recruitment and 
activation. In humans, Siglecs with positively charged residues in the transmembrane 
region include Siglec-14 through 16.88–91 Primarily in the context of the biology of pDCs, 
it is hypothesized that DAP12 ITAMs contribute to the attenuation of TLR signaling in 
an uncharacteristic role for the ITAM motif. 84 Although ITAMs that shut off signaling 
pathways have sometimes been referred to as inhibitory ITAMs92,93, the concept of 
ITAMs mediating unique inhibitory signals has long been studied in the immune context. 
B cell anergy and T cell anergy both involve antigen receptor–linked ITAM activation, 
but the biochemical pathways induced inhibit lymphocyte activation.  
 Finally, CLRs without a clear ITAM or ITIM motif, including MR, DEC-205, 
DCSIGN, Langerin, MGL, CLEC-1, DCAL-1, MCL, and LSECtin. These CLRs can 
engage the endocytic machinery and mediate the capture of antigenic cargo for 
processing and presentation to T cells.94 Nevertheless, triggering of these receptors in 
isolation has not been seen to induce obvious signs of myeloid cell activation without 
interaction with other PRRs. As can be seen in Table 1, some of this group of CLRs (e.g., 
DC-SIGN), has the signaling pathway involved in modulation elucidated, but for most it 
is unknown.  From Table 1 it is clear that depending on the ligand delivered to the lectins 
in this class the downstream effectors of its ligation can vary drastically.  Thus, this class 
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of lectins shows a more complex and nuanced phenotypic modulation of DC phenotype 
as compared to the other two classes in which signaling from ligation is more direct. 
Targeting of CLRs on Dendritic cells 
 Development in the glycoimmunology field will take considerable expenditure of 
resources and time from a diverse range of specialties and thus a large value to this 
research must be shown to justify this expenditure.  To this end, many implications for 
CLRs have been seen in studies with antibody binding of the CLRs to simulate ligand 
engagement.44,95–99 These studies have led to clinical therapies that are just beginning to 
enter the market.5,100  Also, many studies have been done showing that receptors 
expressed on DCs, in their recombinant form, can bind, with high prejudice, glycan 
structures immobilized in micro arrays.101–106 These assays can lead to potent ligand 
identification for use in treating a range of pathologies. A plethora of studies have shown 
altered DC behavior across soluble, phagocytosable, and non-phagocytosable 
presentation of glycans which has potential in vaccine and implant development; which 
has implications across the entire medical community.107–111 Additionally, CLRs found 
on DCs have been expressed in non-DCs and their ability to bind and uptake 
carbohydrates has been assessed and show implications for a mechanistic understanding 
of what these isolated receptors are capable of inducing.112–114 Furthermore, many studies 
have optimized particle and dendrimeric polymer carriers of carbohydrates to increase 
phagocytosis or intercellular transport of ligands.115–117 Finally, several studies have also 
shown enhanced or abrogated migration of DCs due to glycan ligand immobilization to 
non-phagocytosable sufaces.20,118,119  In combination these studies showed that a variety 
of immune responses, both pro-inflammatory and tolerogenic in origin, were possible 
through CLR stimulation and thus this group of PRRs warrants further study.   
3.2.1.2 Antibodies against CLRS 
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 Recent studies suggest that antibodies against C-type lectins such as MMR, DEC-
205/ CD205, or DC-SIGN/CD209 can be used as antigen-delivering vehicles to induce 
immune tolerance, T cell proliferation, or cytokine release.120–126  In these studies non-
traditional phenotypes, where typical maturation markers such as CD80 and CD86 were 
not up regulated, were identified.95,127,128  In the study by Meyer-Wentrup et al. DCs 
showed a reduction in their pro-inflammatory cytokine profile when the DCs were 
stimulated with TLR8 agonists but were first treated with Abs against DCIR. However, 
traditional anti-inflammatory or tolerogenic cytokine profiles (IL-10, TGFβ, and IL-6) 
were not found to be up-regulated.  Another study involving CLEC9A show that murine 
DCs expressing CLEC9A are capable of producing potent CD4+ and CD8+ T cell 
proliferation without increasing the typical activation markers expressed by DCs (surface 
markers MHC class II, CD80, CD86, and CD40) when the CLEC9A receptor was 
stimulated.128  While the exact natural ligand for CLEC9A is unknown this receptor has 
been shown to be a critical player in clearing necrotic tissue without activation associated 
surface markers being up-regulated but with an increase in IFN-γ.129   Furthermore, in a 
study by Meyer-Wentrup et al. DCIR cross-linking selectively inhibited TLR8-mediated 
IL-12 and TNF-α production in DCs. DCIR triggering with Abs showed that it also 
inhibits TLR-induced cytokine production and leaves TLR-induced CD80 and CD86 
expression unaffected.95 Recently, a DCIR peptide containing the phosphorylated ITIM 
domain has been shown to bind to the protein tyrosine phosphatases SHP-1 and SHP-2, 
thus further substantiating an immune-inhibitory role for DCIR.130  Bonifaz et Al. showed 
that injection of anti–DEC-205 mAb coupled with ovalbumin alone induced regulatory T 
cells and leads to suppression of OVA-specific T-cell proliferation.122,123 However, 
simultaneous injection of anti–DEC-205 OVA conjugates with an agonistic anti-CD40 
Ab significantly enhanced host immune responses against an OVA-expressed tumor and 
infection by an OVA expressing vaccina virus.123,126 Similarly, anti–DC-SIGN mediated 
targeting of antigen-induced, specific T-cell proliferation even without the presence of 
 25 
other DC maturation stimuli. 120,126  Again in this study the DCs that were observed to 
promote T cell proliferation did not display typical maturation markers for mature DCs 
(both cytokine and surface marker).  Of note from each of these studies was that they 
were conducted with antibodies to the lectins they were targeting because, in most of the 
cases, the physiological ligand for the receptors is unknown or because of the limited 
amount of purified glycan that is able to be obtained that would be specific for the 
receptor.  Thus, the physiological response of the cells to ligation of the receptors with 
their natural ligand remains unknown and could therefore alter the understanding of the 
function of these receptors in the immune system.  There are lectins, such as DC-SIGN, 
that have both known ligands and anti-bodies against them and an evaluation of receptor 
engagement of both could be performed but a direct comparison between them has not 
been shown in the literature.  However, in the case of DC-SIGN, both have been 
extensively studied independently and through comparison it  can be seen that a 
differential activation and response profile to ligand versus antibody occurs in 
DCs.2,21,21,75,119,120,126,131–134   
 The advantage of using anti-bodies as the triggering agent for these lectins is that 
no glycans or carbohydrate chemistries are needed to perform these assays.  Thus, 
extremely limited amounts purified ligand is not the controlling factor in the above 
studies and cellular readouts such as cytokine profiles, cell surface marker expression, 
and effector cell proliferation were able to be obtained. These readouts are the most 
relevant when analyzing the affect a ligand has on the immune system prior to in vivo 
testing and thus the above studies are fairly complete in terms of cellular analysis.  In fact 
several clinical therapies targeting lectins with anti-bodies are currently in phase I and 
phase II trials and are performing well due to the ease with which antibodies can be 
produced and manufactured.100  However, due to the differential response of CLRs to 
antibodies versus glycan ligands antibody studies do not fully exploit the potential of 
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these receptors and more studies are needed to fully understand their capabilities in 
modulating immune responses. 
3.2.1.3 Natural ligands for CLRS 
 A plethora of studies have shown DC interaction with natural ligands.  These 
ligands are complex in nature and typically consist of glycans from sources such as yeast 
(mannans), bacterial or vial membrane glycoproteins, lipopolysaccharides, parasite 
surface glycans, or beta-glucans.4,41,80,135,136  These complex sugar milieu have been used 
to identify molecular signaling pathways and general receptor specificity.  However, even 
with these resources, in myeloid DCs, almost a third of all lectins currently identified do 
not have a molecular signaling pathway clarified and many more do not have the 
complete reaction cascade defined.17,42,42,100 Generally, for the pathways that have been 
clarified, the CLRs can be divided into receptors that utilize TLR co-stimulation and 
those that signal independently from other receptor pathways.75 The interaction of 
DC-SIGN with mannose-containing pathogens, such as Mycobacterium, HIV-1, measles 
virus, and Candida Albicans, affects TLR mediated immune responses from DCs.137  It 
has been shown that the crosstalk between TLRs and DC-SIGN depends on the prior 
activation of NF-κB by TLR signaling from TLR3, TLR4, and/or TLR5137.  DC-SIGN 
triggering activates the serine/ threonine protein kinase RAF1, which induces the 
phosphorylation of the NF-κB.  This stimulation pathway has been shown to be involved 
in such downstream affecters as IL-8, IL-10, IL6, and IL12b production.76  In contrast 
stimulation of DC-SIGN by antibody MR1, ligand Ara h1 (peanut allergen), or 
Schistosoma mansoni egg antigen as been implicated in activation of eRK. 138–140  The 
stimulation of eRK is linked to the activation of immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) which is conically thought to lead to the inhibition of pro-
inflammatory cytokines.  Thus, differential stimulation of this receptor independent of 
TLR activation may lead to inactivation of the DC.  However, both of these pathways 
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have been discovered via interaction of DC-SIGN with mannosylated and fucosylated 
structures.  The implications for fucose binding to modulate the DC-SIGN cascade has 
yet to be elucidated even though the binding of DC-SIGN to fucosylated glycans has 
been shown to be higher than that of mannose in vitro.22  A further level of complexity 
for DC-SIGN exists in that it has also been shown to have competing roles in DC 
activation when binding to a single pathogen as demonstrated in HIV infection.  Both 
Langerin and DC-SIGN recognize HIV-1 through the high-mannose motifs on its 
envelope glycoprotein gp120 yet they are expressed on distinct DC subsets and they have 
been shown to have opposite functions in handling HIV-1. Langerin targets HIV-1 for 
degradation while DC-SIGN binds HIV-1 and serves as a carrier molecule for HIV 
facilitating HIV transmission to T cells.141  
 Dendritic cell inhibitory immune receptor (DCIR) , MICL, and Siglecs 3-10 have 
been found to associate with ITIM intercellular motifs.  Thus, when DCIR and MICL 
receptors are stimulated an inhibition of the TLR8 and TLR9, and TLR4 (respectively) 
activation in DCs has been shown.142,143  The ITIM domains recruit the phosphatases 
sH2‑domain‑containing protein tyrosine phosphatase 1 (sHP1) or sHP2 following ligand 
engagement which leads to inhibition of the MyD88 pathway (via unknown 
intermediaries.)144  However, similarly to DC‑SIGN, neither DCIR nor MICL have been 
proven to induce immune responses independently of TLRs but instead modulate the 
response of DCs if the TLRs are co-stimulated.  If DCIR is bound by an antibody it 
causes internalization of the opsonized pathogen and trafficking of the complex to the 
endosomal compartments where TLR8 and TLR9 are present.  It simultaneously begins 
the cascade described above to inhibit the affecter function of these TLRs.  If MICL is 
bound activation of eRK is thought to occur and thus suppression of TLR‑induced IL‑12 
expression has been shown.142 Additionally, several studies have shown that siglecs can 
recruit the inhibitory tyrosine phosphatases SHP-1 and SHP-2.145 However, relatively 
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little work has been done specifically on DCs and siglecs.  So while these cells have been 
shown to express many of the Siglec family (See table 1) the exact effect of ligation of 
these receptors in DCs is largely unknown.  However, they have generally been shown to 
contain the same adapter proteins as other immune cells containing these receptors and 
thus it is largely thought that they serve similar functions as they do in macrophages, 
monocytes, and B cells.87,146  For most CD33-related siglecs (Siglec 3, 5-11, and 14) 
ligand engagement results in tyrosine phosphorylation of ITIM by the Src family tyrosine 
kinases with subsequent association with the Src homology 2 (SH2)- domain containing 
phosphatases such as SHP-1 and SHP-2, which control cellular activation by attenuating 
tyrosine phosphorylation.147,148  
 Finally, the lectins Dectin 1&2 have been shown to have a signaling cascade 
independent of other PRRs.  Dectins activate gene expression through the recognition of 
β‑1,3‑glucan PAMPs expressed by a broad range of fungal pathogens, including C. 
albicans, Aspergillus fumigatus and Pneumocystis carinii, which then leads to the 
activation of NF‑κB40,72,149,42. Dectin 1 stimulation leads to the activation of syK which 
has been shown to lead to NF‑κB stimulation via a protein known as Card9149–151.  This 
stimulation pathway has been determined previously for other receptors and thus is 
known as the canonical stimulation of NF‑κB.  But, in addition to the activation of 
NF‑κB via the canonical activation pathway, Dectin 1 has also shown that through 
activation of the syK pathway an induction of the non-canonical NF-κB pathway can 
occur.  Activation of this pathway has previously been described only for a few members 
of the TNF receptor superfamily, such as lymphotoxin‑β receptor and CD40 neither of 
which signals through syK.152,153  Stimulation via this pathway typically ends in TNF 
production and few other pro-inflammatory cytokines unlike stimulation via the 
canonical pathway.  Thus, Dectin 1 is able to signal through several pathways ending in 
diverse cellular outcomes independently of any other PRRs via binding of β-glucans.  
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Dectin 1 and TLRs can cross-talk as well, as demonstrated for dectin-1 and TLR2. Co-
expression of both molecules on the APC surface enables cooperative, synergistic 
signaling by TLR2 and dectin-1 in response to the common ligand zymosan.154,155 Dectin 
2, while not as well studied as Dectin 1, has also shown a diverse range of 
immunomodulatory effects.  Dectin 2 is known to associate non‑covalently with the 
ITAM‑bearing signaling adaptor molecule FcRγ and activation of NF-κB.  Typical 
downstream effects of FcRy activation and NF-κB stimulation are pro-inflammatory 
cytokine production and immune activation.  That engagement of the dectin 2 receptor 
works through this canonical pathway is supported by data showing that dectin 2 
recognition of fungi C. albicans, Trichophyton rubrum and Microsporum audouinii leads 
to production of the pro‑inflammatory cytokines TNFα, IL-1ra, and IL‑6, and 
stimulation of Th17 effector cell activation and proliferation.
42,156,157  Furthermore, dectin 
2 recognition of house dust mite allergens generates allergic inflammation mediators 
known as cysteinyl leukotrienes in the lungs as activated by syk through FcRγ.158  
 The above studies only scratch the surface of natural ligand interactions with DCs 
and their subsequent immunological outcomes.  Extensive reviews have been written 
highlighting these interactions and further detail will not be gone into 
here.3,16,17,42,87,129,131,146,159–162 The understanding of natural ligands that can be bound by 
DCs and cause functional outcomes is important for clinical studies and for etiology of 
disease.  It also has implications in ligand identification when the receptor has no known 
specificity and in molecular pathway elucidation.  The advantages of using natural 
ligands for DCs is that, as long as the pathogen/parasite can be grown in vitro, large 
amounts of the ligand are able to be obtained.  This leads to the ability to determine 
cellular readouts such as cytokine profiles, cell surface marker expression, and effector 
cell proliferation.  Because the receptor is being engaged by its natural ligand the effects 
seen in these studies have direct physiological implications and a much greater 
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understanding of the range of responses possible for CLRs on DCs can be obtained.  To 
this end, the above studies showed a range of DC responses and interactions spanning 
direct pro-inflammatory stimulation upon receptor ligation, to indirect tolerogenic 
phenotype inducement, and everything inbetween.5,76,97,140,159,163  Thus, CLRs are a 
receptor class ripe with possibilities for clinical therapies 
3.2.1.4 Synthetic ligands for CLRS 
 An underlying mechanism for the biological function of carbohydrates is 
multivalent recognition, which is being exploited in vaccine development by displaying 
multiple sugars on the backbone of a polymer to either promote or inhibit 
immunoreactivity.164 However, these delivery systems are not as efficacious if they 
cannot mimic native tissue glycan presentation. Thus, strategies have been developed to 
promote immunoreactivity165, such as combining antigens with naturally occurring 
glycan scaffolding (e.g. chitosan), and using adaptable supramolecular 
pseudopolyrotaxanes that multi-valently display mobile ligands that have rotational 
freedom about the polymer backbone.165,166 These and similar polymer systems, when 
linked to an antigen, such as Diphtheria toxoid, have been shown to significantly increase 
antibody production over delivery of the antigen without polymer-glycan presentation. 
These systems have been shown to provide upwards of 47% antibody production increase 
upon rechallenge with the antigen, showing not only their effectiveness in initially 
creating adaptive immunity, but also in sustaining immune memory.166,167 Similar glycan-
polymer systems have also been used to inhibit infection and promote immune response 
by designing their carbohydrate moieties to mimic the glycan presentation seen in 
bacterial and viral surfaces.164 These polymer-glycan systems act as “subunit” vaccines 
by helping stimulate the immune response against a specific bacteria or virus by 
synthetically inducing immune response against the outer surface components of the 
bacteria or virus without the actual infectant being present. Furthermore, vaccines are 
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targeted to DCs CLRs using glycans, particularly mannosylation of antigens168,169 or of 
polymer carrier systems delivering the antigen170–172 with significant enhancements in 
humoral immune responses and T cell stimulation, supported by DC maturation.  
 Conversely, multivalent carbohydrate presentation can also be used in 
immunosuppression by exploiting the tolerance pathways present in the immune system. 
In areas of high immunostimulation, such as the mucus lining in the lungs or gut, 
tolerance to foreign non-pathogenic antigens is common. The pathway for this tolerance 
is unclear; however, studies have begun to elucidate a complex relationship between 
CLRs and TLRs in tolerance to non-pathogenic antigens.7 It has been postulated that if 
antigens do not present a known pathogenic moiety and do not stimulate other ‘danger 
signals’ from the surrounding tissue, then immunetolerance can occur.7 Thus, polymer 
presentation of self-glycans in such a way as to mimic both density and composition of 
self-glycan could lead to tolerance. It has been shown that with an equivalent passivation 
system, tolerance to ovalbumin, a model antigen, can occur in vivo.121,122 The immune 
evasion strategies of tumors173 and viruses174 based on glycan presentation appear to 
represent other immunosuppressive strategies. Such glycan-based immunosuppressive 
approaches could be applied to develop novel biomaterial surfaces to be used for tissue 
engineered and other implanted devices to induce immune-tolerance to the implanted 
device to enhance device integration and function. The research presented herein is aimed 
at discovering novel glycans with immunomodulatory effects for exploitation in a 
biomaterials context. 
3.3 Overview of Glycan Nomenclature and Glycosylation of Proteins  
 Carbohydrates are referred to in literature under several headings: carbohydrates, 
sugars, saccharides, and/or glycans.  Generally, they divided into four structural 
groupings: monosaccharides, disaccharides, oligosaccharides, and polysaccharides.  
These groupings indicate increasing structural complexity and thus also scale with 
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molecular weight of the carbohydrate. A typical carbohydrate consists of an aldehyde or 
ketone with many hydroxyl groups appended to it; generally a hydroxyl group is linked to 
each carbon atom that is not part of the aldehyde or ketone functional group of the 
carbohydrate. Examples of typical monosaccharides that follow this rule are glucose, 
fructose, and galactose. The hydroxyl rule is not a defining feature of carbohydrates as 
uronic acids and deoxy-sugars such as fucose are considered carbohydrates as well. At 
physiological temperatures carbohydrates exist in both a closed ring and open chain form.  
Mechanistically, the aldehyde carbonyl group carbon and hydroxyl group, from an open 
chain carbohydrate, reversibly react to form a hemiacetal (C-O-C) that closes the ring.  
This state is thermodynamically favored for most carbohydrates and thus most 
carbohydrates at physiological temperatures predominate in the closed ring form.175  
When the aldehyde/ketone reacts reversibly with the hydroxyl group a heterocyclic ring 
forms; these rings typically form to include five or six atoms and are called furanose and 
pyranose forms respectively.   
 While converting from the straight-chain form to the cyclic form, the anomeric 
carbon containing the carbonyl oxygen becomes a stereogenic center with two possible 
configurations either above or below the plane of the ring. The resulting possible pair of 
stereoisomers are called anomers.  The α anomer contains the hydroxyl of the anomeric 
carbon on the trans side of the ring from the CH2OH side branch. The β anomer contains 
the hydroxyl of the anomeric carbon on the cis side of the ring from the CH2OH side 
branch.  Because the ring and straight-chain forms readily interconvert, both anomers 
exist in equilibrium.175 
 Carbohydrates have very complex structures that are difficult to understand using 
IUPAC nomenclature.  For instance lactose, a common disaccharide consisting of a 
glucose linked to a galactose is named β-D-galactopyranosyl-(1→4)-D-glucose under 
IUPAC standards.  This naming strategy conveys much more information than would 
naming the carbohydrates by their atomic constituents (C12H22O11) however, to convey 
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even moderately complex carbohydrate structures the names would take 100s of 
characters.  Thus, a glycan nomenclature was developed by those in the field that used 
abbreviations for the glycan structures separated by their linkages.  An example of this 
can be seen in Figure 1B and in the case of lactose would be Galβ1-4Glu.   However, 
even this nomenclature can become untenable when trying to quickly assess the structure 
of complex carbohydrates such as those shown in Figure 1B and C.  Thus, glycan symbol 
nomenclature was developed.   The symbols and colors of carbohydrates can be seen in 
Figure 1A as well as an example of using these symbols to represent a glycan structure 
can be seen in Figure 1C.  Using this nomenclature allows researchers to quickly and 
easily identify glycan components of complex polysaccharides and their linkage to each 
other.176   
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Figure 1:  Carbohydrate symbol nomenclature.176 
 
3.3.1 Glycosylation of Proteins 
 In Eukaryotes post translational modification of proteins predominantly occurs in 
the endoplasmic reticulum (ER) and Golgi apparatus.  In both the ER and Golgi 
carbohydrates are added to proteins via enzymes known as glycosyltransferases.  
Additionally, many O-linked glycans are added to proteins in the cell cytoplasm.176  
Regardless of the location, most glycosylation reactions use activated forms of 
monosaccharides (most often nucleotide sugars) as precursors for reactions that are 
catalyzed by the glycosyltransferases.  Functionally, post translation of a protein the 
protein is shuttled to the Golgi where specific glycosyltransferases attach saccharides to 
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the protein’s polypeptide side chains.  Two main classes of glycosylation occur Nitrogen-
linked (N-linked) and oxygen linked (O-linked) and the glycosyltransferases for each of 
these classes are unique.   
 O-glycosyltransferases transfer N-acetylgalactosamine from UDP-GalNAc to 
serine or threonine residues, which is catalyzed by a polypeptide-N-acetyl-
galactosaminyltransferase (ppGalNAcT).176 There are at least 21 polypeptide-N-
acetylgalactosaminetransferases (ppGalNAcT-1 to -21) that differ in their amino acid 
sequences and are encoded by different genes. 176 Post modification of the GalNAc 
residue occurs in the Golgi apparatus and appears to be a stochastic event in which the 
longer the residence time of the protein in the Golgi, the more modification of the protein 
occurs.  This modification is performed by a plethora of glycosyltransferases and is 
heavily dependent on cell type, cell cycle status, extracellular signaling, etc.176  However, 
in general each glycosidic linkage is the product of a single enzyme176  (with a few 
exceptions not covered here). The human B blood group α1–3 galactosyltransferase 
provides an excellent example of such specificity.176  This enzyme catalyzes a 
glycosylation reaction in which galactose is added in α linkage to the C-3 hydroxyl group 
of a galactose residue on the protein. However, the enzyme only acts on galactose 
containing fucose in α1–2 linkage. 176 
 In contrast, N-linked glycans are initiated by the action of 
oligosaccharyltransferase, an enzyme that transfers the glycan Glc3Man9GlcNAc2 to the 
side chain of asparagine residues in the sequence motif Asn-X-Ser/Thr.176  N-glycan 
modification begins on the ER membrane with the transfer of GlcNAc-P from UDP-
GlcNAc to the lipid-like precursor dolichol phosphate (Dol-P) to generate dolichol 
pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc).176  Fourteen sugars are 
sequentially added to Dol-P before en bloc transfer of the entire glycan to an Asn-X-
Ser/Thr sequence onto a protein.176  The protein-bound N-glycan is subsequently 
remodeled in the ER and Golgi by a complex series of reactions catalyzed by membrane-
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bound glycosidases and glycosyltransferases. Glycosidases are enzymes that remove 
monosaccharides to form intermediate sugar structures that are then able to be recognized 
by glycosyltransferases and have more sugars attached or removed from them.  Most of 
these enzymes are sensitive to the physiological and biochemical state of the cell in 
which the glycoprotein is expressed.176  Thus, the populations of sugars attached to each 
glycosylated asparagine in a mature glycoprotein will be completely dependent on the 
cell type in which the glycoprotein is expressed and on the physiological status of the 
cell, a status that may be regulated during development and differentiation and altered in 
diseases such as cancers and prion diseases.176   
3.4 High Throughput Methodologies in Glycobiology and Immunology 
 A HTP approach is necessary to assess functional phenotypic effects of complex 
carbohydrates on DC phenotype for four key reasons.  First, only limited amounts of 
oligosaccharides (typically at sub-µmol levels) can be isolated from natural sources when 
cleaved from proteins or lipids and they are highly heterogeneous in structure. 4,177–179  
Second, the structural diversity of oligosaccharides leads to difficulties in their structural 
characterization; currently, there is a lack of an efficient means of automated assignment 
and the characterization is mainly reliant on expert interpretation by MS analyses.180 
Third, the biosynthesis of oligosaccharides is not template driven like DNA or protein 
synthesis, and thus the diverse repertoire of oligosaccharides that would be representative 
of the glycoform of a typical glycoprotein is extremely difficult to reproduce by chemical 
synthesis.181–183 Fourth, most carbohydrate-protein interactions are of low affinity, and 
there is a requirement of multivalent presentation of carbohydrate ligands for detection of 
binding in microscale screening analysis.104,105,184 To mitigate these concerns several 
approaches have been attempted by current laboratories.  The most predominant approach 
is to create glycan microarrays using shotgun glycomics or solid state carbohydrate 
synthesis.  
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 Currently, many high throughput screening technologies are being used to show 
relationships that they were not designed to elucidate and thus the results from these 
assays are said to only have “indications” for further study.  The most common and well 
known is genomic and transcriptional HTP screening using DNA and RNA microarrays 
that are used to measure the change and/or quantity of transcription that occurs in cells in 
response to a challenge.  While these assays are excellent to determine what is happening 
to a cell in terms of transcription, it has been confirmed many times and in multiple 
models that transcriptional activity does not necessarily directly relate to translational 
activity, which does not necessarily lead to functional protein expression/ secretion. Thus, 
because the assay does not directly show functional effects many more, non-HTP, 
techniques must be used in order to actually confirm what was implicated in the original 
HTP assay.  This process, while significantly reducing the complexity of the original 
problem, is not ideal as the HTP assay tells very little about actual functionality and in 
order to add this level of analysis non-HTP techniques that are very time and resource 
intensive must be employed.    Ideally, HTP screening utilizes only HTP strategies and 
directly assesses what the investigator is interested in.  To address this need many novel 
HTP strategies are being developed, specifically in immunology, where assessment of 
relevant effector functions are critical for designing potent therapies.  Immunology 
presents a unique level of complexity in that it involves an unusual dearth of interactions.  
The complete immune response requires an analysis of surface molecule expression, intra 
and intercellular interaction, secreted molecules, and temporality of these factors.  Just a 
few of the functional outcomes of these processes is a recruitment of other immune cells 
to the site of infection, secretion of pro- or anti-inflammatory molecules, development of 
distinct cellular phenotypes, clonal expansion of cells, cell inactivation/death, antibody 
production, etc.  These outcomes all rely on multiple factors occurring simultaneously or 
in a specific time frame and sequence in order for them to elicit the desired immune 
response.64  Thus, designing a HTP strategy that can monitor multiple factors over a 
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relatively long time course (days) is necessary for the investigator to obtain an idea of the 
functional effect of their treatment. This has yet to be seen in the literature.  The current 
state of the art for high throughput technology in immunology involves one of ten 
reporters: 
1. Live dead assays to determine a ligand or biomaterial cytotoxicity185 
2. Cellular proliferation186 
3. Phagocytosis of functionalized micro/nano-particles187–189 
4. Adherence/migration assays to determine if ligands affect cell binding and 
migration187,190 
5. Transcriptional analysis of RNA or DNA regulated after stimulation191–193  
6. Proteome analysis 194  
7. Colorimic or fluorescent production obtained from immune cell transduction/ 
tranfection195,196  
8. Colorimic or fluorescent production obtained from non-immune cells transduced 
to produce immune receptors197 
9. Assessment of phosphorylation of key intracellular intermediates198,199 
10. Microarray analysis of recombinant proteins to determine if receptors found on 
leukocytes can bind to a variety of ligands200–202    
 Reporters one through three are binary assays in that they measure the extent that 
an outcome either occurs or does not occur.  While if a cell lives, proliferates, or 
phagocytosis a particle in response to a challenge is useful information to know, the 
immune response is a much more complex and intricate process than the above factors.  
An analysis of functional intermediaries such as soluble factors and surface marker 
expression are not assessed in these methodologies and in order to understand the 
immune response these factors must be analyzed.  In particular DCs are insensitive to 
reporters two and three because they are not typically considered proliferative cells203 and 
thus their proliferation or lack thereof has little immunological consequence.   Similarly, 
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phagocytosis can lead to a variety of phenotypes in DCs or no change in phenotype at 
all45,204,205 and thus phagocytosis is also a poor reporter for DC function.   
 The fourth reporter, cellular adhesion/migration, is a poor indicator of DC 
phenotype as DCs up and down regulate many adhesion receptors throughout their 
maturation process.206  The end result of this maturation process, whether its pro or anti-
inflammatory, CD4 or CD8 stimulating, etc. is independent of adhesion and thus, 
adhesion is also not an ideal reporter for DC, and in general APC, activation.207    
 The next two factors are also not ideal candidates to assess DC phenotype because 
of their inability to be used across a large number of treatments in a cost effective 
manner.  Proteomic microarrays are able to assess a large variety of secreted proteins 
simultaneously and if cells are lysed they are also able to assess the expression of many 
intracellular proteins.  However, each array can only be used once and are extremely 
costly to purchase or develop.  Thus, each treatment you perform on your DCs requires 
its own assay which, if you have a 100 treatment groups, means you must have 100 
separate assays.  This approach also doesn’t account for temporality of expression which 
is also a factor in immunology and therefore more assays would be needed to determine 
the protein expression as a function of time.  Therefore, while an extremely powerful 
method, proteomic analysis is too cost prohibitive in its approach to screen multiple 
treatment groups.  A discussion of the other limitations of using transcriptional 
DNA/RNA microarrays have been discussed previously in this review and will not be 
further expounded upon here.     
 Reporters seven and eight, cell transfection/transduction assays, are limited in 
several respects.  First, these assays utilize a reporter for a single protein such as NF-B 
and then quantify how much of this factor is expressed in the cells over different 
treatments.  Because the immune response involves multiple secreted and surface 
presented proteins an analysis of a single factor, even a very important factor such as NF-
B, is insufficient to determine the functional immune response.  Secondly, DCs are very 
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difficult to stably transfect or transduce and are canonically thought to be completely 
insensitive to transduction.203 While recent reports have shown that transfection of DCs is 
possible, the efficiency of transfection is still relatively low, the amount of plasmid used 
to achieve this transfection very high, and  the transfection was only seen transiently.196  
Thus, transfecting DCs is still not a viable option for true high throughput screening 
because of its relative cost and time commitment as well as its limited timespan for use as 
a reporter.  Successful transduction of DCs has also recently been reported, however the 
MOI to transduce the cells efficiently was very high195 and thus this methodology is also 
not seen as a truly viable approach as it is cost prohibitive to transduce multiple donors at 
a quantity of cells that is high enough to be able to use in HTP screening. 
 Reporter nine, protein phosphorylation, has broad applicability for identifying 
signaling intermediates in a signaling cascade.  It has been shown that the 
phosphorylation of key signaling proteins such as JAK and STAT can be measured in 
high throughput arrays with great specificity.198,199  However, these proteins are not the 
functional effectors of the cells.  Thus, what the actual phenotypic outcome of the 
phosphorylation of these proteins is remains unknown with these assays.  Dendritic cells 
utilize the same signaling proteins across multiple receptors, (MyD88, TRIF, TRAF, 
etc.)64 and thus the increased/decreased phosphorylation of any of these signaling 
intermediates is not able to identify specifically what proteins were stimulated and what 
the likely functional outcome will be.   
3.5 Engineered Presentation of Glycans to Dendritic Cells 
 In order to harness and modulate DC phenotype in a controllable manner with 
CLRs a more mechanistic understanding of how specific glycan structures, presentation 
modalities, and molecular environments effect DC phenotype and systemic immunity 
must be had.  Natural ligands are often complex and heterogeneous in nature and can 
provide confounding factors to mechanistic studies.  In the majority of the studies 
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previously mentioned there were multiple opportunities for confounding ligand-receptor 
interactions, e.g., through protein epitopes, opsonization of the carrier, non-specific 
recognition by other CLRs, etc. While these studies were well done and had appropriate 
controls their models did not allow for a controlled mechanistic assessment of DC 
interaction.  Thus, it makes elucidation of exact molecular motifs and environments 
necessary for modulation of DC behavior (whether that be pro-inflammatory, tolerogenic, 
or phagocytic) difficult. Several studies have attempted to do this and from them better 
understanding of exact molecular characteristics necessary for modulation of DC 
phenotype have been found.  
3.5.1 Glycan Structure and Dendritic Cell Phenotype 
 In an elegant study by Wattendorf et al. human DCs were cultured with 
phagocytosable polystyrene microbeads functionalized with di-branched PLL-PEG that 
had a man, triman (α1-3 α1-6), or mannan attached to the end of the PEG branch.107  The 
mannan and PLL were passively adsorbed onto the PS beads leaving the mannan and 
PEG functionalized glycan monomers free in solution instead of being found on the bead 
surface.  This PEG branch coating had been found previously to remove non-specific 
protein adsorption and thus interactions with the bead were mediated solely by the 
intended glycan-lectin interactions. A comparison of phagocytosis between sugar 
structures was performed and it was found that the mannan coated particles had the 
highest uptake, followed by the mannose, with the lowest phagocytosis seen in the triman 
functionalized particle.  In general, however, mannose-mediated phagocytosis was lower 
than other reports in the literature and was not statistically higher than RGD immobilized 
in an identical system.  The paper accounts the absence of other mediators in the 
conjugate, such as lipid components in the lipisome used by other groups, as the reason 
for this lower uptake. Also, the study took the beads that showed the highest level of 
phagocytosis for the mannan, tri-man, and mannose and looked at DC surface marker 
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expression after incubation with these conjugates.  No change was seen in CD80, CD86, 
and MHCII from iDCs for any of the conjugates, including the mannan.  The negative 
outcome of the mannan conjugates goes against previous studies that showed that 
mannan was an immune agonist.108,208,209 However, in these studies mannan was 
combined with particulates based on liposomes linked through membrane lipids, such as 
cholesterol108 or palmitoyl-mannan.208 Therefore, it could have been the synergistic effect 
of the lipids and the mannan that led to these activation reports.  This implies that the 
Th1/Th2 cell proliferation that was seen in these studies, that were thought to be 
mediated through mannan, may not represent the result of the ligand alone but through 
the synergistic recognition of the conjugates by TLR4 and CLRs. Unfortunately, in the 
Meyer-Wentrop et al. study no analysis of cytokines was performed and thus the 
phenotype of the cells remains elusive as several reports have shown differential cytokine 
profiles without up-regulation of surface receptors in response to CLR stimulation.49,81,126   
 Several labs have shown the high specificity of lectins by taking recombinant 
forms of the receptors and incubating them with glycan structures of interest or with 
glycan microarrays.  Feinberg et al. did one of the most thorough analysis of glycan 
binding specificity of DC-SIGN to carefully controlled glycan structures.  In this paper it 
showed that di-mannose and tri-man structures have a higher affinity for DC-SIGN than 
did mannose alone and that either of two Man6 isomers bind with similar affinity which 
was 9–14-fold higher than mannose, whereas two isomers of Man9 bound approximately 
twice as strongly then the Man6 glycans. The full Man9GlcNAc2 glycan consistently 
showed 2–3-fold stronger binding than either of the Man9 isoforms.  In general anything 
with an α1-α2 mannose linkage showed a drastically higher binding affinity than did 
those structures that did not and that branched structures bound with higher affinity than 
did linear structures.  Another study by van Vliet et al. showed high specificity for MGL 
to terminal GalNAc structures when coupled to a variety of sugar backbones.  While 
binding affinity wasn’t directly assessed in this study amount of binding of glycan to an 
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array, a rough proxy for binding affinity, was assessed and it was found that terminal 
GalNAc structures showed a 12-20 times higher amount of binding than did non-GalNAc 
structures.78   Similar results to the DC-SIGN study have been confirmed by other 
researchers across different systems and array based assessment of other several other 
lectins have been performed by multiple researchers and thus these results are seen as 
robust and applicable to in vitro receptor specificity.101,210–213   
3.5.2 Molecular Factors of Glycoconjugates and DC Phenotype 
 In the study by Wattendorf et al. mentioned above not only was the glycan 
structure altered in a controllable fashion but also the density of the displayed ligand was 
varied.  Carbohydrate density on the microspheres’ surface was controlled through the 
adsorption of polymer mixtures with (ligand-free) PLL-PEG and mannoside 
functionalized PEG.  Two linker lengths were also chosen to allow for adjusted glycan 
mobility for receptor binding.  It was found that the efficiency of phagocytosis by DCs 
increased with increasing amounts of mannose exposed from microspheres’ surface 
regardless of sugar structure used.109 This was in agreement with the findings of other 
groups with different platforms for sugar presentation, such as mannosylated 
emulsions214 or liposomes.215  While the characterization of the DC phenotype in each of 
these studies was limited, generally it was found that regardless of sugar structure DC 
phenotype was not altered but phagocytosis was statistically increased as sugar density 
was increased.  Also, in a study varying density of anti-bodies to Dec-205 on the surface 
of nanoparticles the amount of anti-inflammatory cytokines increased with increasing 
amounts of Abs immobilized on the bead surface.99  Furthermore, the phagocytosis of the 
beads was also shown to increase.  While, this study was not a ligand for the CLR it does 
show phenotypic modulation of DCs with increasing ligation of CLRs. 
 To date no direct studies have been performed that compare how charge of a 
glyco-conjugate alters DC phenotype.  However, historically cationic vaccine conjugates 
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have been found to play an important role in increasing the immune response to any 
conjugate.24–28  The addition of protamine (small, arginine-rich, nuclear proteins that are 
highly positive) is a common component in microparticle vaccines to enhance 
immunogenicity.  Protamine has been shown to produce more potent anti-tumor 
vaccines,216 non-viral transduction of cells, enhanced siRNA delivery,217 enhanced 
allergy vaccine efficacy218, etc.  Another cationic polymer, poly L-lysine (PLL), has been 
shown to induce similar effects but in a more tunable fashion due to its ability to be 
engineered to desired lengths and levels of branching. 219–221 Furthermore, several 
cationic glycan carriers have shown increased phagocytosis higher than that of other 
reported glycoconjugates.222  Due to these reports carrier charge appears to be a 
promising field where little direct research has been done in the glycoimmunology field.  
 Finally, the carrier and linker that a glycan is attached to could play a large role in 
how the glycan is recognized and in what way DC phenotype is affected.  This has not 
been shown directly in immune cells.  However, Andre et al. displayed glycans to cells 
expressing transduced forms of CLRs and compared cell adhesion to glycan presenting 
compounds across flexible and rigid scaffolds and also compared differing spatial 
arrangement of ligands presented on two rigid macrocyclic scaffolds.223 They found that 
reduction of the inherent level of flexibility of the linker had a favorable impact on cell 
binding especially for cells displaying a high CLR density, and the structure of the carrier 
can modulate inhibitory potency when comparing different lectins.  This not only shows 
that lectin affinity can be modulated via linker properties but it also shows that different 
lectins have a differential ideal molecular signature that is optimal for maximum glycan 
binding.   In addition to conformational restraints it was shown that three-dimensional 
presentation of glycans drastically altered cellular adhesion.223  While a fully reductive 
study has not been performed with DCs the important role that carrier and linker play in 
CLR recognition in DCs can also be indirectly observed by the differential phenotypes 
noted in the papers displaying mannan to DCs via differential linkers.108,208 Cui et al. 
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utilized cholesterol as the linker and found enhanced CD80 and CD86 levels on the 
surface of DCs and increased peptide presentation by the MHC class-1 molecule.108  
While the paper by Jain et al. showed DC phenotype that had been pushed toward 
increasing the Th2 responses due to increased IL2 and MHC class II presentation.  The 
conclusion that carrier properties can modulate DC response was further supported by 
literature from van Stijn et al.149 which showed that recognition of soluble glycolipid 
motifs were able to activate DCs but could not activate DCs with any single component 
of the carrier.   
3.5.3 Modality of Glycan Display Altering DC Phenotype 
 Soluble and phagocytosable glycan presentation to APC has been studied but little 
direct comparative data between the two and no comparison to non-phagocytosable well 
surface displayed glycans has been seen.20,21  Furthermore, due to the extremely limited 
supply of well-defined oligosaccharides capable of being obtained via synthetic or 
biological means surface interaction with recombinant CLRs or other lectins to glycan 
microarrays has been used as a proxy for direct cellular response for glycoconjugate 
creation and therapeutic approaches.22,23  The experiments performed herein seek to 
address these issues by use of a novel cellular HTP methodology perfected in house.224  
This method allows for an order of magnitude less glycan to be used than previous 
functional assays, both pro- and anti-inflammatory immune responses to be monitored, 
and testing of multiple surface display modalities simultaneously. Additionally, the 
studies performed here challenge the conventional view that glycan structure and density 
of presentation alone determines phenotypic modulation of DCs.  
 Several studies have analyzed the cell response to glycans between soluble and 
particulate modalities but these studies used complex not well defined systems to identify 
differential activity that could be confounded by a variety of factors.  For instance Qi et 
al.225  looked at the differential effect of β-glucan in particulate (nanoparticle) and soluble 
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form on DC phenotype.  They found that β-glucan particles, derived from yeast, activated 
DCs and macrophages via dectin-1 stimulation and that β-glucan delivered in its soluble 
form caused no increase in activation markers.225  When used in an in vivo study the 
particulate delivered β-glucans showed potent anti-tumor effects: down-regulating Tregs 
and delaying tumor progression while the β-glucan in soluble form had no therapeutic 
effect but significantly augmented antitumor monoclonal antibodies.225 However, the β-
glucan particles were not characterized for molecular weight, size, glycan structural 
composition, and were known to have variability in protein composition. All of these 
factors could easily influence the affects seen and confound the results obtained.  Another 
study comparing particulate and soluble presented carbohydrates was performed by Le 
Cabec et al.112 who showed that when chinese hamster ovary (CHO) cells were 
transfected to express mannose receptor (MR) it mediated endocytosis of mannosylated 
glycoproteins in solution but did not support phagocytosis of three of its known 
particulate ligands: zymosan, Mycobacterium kansasii, and mannosylated latex beads. 
The cells were shown to possess phagocytic machinery when other receptors were 
expressed on them and thus it was concluded that MR alone was not sufficient to trigger 
phagocytosis and that there must be co-stimulatory receptors on macrophages and DCs 
that, in concert with MR, were able to cause phagocytosis.  Furthermore, a differential 
response from DC receptor ligation when identical ligands were presented in different 
modalities was shown in this study.  However, in this study CHO cells were transduced 
to express human MR and therefore strict conclusions between these cells and naturally 
occurring DCs/macrophages is difficult. 
 A variety of studies have shown that modulation of DC phenotype with 
phagocytosable nano- and micro-particles bearing carbohydrates is possible.107,108,208,209,226  
These studies have shown that increased ligand density as well as sugar structure play an 
important role in phenotype modulation.  Thus, it is known that particulate delivered 
glycans are able to be seen and recognized by DCs but no comparisons have been 
 47 
performed as to whether this response is consistent when ligands are displayed across 
different modalities. 
 Non-phagocytosable surface display of glycans has not been as intensively 
studied as soluble and particle delivery of glycoconjugates.  However, van Vliet et al. 
showed that GalNAc (Tn antigen) when immobilized on a non-phagocytosable surface, 
drastically alters DC mobility as compared to other sugars.20  The Tn antigen has also 
been shown to affects DC differentiation and maturation227 whereas MUC1 purified from 
tumor cells, which is extremely high in GalNAc, induced differentiation of DCs, but 
prevented the development of an efficient Th1-type response.
228  Napoletano et al. 
observed that a Tn- conjugated protein did not affect DC differentiation or their ability to 
produce IL-12p70 and that Tn-protein can specifically bind MGL expressed by iDCs and 
this binding resulted in the internalization of the glycopeptides and their delivery into 
HLA class I and II compartments.229  Furthermore, several labs have shown the high 
specificity of lectins by taking recombinant forms of the receptors and incubating them 
with glycan structures of interest or with glycan microarrays.  A study by van Vliet et al. 
showed high specificity for MGL to terminal GalNAc structures when coupled to a 
variety of sugar backbones.78  While binding affinity wasn’t directly assessed in this 
study amount of binding of glycan to an array, a rough proxy for binding affinity, was 
assessed and it was found that terminal GalNAc structures showed a 12-20 times higher 
amount of binding than did non-galNAc structures.78   Similar results have been seen 
with DC-SIGN and have been confirmed by other researchers across different systems 
and have been performed by multiple researchers and thus these results are seen as robust 
and applicable to in vitro receptor specificity.101,210–213  In conclusion, from these reports 
it is clear that modality of presentation of glycan to DCs drastically alters the outcome 
and that a direct comparison between display modalities using well defined ligands is 
needed. 
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3.6 Motivations for Research 
 From the literature review it is clear that DCs are powerful immunomodulators 
and that the lectins they express have the ability to tune the DC phenotype toward a pro-
inflammatory or anti-inflammatory phenotype.  Furthermore, glycan presentation to DCs 
has been shown to produce sensitive and specific immune responses from DCs. Thus, it is 
hypothesized that glycans could have significant impacts when designing the next 
generation of biomaterials and combination products.  However, from Chapter 3.5 it is 
clear that current research has focused little attention to non-phagocytosable display of 
glycans to DCs.  To date few studies have placed glycans on a non-phagocytosable 
surface and analyzed the DC response to the presented glycans.  Thus, little information 
is known about optimal molecular factors for phenotype modulation of DCs toward a 
pro-inflammatory or anti-inflammatory state.  If glycans are to be used in biomaterial 
coatings or combination products a more in-depth knowledge of the molecular factors 
important for DC stimulation must be had.  Also, no evidence linking the DC response to 
glycans and glycoconjugates delivered across different presentation modalities has been 
seen in the literature.  This is of importance to the field because with the growing 
popularity of glycan microarrays in glycomics it is critical that an association between 
lectin binding on these surfaces and functional cell responses in vitro and in vivo be 
obtained.  Finally, due to the extremely limited supply of complex glycan structures that 
are capable of being obtained, in-depth, fully reductive cell response to glycans and 
glycoconjugates experiments are almost impossible to perform.  Thus, it is thought that 
modeling can solve these problems by identifying molecular factors of importance for 
simple sugars and extrapolating them to more complex sugar structures.  This has been 
performed previously with other materials and DCs47,55 and thus it is expected that 
modeling can be used with glycans to predict DC phenotype in response to surface 
presented glycoconjugates.   
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CHAPTER 4  ELUCIDATION AND OPTIMIZATION OF 
PERTINENT MOLECULAR FACTORS FOR DENDRITIC CELL 
RESPONSE TO ADSORBED GLYCOCONJUGATES 
4.1 Overview 
Optimal molecular factors for glycans presented from non-phagocytosable surfaces 
to DCs for maximal phenotypic modulation has not been studied to date.  Due to the 
pleiotropic effects of CLRs in DCs, the optimization of presentation of glycans to the 
immune system has implications in both vaccine design and implanted devices where a 
tolerogenic immune response is desired.  This study began with an assessment of carrier 
appropriateness for glycan presentation to DCs using a novel, in house, high throughput 
assay.  Then DC response to a range of carriers that had been engineered to vary in 
charge and density of glycan presentation was assessed.  Next, the properties of the 
carrier were modeled using a multivariate regression and trends for ideal properties of 
non-phagocytosable display of glycan for maximal DC inflammatory response were 
identified.  The DC response to the adsorbed conjugates was then assessed in the 
presence/absence of EDTA to determine the CLR dependence of the interaction with the 
conjugates.  Next, conjugates were created with the optimized carrier charge and density 
found from the modeling but with six new complex carbohydrate structures.  Finally, 
after assessing DC phenotype to these conjugates a model was created to assess the 
importance of various structural motifs found in the carbohydrate structures.  
It was found that highly cationized (pI above 9.75) high density (more than 20 
glycans/BSA) glycoconjugates were able to stimulate DC phenotype to the greatest 
extent.  Furthermore, DC response to these conjugates was mediated by EDTA and 
therefore inferred to be CLR mediated.  Finally, DC response to optimized conjugates 
presenting oligomannose glycans was found to be structure dependent and when 
modeled, unique epitopes were found to be predictive of DC phenotype. 
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The experiments in this chapter show that density of glycan display and charge of 
carrier are critical for significant alteration of a proinflammatory maturation factor used 
to assess DC phenotype.  This response is mediated by lectins and is structure specific as 
several polymannose structures did not show DC maturation.  Furthermore, the model 
from this chapter show that grouping glycan structure by terminal glycan motif 
significantly influences a proinflammatory maturation factor used to assess DC 
phenotype.  The exact molecular mechanisms for why and how phenotype modulation is 
occurring were not uncovered in this report but future works are discussed to address this 
shortcoming.   
4.2 Materials and Methods 
4.2.1 Fluorescent Modification and Biotinylation of Glycans 
 Isolation, functionalization, and quantification of Man5-br was performed via an 
established method.210  Briefly, ribonuclease B (RNase B) was denatured using a 
denaturing buffer (20%SDS, 2.5M Tris pH 6.8, 14.3mM beta-mercaptoethanol) at 100˚C 
for 10 minutes. The solution was then allowed to cool and the denatured protein was 
digested using pronase.  After digestion the RNase B was diluted 1:5 with Nonidet-P40 
and 1:5 of solution of 50 mM Sodium Phosphate and the N-linked glycans were removed 
by Peptide N-Glycolsidase F (PNGase F).  The cleaved free reducing glycans were then 
isolated via carbograph and C18 cartridges (Pierce).  
 The glycans were then functionalized with a fluorescent linker to be used to 
further purify and isolate individual glycan structures.  This functionalization was done 
using a 90mg/ml 2-Amino-N-(2-amino-ethyl)-benzamide (AEAB; A gift from Dr. 
Richard Cummings, Emory University) solution which was prepared in a DMSO/Acetic 
acid (7:3 v/v) solution.  To this solution NaCNBH3 was added to a concentration of 1M, 
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64mg/ml.  To this solution free reducing glycans were quickly added at a molar ratio of 
1:10 to the AEAB.  The solution was vortexed heavily for 20 seconds and allowed to 
react for three hours at 65˚C.  After which acetonitrile was added to the solution at a 10:1 
volume ratio and vortexed.  The solution was then cooled to -20°C and spun down at 
10,000g for 5 minutes.  The supernatant was aspirated and discarded and the glycan-
AEAB/AEAB pellet was vacuum centrifuged for 2 hours or until the remaining pellet 
was completely dry.  The pellet was then dissolved in 1ml of water and fractions were 
collected using reverse phase HPLC with an excitation of 330 nm and emission at 420 
nm.  The collected conjugates were then frozen and lyophilized.  
 Glycan-AEAB conjugates were thiolated via Traut’s reagent using a known 
protocol.230  Briefly, Glycan-AEAB conjugates were dissolved in 2 mM endotoxin free 
EDTA (Sigma).   A 10 fold molar excess of Traut's reagent (Pierce) was then added to 
the protein solution and allowed to react for one hour at room temperature. After 
conjugation the glycoconjugates were purified using 10K Membrane Centrifugal Filter 
Unit (Milipore) using 9 rounds of 1:10 buffer exchanges against distilled, endotoxin free, 
water.  The glycan solutions’ sulfhydryl groups were then measured using Ellman's 
Reagent (Pierce) and compared to a standard thiol solution for molar concentration.   
Glycan-biotin conjugates used in the carrier selection study were created using 
thiol-OEG2 functionalized glycans (Sussex Research) and maleimide-PEG2-biotin 
(Pierce) using a standard protocol.231  Briefly, thiol-OEG2 functionalized glycans (Sussex 
Research) were reduced in TCEP reducing gel (Pierce) in sealed spin cups (Pierce) for 
one hour in degassed buffer 1 (0.1M EDTA, 0.15M NaCl, 0.1M NaH2PO4) at room 
temperature while shaking at 600RPM.  Glycans were then spun down at 100 RCF and 
the resultant effluent was immediately added to 20mM maleimide-PEG2-biotin to a 
concentration of 10 to 1 molar ratio of biotin to glycan.  The maleimide-PEG2-biotin was 
dissolved in moisture free DMSO prior to addition of the glycan solution.  The solution 
was allowed to react overnight at 4°C  
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4.2.2 Carrier Functionalization and Purification 
Thiol-OEG2 functionalized glycans (Sussex Research) or OEG3-SH (A kind gift 
from Dr. Daniel Ratner) were reduced in TCEP reducing gel (Pierce) in sealed spin cups 
(Pierce) for one hour in degassed buffer 1 (0.1M EDTA, 0.15M NaCl, 0.1M NaH2PO4) at 
room temperature while shaking at 600RPM.  Glycans were then spun down at 100 RCF 
and the resultant effluent was immediately added to 1mg/ml Maleimide functionalized 
carrier protein, OVA or BSA (Pierce) in the indicated molar ratio as compared to the 
maleimide functionalized carrier (0:1, 1:1, 25:1 or 100:1 sugar: carrier ratio).  The 
conjugates created for the initial carrier selection study were all reacted at 100:1 sugar to 
carrier molar ratios.  The carriers were dissolved in degassed Buffer 1 and after 
combining the reduced glycan and the carrier, argon gas was passed over the solution and 
the tubes were sealed with paraffin and allowed to react for 16 hours at room 
temperature.  After conjugation the glycoconjugates were purified using 10K Membrane 
Centrifugal Filter Unit (Millipore) using 9 rounds of 1:10 buffer exchanges against 
distilled, endotoxin free, water.  The glycoconjugate solutions were then assessed for 
their protein concentration using a micro-bicinchoninic acid (BCA) assay and 
resuspended at 1mg/ml.  Conjugates with permanently opened rings were created via 
periodate oxidation and sodium borohydride reduction via the standard protocol.232 
An identical procedure was followed for the GlcNAc, Man3-Br, Man3-A2, Man4-
A2, Man5-Br, and Man5-A conjugates except that only a molar ratio of 100:1 
glycan:BSA was used. All glycan thiols were given by Dr. Daniel Ratner, University of 
Washington or produced as discussed in section 4.2.2 of this document and thiolated via 
Traut’s reagent (Pierce). 
4.2.3 Cationization of Carrier 
 Prior to beginning cationization, three solutions of ethylenediamine (EDA) (0.1, 
0.3, or1.8M) were prepared and pH adjusted to pH 4.5 using 2M NaOH and ultrapure 
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endotoxin free water.  Additionally, a 200mg/ml 1-Ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC or EDAC; Pierce) was prepared using ultrapure 
endotoxin free water.  Using a stock 1mg/ml glycoprotein solution a 1:1 volume ratio of 
EDA was added to the glycoprotein making the final concentration of EDA 0.05, 0.15, or 
0.9M.  0.9M EDA was used in all cases where excess EDA is specified.  To these 
solutions EDC was added until EDC reached a 7.5mM concentration. The resultant 
glycoprotein, EDA, and EDC solution was then immediately vortexed for 30 seconds and 
allowed to react for two hours at room temperature while being shaken at 900RPM.  
Then, 0.5 volume percent of 4M acetate buffer, pH 4.75, was added to the glycoprotein 
solutions to quench the EDC reaction.  After conjugation the glycoconjugates were 
purified using 10K Membrane Centrifugal Filter Unit (Millipore) using 9 rounds of 1:10 
buffer exchanges against distilled, endotoxin free, water.  Figure 2 shows an overview of 
the process of creating each of the conjugates and gives a list of all 40 conjugates created. 
 
Figure 2:  Process and characterization methodology that was used to create the 40 
conjugates tested in Figure 9. 
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4.2.4 Streptavidin Preparation and Glycoconjugate Presentation 
 A 384 well tissue culture polystyrene (TCPS) plate was coated with 20µg/ml 
streptavidin or 20µg/ml of the BSA glycoconjugates overnight at room temperature.  
Next, for the streptavidin coated wells, the plates were washed 5 times with a wash 
solution 1 (1mM PBS, 0.5mg/ml HSA, and 0.01% TWEEN20) and then biotinylated 
glycans at 40µM were incubated in the plate for 2 hours at 37°C.  Then, all the wells 
were washed with complete DC medium (RPMI-1640 (Invitrogen) supplemented with 
10% heat inactivated fetal bovine serum Cellgro MediaTech) and 100 U/ml 
penicillin/streptomycin (Cellgro MediaTech)) and blocked for two hours at 37°C with 
5mg/ml biotin free HSA in 0.1M NaHCO3.  After blocking the plates were then washed 
5x with complete DC media and 40 µl of cells at 7.5x 105 cells/ml were added to each 
well.   
4.2.5 Preparation and Assessment of ζ-Potential, Mass and Endotoxin Content of 
Glycoconjugates 
 Mass spectra of the cationized and non-cationized glycoconjugates were 
determined using Matrix Assisted Laser Desorption Ionization (MALDI) Mass 
Spectrometry.  The glycoconjugates were first dissolved in ultrapure, endotoxin free 
water, and then were spotted in a 1:1 vol. ratio with diammonium hydrogen citrate (DHC) 
onto a MALDI plate.  A linear positive detection method was used for the conjugates.  
Mass profiles were then exported, plotted and the mean of each mass peak was 
determined.  After verification of functionalization and determination of number of 
glycans/BSA the glycoconjugates were then resuspended at 3.0 mg/ml in PBS, aliquoted 
and frozen for later use.   
 To determine the isoelectric point of all glycoconjugates conjugates were diluted 
to 500ng/ml in ultrapure endotoxin free water and then each conjugate was divided 
between five different cuvettes.  The pH in each cuvette was then adjusted to 3.0, 5.0, 
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7.0, 9.0, or 11.0 using 1M sterile NaOH or 1M sterile HCl. Using a Malvern Nano-
zetasizer the ζ-potential and hydrodynamic radius of each solution was then determined.  
The pH vs the ζ-potential was then plotted and the subsequent isoelectric point of each 
conjugate was then determined via interpolation of the least squares regression to which 
point the ζ-potential equaled 0.  The solutions for each conjugate were then recombined, 
lyophilized, quantified via BCA assay, resuspended at 3000ug/ml in PBS, and aliquoted 
and frozen for later use. 
 The endotoxin contents of the glycoconjugates at a concentration of 100µg/ml (5x 
the coating concentration used) were measured using an endotoxin assessment kit (QCL-
1000 LAL assay, Lonza).  Briefly, 50µl of 100µg/ml of pre-warmed glycoconjugates in 
PBS were incubated at 37˚C with 50 µl of LAL Proenzyme for 10 minutes.  Next, 100µl 
of chromogenic substrate was added and allowed to incubate for six minutes.  Then 100 
µl of 25% (v/v) Glacial acetic acid in distilled water was added to stop the reaction.  The 
absorbance at 405 nm was taken for conjugates and standards and the endotoxin content 
of all glycoconjugates was determined to be less than 0.2 EU/mL, which is well below 
the FDA limit of 0.5 EU/mL.  Furthermore, all mannose conjugates were below the 
detection limit of the assay for endotoxin content.  All conjugates tested in this paper 
were from a single preparation and thus the parameters determined by the above 
procedure are applicable for all figures and tables seen in this report. 
4.2.6 Enzyme Linked Lectin Assay for Adsorbed Glycoconjugates   
 A tissue culture polystyrene (TCPS) plate was coated with 20µg/ml streptavidin 
or 20µg/ml of the cationized BSA glycoconjugates overnight at RT.  Next, for the 
streptavidin coated plates, the plates were washed 5 times with a wash solution 2 (1mM 
PBS, 0.5mg/ml BSA, and 0.01% TWEEN20) and then biotinylated glycans at 40µM 
were incubated in the plate for 2 hours at 37°C.  Then, all the plates were washed and 
blocked for two hours at 37°C with 5mg/ml biotin free HSA in 0.1M NaHCO3 and 0.1% 
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TWEEN 20.  After blocking the plates were washed 5x with the wash solution 2. Next, a 
lectin specific for the given sugar 15 µg/ml Narcissus pseudonarcissus-biotin (NPA-
biotin) (EY Labs; specific for α-D-mannose) or 15 µg/ml Concanavalin A-biotin (ConA-
biotin) (Sigma; specific for mannose or glucose) was incubated with the adsorbed 
conjugates for two hours at 37°C. The plates were then washed 5 times with the wash 
solution 2 and 50µl of a streptavidin-HRP (BD Pharmingen) solution diluted 100x with 
PBS from stock was added to each well and allowed to incubate in the well for 2hrs at 
RT.   The plate was then washed 5x more with the wash solution 2 and a TMB (3,3',5,5'-
tetramethylbenzidineperoxide) substrate (BD Pharminogen) was added and the plates 
allowed to develop for 10 minutes.  Then, 1.0N sulfuric acid was added to stop the 
reaction and the absorbance at 450nm was determined.  A preliminary study was 
performed and it was found that for all biotinylated sugar structures 4000 pmol of 
biotinylated glycan needed to be delivered per well, (40 µM) in order for binding sites to 
be maximized, data shown in Appendix Figure A 1.  Figure 3 below shows the overall 
process used in this assay for either streptavidin presented glycans or BSA-adsorbed 
glycoconjugates.   
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Figure 3:  Procedure for ELLA used for adsorbed streptavidin or adsorbed BSA 
glycoconjugates. 
4.2.7 Dendritic Cell Culture 
 Human blood was collected from healthy donors with informed consent and 
heparinized (333 U/ml blood) (Abraxis Pharmaceutical Products, Schaumburg, IL) at the 
Student Health Center Phlebotomy Laboratory, in accordance with protocol H10011 of 
the Institutional Review Board of Georgia Institute of Technology. Dendritic cells were 
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derived from human peripheral blood mononuclear cells (PBMCs) using a previously 
described method233 with some modifications.224 Briefly, the collected blood was diluted 
1:1 in Mg2+ and Ca2+ free phosphate buffer saline (D-PBS; Invitrogen, Carlsbad, CA), 
and the PBMCs were isolated by differential centrifugation using lymphocyte separation 
medium (Cellgro MediaTech, Herndon, VA). After the lysis of residual erythrocytes with 
RBC lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA), the PBMCs were 
washed with D-PBS. Ten milliliters of PBMCs were plated in a Primaria 10x20 mm2 
tissue-culture dish (Becton Dickinson, Franklin Lakes, NJ) at a concentration of 5x106 
cells/ml in DC media [RPMI- 1640 (Invitrogen), 10% heat inactivated FBS (Cellgro 
MediaTech) and 100 U/ml of penicillin/streptomycin (Cellgro MediaTech)]. After 2 
hours of incubation at 95% relative humidity and 5% CO2 at 37˚C for the selection of 
adherent monocytes, the dishes were washed three times with warm DC media to remove 
non-adherent cells. The remaining adherent monocytes were incubated with 10 ml/plate 
fresh warm DC media, supplemented with 1000 U/ml GM-CSF and 800 U/ml IL-4 
(PeproTech, Rocky Hill, NJ), for 5 days to induce the differentiation of monocytes into 
iDCs 
4.2.8 Exposure of DCs to glycoconjugate adsorbed wells 
 On day 4 after DC isolation glycan solutions were added to wells of a 384-well 
TCPS plate in quadruplicate.  The solutions were allowed to incubate in the well in a 
humidity chamber at 37°C overnight.  On day 5 of culture, loosely adherent and non-
adherent cells containing iDCs were harvested and resuspended in DC media with 1000 
U/ml GM-CSF and 800 U/ ml IL-4 at 7.5x105 DCs/ml. These cells were plated in 40 µl 
of cell suspension (3.0x104 DCs) on glycoconjugate adsorbed wells in quadruplicate in 
the wells of the coated 384 well TCPS plate. The extent of DC maturation was compared 
to untreated DCs (iDCs) for the negative reference control and lipopolysaccharide (LPS) 
(1 mg/ml; E. coli 055:B5; Sigma)-treated DCs (mDCs), adsorbed zymosan A 
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(Saccharomyces cerevisiae; Sigma), or Mannan (Saccharomyces cerevisiae; Sigma) for 
the positive reference control for IMF.  The positive control for the TMF (tDC) is human 
IL10 and human IFNα (R & D Systems) treatment of DCs for 24 hours at 3500 units/ml 
and 35000 units/ml respectively.   
4.2.9 High Throughput Evaluation of Dendritic Cell Phenotype to Adsorbed 
Glycoconjugates 
 Differentially-treated and reference control DCs were harvested after 24 h for 
analysis using an HTP method previously described with modifications. 224  Briefly, DCs 
were placed in treatment wells on day 5 after isolation at 7.5x105 cells/ml.  After 24 hours 
all treated DCs and controls were transferred via multi-channel pipette to a black 384-
well filter plate (Pall Life Sciences), and the supernatants were immediately collected 
into a 384-well plate through the filters by stacking the filter plate on top of the collection 
plate and centrifuging at 300 RCF for 4 min.  While spinning down the filter plate, wells 
of the TCPS plate with glycoconjugates adsorbed to them were incubated with Non-
Enzymatic Cell Disassociation Solution (CDS; Sigma).  The CDS treated cells were then 
lightly pipetted up and down and transferred to the black filter plate after its first spin-
down. The CDS was removed by stacking the filter plate on top of a new collection plate 
and centrifuging at 400 RCF for 4 min.  To the retained cells 50 µl of 0.05% 
formaldehyde solution was added and the cells were allowed to fix for 40 minutes at 
room temperature while being shaken at 600 RPM. The formaldehyde solution was then 
removed via centrifugation at 400 RCF for 4 minutes.  The cells retained in the wells 
were assessed for phenotype by immunostaining using antibodies anti-CD86-PE (Clone 
BU63; Ancell), anti- DC-SIGN-FITC (Clone 120507; R & D Systems), and anti-ILT3-
AF647 (Clone ZM4.1, Biolegend). IgG1-PE (clone MOPC31C; Ancell) and IgG2B-FITC 
(clone 133303; R&D Systems) isotype-stained DCs were used for background 
fluorescence subtraction in separate treatment for control wells. CD86 is a costimulatory 
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molecule that is up-regulated upon pro-inflammatory DC maturation,224 DC-SIGN is an 
endocytic receptor that is slightly down-regulated upon pro-inflammatory maturation,224 
and ILT3 is a member of the immunoglobulin superfamily which signals via the 
immunoreceptor tyrosine-based inhibitory motifs and is up-regulated upon anti-
inflammatory DC maturation.234  After 30 minutes of staining the cells were washed three 
times. For each well, at the emission/excitation wavelengths for each fluorophore 
535/590 PE, 485/535 FITC, and 650/668 AF647.  The geometric mean fluorescent 
intensities (gMFIs) were then calculated with a Tecan Infinite F500 microplate reader, 
and the ratio of respective gMFIs were determined as CD86/DC-SIGN, a cell number 
independent metric named “inflammatory maturation factor” (IMF), and ILT3/CD86, a 
cell number independent metric named “tolerogenic maturation factor” (TMF) was used 
to represent DC phenotypic outcomes.  Figure 4 shows a schematic of the 384 well plate 
high-throughput methodology for assessment of DC phenotype to adsorbed 
glycoconjugates.   
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Figure 4:  Diagram of the high throughput cellular assay to assess IMF and TMF of 
DCs when exposed to adsorbed glycoconjugates.   
 
For the studies where EDTA was used to block CLR receptors, cells were treated 
with either 10mM or 5mM EDTA for one hour at 37°C before exposure to 1 µm bead 
adsorbed glycoconjugates.  Cells were then transferred, with media still containing 
EDTA, to the wells with the adsorbed glycoconjugates and the subsequent phagocytosis 
of the 1 µm beads was assessed after 4hrs or DC phenotype assessed via the above HTP 
methodology after 24hrs.  For assessment of phagocytosis cells were transferred to a filter 
plate, washed with PBS, fixed with 1% formaldehyde for 30 minutes, washed again with 
PBS, and incubated with 0.1% trypsin for 1 minute.  Cells were then washed three times 
with PBS, and visualized via a Nikon Ti fluorescent microscope (Nikon, Tokyo).   
 62 
4.2.10 Viability/Cytotoxicity of Glycoconjugates 
 Cytotoxicity associated with adsorbed glycoconjugate treatment was assessed via 
live/dead staining of the cells using a predefined method.235  Briefly, cells were treated 
with adsorbed glycoconjugates as in the HTP methodology for 24 hours.  Cells were 
transferred to a 384 well filter plate and supernatants removed as in the HTP 
methodology.  The cells were then stained with calcein AM and ethidium homodimer-1 
for 40 minutes.  Cells were then washed 3x with PBS and the fluorescent intensity of the 
cells (excitation/emission 495/530 nm – live and 528/630nm – dead) was taken.  
Additionally, the amount of cell apoptosis was of interest due to possibility that cells 
were impermeable to Ethidium homodimer but still in the process of apoptosis.  To assess 
apoptosis DCs were stained for Annexin V-FITC and the extent of binding to 
phosphatidylserine was measured via the HTP format.  No treatments showed a 
significantly different viability from untreated cells and no treatment showed a statistical 
increase in Annexin V binding. 
4.2.11 Statistical Analysis 
 To observe any significant differences between all sample groups in pairs, a 
pairwise two-way ANOVA followed by Tukey’s posttest was performed using the SAS 
software (Cary, NC), and the p-value equal to or less than 0.05 was considered 
significant.  Significance of general linear statistical model parameters discussed in 
section 4.2.12 of this report and seen in Equation 1a-d and Equation 2 was determined 
by T value in reference to referent group discussed in section 4.2.12 of this report. 
4.2.12 Statistical Modeling  
Table 2 lists the quantitative parameters that were collected and separates them by 
variable classification: Continuous, categorical/nominal, and binomial.  The 
characterization of the variables Inflammatory Maturation Factor (IMF), Tolerogenic 
Maturation Factor (TMF), isoelectric point of glycoconjugate, ligand  attached to carrier, 
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donors, and density  of sugars per glycoconjugate can be seen in Table 2A-C.  Table 2A 
contains IMF, TMF, isoelectric point, and density continuous variables.  Table 2B 
contains the variables:  Ligand, Isoelectric point, density and donor.  There were 13 total 
donors for this analysis.   
Equation 1a-d shows general linear models that have IMF (a,b) or TMF (c,d) as 
outcome variables and are a function of the isoelectric point of the conjugates, the ligand 
conjugated to BSA, the number of ligands per BSA, and the donor. The models in 
Equation 1a-d sought to isolate and compare the isoelectric point, or ligand density to 
that of a reference group, denoted below.  The null hypothesis was that charge or density 
did not play a role in IMF or TMF and thus that these variables, is continuous or 
categorical form, would not have a significant T value when compared to the referent 
group discussed below.  Equation 1a and Equation 1c both use isoelectric point and 
density as continuous variables while Equation 1b and Equation 1d treat isoelectric 
point and density as categorical variables.  This was done to first isolate the significance 
of these factors in their continuous form and then to quantitatively compare the effect of 
the categories to each other without bias of scale in the categorical models.  The coding 
of these variables is shown to denote the reference group, always denoted by the coding 
value of 0.  The reference ligand was none and thus its value for this variable is shown as 
0 in Table 2B.  Three other ligands were analyzed in this model:  oligoethylene glycol 
linker (OEG), glucose (Glc), and mannose (Man).  Similarly, non-cationized conjugates 
with no ligands attached to them were counted as the reference groups for both isoelectric 
point and density.    Finally, the variable donor was included in the analysis to account 
for the repeated measures of each donor across conjugates and to help limit the large 
inter-donor variability that is seen with primary donors.  The reference donor was chosen 
at random and because all other factors control for donor in their calculation of beta no 
influence on the calculated coefficients or their significance was seen when changing 
between reference donors.   
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IMF = β1 + β2*Isoelectric + β3*ligand + β4*density + β5*donor Equation 1a 
IMF = β1 + β2*Isoelectric_cat + β3*ligand + β4*density_cat + β5*donor Equation 1b 
TMF = β1 + β2*Isoelectric + β3*ligand + β4*density + β5*donor Equation 1c 
TMF = β1 + β2*Isoelectric_cat + β3*ligand + β4*density_cat + β5*donor Equation 1d 
 
To better understand how the models utilizes these categorical variables Table 2C 
further divides several of the variables defined in Table 2A and B into binomial variables.  
In each case the variables have been divided such that the group that is being analyzed is 
singled out from the rest of the population.  For instance the ligand is divided into three 
dummy variables OEG, Glc, and Man and the no ligand is still the global reference group 
and thus its value is always 0 so no dummy variable is needed to define this parameter.  
The variables density and isoelectric point were also divided into three dummy variables 
denoted as low, medium, and high respectively.  Finally, the donor variable was redefined 
as a series of binomial variables each depicting a unique donor (not shown in Table 2C).  
Therefore, the reference group was any donor with a conjugate that had no cationization, 
no ligand, and thus no ligand density.  
Table 2:  Analysis of Continuous Variables Measured for Regression Analyses 




Number of Measures 
520 520 520 520 
Mean 0.952 0.109 8.102 8.905 
Standard Dev. 0.433 0.133 2.097 9.418 
Minimum 0.326 -0.491 3.47 0 
Maximum 3.846 0.527 10.1 34 
Skewness 1.481 0.033 -0.932 1.113 
Kurtosis 1.040 2.030 -0.642 0.018 
 
Table 2B:  Analysis of Nominal Variables Measured and Coding Convention for 
Regression Analyses.  Count refers to number of measures of IMF or TMF for that 
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class of variable that were measured.  Percentage refers to the percent of total 
measures the individual class variable count accounts for. 
Variable Sub Category Code Count*1 Percentage*2 
Ligand     
 
None 0 52 10.0 
 
OEG 1 156 30.0 
 
Glc 2 156 30.0 
 







No Cationization (pI < 5.5) 0 117 22.5 
 
Low (5.5 ≤ pI < 7.75) 1 39 7.5 
 
Medium (7.75 ≤ pI < 9.5) 2 169 32.5 
 







None ( 0 ) 0 52 10.0 
 
Low (den. < 5) 1 182 35.0 
 
Medium (5 ≤ den. < 20) 2 182 35.0 
 







1-13 1-13 40 100.0 
*1 Count refers to number of measures of IMF or TMF for that class of variable that were measured.   
*2 Percentage refers to the percent of total measures the individual class variable count accounts for. 
 66 
Table 2C:  Analysis of Binomial Variables Measured and Coding Convention for 
Regression Analyses.  
 
Category Coding Count*1 Percentage*2 
Ligand     
      OEG      Not OEG 0 364 70.0 
      OEG OEG 1 156 30.0 
    Glc Not Glucose 0 364 70.0 
    Glc Glucose 1 156 30.0 
       Man 
Not 
Mannose 
0 364 70.0 
       Man Mannose 1 156 30.0 
Isoelectric Point 
    
       Low Not Low 0 481 92.5 
       Low Low 1 39 7.5 
              Medium Not Medium 0 351 67.5 
              Medium Medium 1 169 32.5 
         High Not High 0 325 62.5 
         High High 1 195 37.5 
Density 
(Sugars/BSA)     
       Low Not Low 0 338 65.0 
       Low Low 1 182 35.0 
              Medium Not Medium 0 338 65.0 
              Medium Medium 1 182 35.0 
         High Not High 0 416 80.0 
         High High 1 104 20.0 
*1 Count refers to number of measures of IMF or TMF for that class of variable that were measured.   
*2 Percentage refers to the percent of total measures the individual class variable count accounts for. 
 
Equation 2 shows a general linear model that has IMF as an outcome variable 
and is a function of the ligand conjugated to BSA (ligand), the number of ligands per 
BSA divided as indicated in Table 3B (density_cat), and the donor (donor). The models 
in Equation 2  sought to isolate and compare the structural motifs present in the ligands 
outlined in Table 3B controlling for ligand density and donor.  The null hypothesis was 
that ligand structure did not play a role in IMF and thus that this variable would not have 
a significant T value when compared to the referent group discussed below.  Table 3 lists 
the quantitative parameters that were collected and separates them by the variable 
classifications continuous and categorical/nominal.  The variable breakdown and 
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nomenclature is identical to that of the first model for the second model in this paper but 
instead of four ligand structures in the second model there are seven.  Also, because an 
optimized carrier was used no ranges in cationization were seen and the TMF was not 
assessed due to its insignificance from the first model.  The seven structural motifs 
assessed in the second model are None, OEG, N-acetylglucosamine (GlcNAc), Mannose 
(Man), Glucose (Glc), Terminal Branched Mannose (Branch), and α1-2 Terminal 
Mannose (Alpha).  The model from Equation 2 utilizes an identical subdivision of 
categorical variables into binomial variables as model 1 (seen in Table 2C). However, an 
equivalent table was not created for this model because structurally it is an identical 
process as that of model 1.  All categorical variables were sub-divided into binomial 
variables and the reference group remains the group that had a 0 value in Table 3B.  Also, 
similarly to model 1, the donor variable is counted as a categorical variable to account for 
the repeated measures of each donor across conjugates and to help limit the large inter-
donor variability that is seen with primary donors.  The reference donor was chosen at 
random and because all other factors control for donor in their calculation of beta no 
influence on the calculated coefficients or their significance was seen when changing 
between reference donors.  For either model the R2 and correlation coefficients between 
variables were compared to determine how well the model fits the data.  Furthermore, the 
IMF data has historically been shown to be approximately normal and the variance of the 
data remains constant across all samples thus the linear model used herein is further 
deemed as a valid analysis method.224   
 






Table 3A: Analysis of Continuous Variables Measured for Regression Analyses 
 




Mean 0.951 9.535 
Standard Dev. 0.613 8.35 
Minimum 0.258 0 
Maximum 3.184 26.2 
Skewness 1.560 0.901 
Kurtosis 2.262 -0.527 
 
Table 3B:  Analysis of Nominal Variables Measured and Coding Convention for 
Regression Analyses 




Ligand     
 
None 0 17 13.0 
 
OEG 1 17 13.0 
 
GlcNac 2 10 7.6 
 
Glc 3 13 9.9 
 Man 4 17 13.0 
 
Branched  
(Man3-Br and Man5-Br) 
5 20 15.3 
 
Alpha  
(Man3-A2, Man4-A2, Man5-A2) 




   
 
None ( 0 ) 0 27 20.6 
 
Low (den. < 5) 1 20 15.3 
 
Medium (5 ≤ den. < 15) 2 54 41.2 
 
High (den. ≥ 15) 3 30 22.9 
Donor 
 
   
 
1-17 1-17 10 100.0 
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4.3 Results  
4.3.1 Carrier Selection 
This study began with an assessment of carrier appropriateness for glycan 
presentation to DCs.  It was found that BSA cationized with an excess of EDA and 
functionalized with mannose had the largest change in DC IMF as compared to its 
unfunctionalized control and thus this platform would be used for further study.  To 
determine this Ovalbumin (OVA), bovine serum albumin (BSA), and streptavidin (SA) 
and their highly cationized counterpart were chosen as three model carriers.  Each of 
these six carriers was then adsorbed to the wells of a 384 well plate and the subsequent 
DC phenotype in response to these adsorbed conjugates was assessed after 24 hrs.  It was 
found that all the carriers except cationized OVA did not show an increase in IMF or 
TMF over untreated cells (data not shown).  Thus, five protein carriers were initially 
functionalized with glycans or linkers to determine a suitable glycan carrier that had no 
appreciable alteration in DC phenotype but that could serve as a platform for glycan 
presentation.  Figure 5 shows the results of this study.  Both cSA and cBSA were able to 
increase the IMF above that of untreated cells (iDCs) to a statistically significant degree.  
No change in TMF from untreated cells was shown for any conjugate (data not shown).  
Positive control, lipopolysaccharide (LPS) treated cells (mDCs) were also shown to 
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Figure 5:  Selection of a carrier for use as a platform for assessment of DC response 
to adsorbed glycoconjugates.  The DC response to adsorbed conjugates and 
subsequent measured IMF is shown.  The IMF was shown to be statistically 
different than untreated cells (iDC) for both cationized streptavidin presenting 
biotinylated mannose and cationized BSA presenting mannose.  No other conjugate 
showed a statistical increase in IMF as compared to untreated cells.  The positive 
control for IMF, LPS treated DCs (mDC), also showed a statistical increase in IMF.  
N=7 donors. Error bars represent standard error, red line indicates mean iDC 
response, * indicates statistical difference from iDC.   
 
4.3.2 Conjugate Creation and Validation 
4.3.2.1 Glycoconjugates were engineered to scale in density and charge.  
The conjugates from Figure 5 were cationized with an excess of EDA and 100:1 
molar ratios of ligand to carrier and thus no idea of the level of cationization or glycan 
density necessary for DC phenotype modulation could be obtained from this study.  Thus, 
40 glycoconjugates were made that scaled both density and charge of BSA from its non-
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cationized state, pI of approximately 4.6, to a pI of approximately 10 and from no ligand 
per BSA to approximately 26. 
After formulation all conjugates’ mass spectra ware taken via MALDI mass 
spectrometry and the subsequent average molecular weight was calculated.  The change 
in mass between the conjugate and its unfunctionalized analog was calculated and the 
molecular weight of the ligand was divided into the change in mass for a calculation of 
the average number of ligands/BSA.  Figure 6A shows the average number of 
ligands/BSA of the 36 conjugates.  For glucose and mannose conjugates ligand density 
scaled well with increased molar ratios.  At higher molar ratios more glycans per BSA 
were found.  The OEG linker however showed no trend of increasing number of 
functionalizations per BSA regardless of molar ratio used.  The average number of 
ligands per BSA also showed very little variance between conjugate cationization levels.  
Thus, in Figure 6A the average number of ligands per BSA can be seen as a function of 
molar conjugation ratio below the graph.  Additionally, a preliminary study with a 500:1 
glycan to protein carrier ratio was also performed and showed no increase in number of 
ligands/BSA over that of the 100:1 molar ratio (data not shown). 
Figure 6B shows the calculated isoelectric point (pI) for each conjugate.  For all 
conjugates the isoelectric point increased with increasing concentration of EDA.  The 
mean isoelectric point of each conjugate showed very little variance between EDA 
concentrations.  Thus, in Figure 6B the average pI for each level of cationization is 
shown in the table below the graph.  Between each level of cationization there is a ~1 pI 




Figure 6: Mass and isoelectric point of all conjugates. All from Figure 2. were 
characterized for their mass and average number of ligands per BSA (A) and for 
their mean isoelectric point (B).  The average mass of each conjugate discussed in 
Figure 2 was determined via MALDI mass spectrometry.  The arithmetic mean of 
the mass peak profile was calculated and plotted in (A).  The table under (A) shows 
the average number of ligands per BSA across each level of cationization.  The 
isoelectric point was calculated for each conjugate from the conjugate’s ζ-potential 
versus pH plot and can be seen in (B).  The average isoelectric point at each ligand 
density can also be seen in the table below (B).   
 
4.3.2.2 Glycoconjugates contain bioavailable glycans that scale in density and are 
structurally distinct.  
Finally, to confirm that the adsorbed conjugates still had biologically available 
glycans and that the adsorption of these conjugates produced relatively consistent 
presentations of glycans; ELLAs were performed with two different lectins on all 
conjugates adsorbed to the wells of TCPS plates.  It was found that conjugates with 
increased glycan/BSA bound more lectin and that this presentation was structure specific 
as lectins that were specific for mannose did not bind glucose conjugates. 
Figure 7 shows the results of the ELLAs performed with both ConA and NPA. 
Figure 7A-C shows the normalized absorbance of ConA ELLAs at 450nm when 
incubated with the adsorbed glycoconjugates.  Conjugates with more glycans/BSA show 
increased functional binding of lectins as evidenced by increased absorbance in wells 
containing higher density conjugates.  Also, as cationization level of conjugate increased 
so did the amount of lectin bound to the plate.    Additionally, the signal from the non-
cationized, low, and medium cationized glucose conjugates (Figure 7A,C) is significantly 
lower than that of the same conjugates when conjugated to mannose (Figure 7B).  
However, the trend between these conjugates is similar as can be seen from the subset of 
Figure 7A shown in Figure 7C. Figure 7D shows the results of uncharged and highly 
charged mannose and glucose conjugates with the lectin NPA which is specific for 
mannose conjugates.  Figure 7D shows that the signal from NPA-HRP for the adsorbed 
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mannose conjugates is much higher than for that of the adsorbed glucose conjugates 
especially for any conjugate above 6 sugars/BSA.  This is expected as NPA is a 
multivalent receptor and thus as glycan density increases so should the specific binding 
of the lectin.  
 
Figure 7: ELLA using plant lectins on adsorbed glycoconjugates from Figure 2 in a 
384 well plate.   Lectin affinity increases with increasing amounts of sugar on 
conjugates and lectin binding is higher for highly cationized glycoconjugates than 
for non-cationized conjugates.  Binding of the lectin ConA to adsorbed glucose 
glycoconjugates (A) and to adsorbed mannose glycoconjugates (B) can be seen.  The 
subset of (A) shows a consistent trend with what would be expected.  Also, sugar 
linkage to carriers shows lectin binding specificity as shown by (C) which shows that 
NPA (mannose specific) binds to the mannose glycoconjugates with a much high 
affinity than it does to glucose glycoconjugates.  N=3 for A and B, N=5 for C.  Error 
bars represent SE. Conjugate absorbance normalized by treatment with highest 
absorbance to provide similar scales between ELLAs. 
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4.3.3 Cationized, High Density, Mannose Conjugates were Able to Activate 
Dendritic Cells. 
After the conjugates had been characterized and validated for biological availability 
the DC response to each adsorbed conjugate was obtained via the HTP method shown in 
Figure 4.  It was found that the IMF was statistically increased for all levels of high 
density mannose conjugates above that of iDCs and TMF was not significantly 
unregulated for any of the glycoconjugates.  Figure 9 shows the results from these 
studies.  Controls mDC (LPS treated DCs), adsorbed mannan, and adsorbed β-glucan all 
showed a statistical increase in IMF as compared to untreated cells (iDC).  Also of 
interest from Figure 9A is that the level of IMF for the cationized glucose conjugates was 
raised.  No known receptors on DCs can bind to single glucose and thus the glucose 
conjugates were thought to be a control.   
While the glucose glycoconjugate treatments did not obtain statistical significance 
the trend is obvious and thus another control was tested to ensure that any glycan 
presented from the conjugates did not activate the DCs.  The highly cationized mannose 
and glucose glycoconjugates were treated with periodate and sodium borohydride and 
thus their carbohydrate rings were permanently opened.  These conjugates were then 
adsorbed to the wells of TCPS plates and the subsequent DC phenotype was assessed via 
the HTP methodology.  No statistical increase in IMF or TMF was seen from these 
conjugates as seen in Figure 8. 
Figure 9B shows the mean TMF of DCs for all treatments. No treatment other than 
the positive control, tDC, showed an increase in TMF as compared to untreated cells.    
Of note is an inverse trend of that which was seen in the IMF.  Low density low 
cationized conjugates appeared to increase the level of TMF.  The apparent shift in trends 





Figure 8: DC Response to open ringed glycoconjugates.  No statistical increase in 
IMF or TMF can be seen for any conjugate at any cationization level if the 
carbohydrate ring has been opened.  The positive control for IMF, mDCs, showed a 
statistical increase in IMF as did the positive control for TMF, tDCs.  N=3 donors. 
Error bars represent standard error, red line indicates mean iDC response, * 




Figure 9:  Dendritic cell IMF and TMF levels in response to all engineered well 
adsorbed conjugates from Figure 2.  All positive controls were statistically different 
from iDC and L-, M-, and H-BSAMan100 conjugates showed a statistically 
increased fold change in IMF (A).  No treatment showed a statistically increased 
TMF level as compared to iDCs (B).  The positive control, tDC, did show an 
increased level of TMF as compared to iDC (B).  Error Bars Represent ±SE, * = 
P<0.05 from iDC, n=13 donors, red line indicates mean iDC response. 
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4.3.4 Density and Carrier Charge Significantly Influence Dendritic Cell IMF but 
not TMF. 
From Table 2 the mean IMF, TMF, isoelectric point and density were all found to 
have a skewness and kurtosis less than |3.0| which is associated with mild non-normality.  
From Table 3 the mean IMF and density were also found to have a skewness and kurtosis 
less than |2.0| which again is associated with mild non-normality.  Additionally, while the 
TMF factor from Table 2A has a relatively large skewness and kurtosis upon analysis of 
residuals all factors fall close enough to a normal distribution that they can be assessed 
using analyses that assume normal distributions of data.  Also, all four variables were 
plotted against normal percentiles and no outliers of the data were seen (data not shown).  
These measures further validate the assumptions of normalcy of variables used in general 
linear modeling and allowed for the analyses of the data using parametric analysis means.   
An assessment of the statistical significance of each factor and its global ability to 
influence the DC phenotype controlling for all other factors was desired.  A general linear 
model was created and can be seen in Equation 1a.  From this model it can be seen that 
isoelectric point, density of conjugates, and donor all had significance in the model 
indicating that each of these factors significantly alters IMF in DCs and is important to 
phenotypic modulation of DCs.  Furthermore, both density and isoelectric variables 
showed a positive increase in IMF (positive β coefficients), meaning that as they 
increased so too did the IMF, when controlling for all other variables measured.  Also of 
note, is that each ligand did not significantly influence IMF and thus density and charge 
are dominant factors for presentation of glcyans to DCs.  The significance of the ligand 
variables was seen when controlling for density, charge and donor used.  The results from 
this model can be seen in Table 4A.  The model shown in Equation 1a was run treating 
both ligand and donor as categorical variables and the isoelectric and density variables as 
continuous variables.  The reference for this model was any donor who was treated with a 
conjugate that had no cationization, no ligand immobilized and thus no density of ligand.   
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The model shown in Equation 1a treats both isoelectric point and density as 
continuous variables and shows them both to be significant.  However, what specific 
levels or ranges were significant of each variable would be valuable information for those 
trying to design optimized glycoconjugates for activation of DCs.  Thus, Equation 1b 
was created.  This equation treats both isoelectric point and density as the categorical 
variables with the ranges shown in Table 2B and C.   The results for this model, shown in 
Table 4B, indicate that high glycan density had the greatest impact on IMF while having 
a high cationization level was next as shown by the magnitude of their β coefficients.  
The variables medium isoelectric point, medium density, and any donor were all also 
significant variables in the model.  Of note is that low isoelectric point conjugates, those 
with a pI below 7.5, had no significant impact on IMF.  Also, it should be noted that low 
density conjugates were linearly related to the conjugates with no ligand and thus these 
conjugates had to be excluded from the model.   Both low isoelectric point conjugates 
and OEG ligands had a negative effect on IMF.  No ligand had a statistically significant 
impact on IMF when controlling for density and isoelectric point.  The results of 
Equation 1b can be seen in Table 4B.   
   Finally, the R2 of both models was calculated to determine the goodness of fit 
and the appropriateness of these models in assessing the data.  Equation 1a had an 
adjusted R2 of 0.621 and Equation 1b had an adjusted R2 of 0.639.  These indicate that 
approximately 60% of the variance seen in the data can be explained by the model used.  
These R2 values were seen as fairly good for the relatively small sample size used (13 






Table 4A:  Parameter estimates for model 1 using continuous isoelectric point and 






t Value Pr > |t| 
Intercept β1 0.50603 0.05453 9.28 <.0001 
Isoelectric Point β2 0.03965 0.00592 6.7 <.0001 
Ligand OEG β3 -0.03324 0.04325 -0.77 0.4425 
Ligand Glc β4 -0.0041 0.04718 -0.09 0.9308 
Ligand Man β 5 0.06817 0.04623 1.47 0.141 
Density β6 0.01382 0.00152 9.07 <.0001 
Donor* β7-18 -0.59434 - 0.66049 0.05966 -9.96 - 11.07 <.0001 
* All donor estimates, standard errors, t values, and probabilities can be seen in the Table A 1 in the appendix. 
   







t Value Pr > |t| 
Intercept β1 0.92276 0.01557 59.57 <.0001 
Isoelectric High β2 0.17195 0.03355 5.12 <.0001 
Isoelectric Med. β3 0.15722 0.03243 4.85 <.0001 
Isoelectric Low. β4 -0.00784 0.04854 -0.16 0.8718 
Ligand OEG β5 -0.0042 0.04426 -0.09 0.9245 
Ligand Glc β6 0.0145 0.04791 0.3 0.7622 
Ligand Man β7 0.06549 0.04656 1.41 0.1602 
Density High β8 0.38133 0.03736 10.21 <.0001 
Density Med. β9 0.09719 0.03118 3.12 0.0019 
Density Low** β10 0 . . . 
Donor* β11-22 -0.59434 - 0.66049 0.05818 -10.21 - 11.35 <.0001 
* All donor estimates, standard errors, t values, and probabilities can be seen in the Table A 2 in the 
appendix.  
** Low density conjugates varied linearly with the control due to no difference between cell response 
to low density and no ligand groups.  Thus, this group had to be removed from the model. 
 
An identical model to those shown in Equation 1a and b was run for TMF and can 
be seen in Equation 1c and d.  Similarly to the IMF models, the reference for the TMF 
model was any donor who was treated with a conjugate that had no cationization, no 
ligand immobilized and thus no density of ligand. Table A 3 in the appendix shows the 
results of the model shown in Equation 1c.  From this model it can be seen that 
isoelectric point, density of conjugates, and donor all had significance in the model.  
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Interestingly, both density and isoelectric variables showed a negative trend in TMF 
(negative β coefficients), meaning that as they increased the TMF decreased, when 
controlling for all other variables measured.     
The trends seen in the continuous model shown in Equation 1c were recapitulated 
in the categorical model depicted by Equation 1d.  Table 5 shows the results of this 
model.  Table 5 shows that the higher density and higher cationization levels caused 
significant decreases in TMF.  Conjugates with an isoelectric point less than 7.5 showed a 
significant positive increase in TMF.  Finally, the R2 of both models was calculated to 
determine the goodness of fit and the appropriateness of these models in assessing the 
data.  Equation 1c had an adjusted R2 of 0.530 and Equation 1d had an adjusted R2 of 
0.539.  These indicate that approximately 53% of the variance seen in the data can be 
explained by the model used.  While these values were approximately 10% lower than 
those for the IMF these R2 values were seen as fairly good for the relatively small sample 
size used (13 donors) and high variability of primary donors.   
 







t Value Pr > |t| 
Intercept β1 0.12018 0.00543 22.15 <.0001 
Isoelectric High β2 -0.02412 0.01169 -2.06 0.0397 
Isoelectric Med. β3 -0.00020723 0.0113 -0.02 0.9854 
Isoelectric Low β4 0.03534 0.01692 2.09 0.0372 
Ligand OEG β5 0.00662 0.01543 0.43 0.6681 
Ligand Glc β6 -0.0291 0.0167 -1.74 0.0819 
Ligand Man β7 -0.02491 0.01623 -1.54 0.1253 
Density High β8 -0.06402 0.01302 -4.92 <.0001 
Density Med. β9 -0.02769 0.01087 -2.55 0.0111 
Density Low** β10 0 . . . 
Donor* β11-22 -0.59434 - 0.66049 0.05818 -6.22 - 10.57 <.0001 
* All donor estimates, standard errors, t values, and probabilities can be seen in the Table A 5 in the 
appendix.  
** Low density conjugates varied linearly with the control due to no difference between cell response 
to low density and no ligand groups.  Thus, this group had to be removed from the model. 
 
 82 
4.3.5 Dendritic Cell IMF and Phagocytosis of Glyconjugate Coated Microbeads is 
Inhibited by EDTA  
 Finally, determining whether the interaction with the ligand coated wells was 
lectin mediated or whether it was through some other receptor was desired.  A pan CLR 
inhibitor rather than a specific antibody was chosen as an inhibitor because of the 
numerous receptors capable of binding mannose conjugates on DCs.236 Figure 10 shows 
the results of this test.  Two different methods were used to assess CLR interaction with 
the adsorbed glycoconjugates.  First conjugates were adsorbed to 1µm fluorescent 
polystyrene beads and then incubated with DCs for 4 hours.  Fluorescent images were 
then taken of the cells and beads for a visual assessment of bead internalization or 
binding when incubated with cells in the presence of EDTA and not.  Figure 10A-C 
shows the micrographs of DCs with H-BSA and H-BSA-Man100 coated beads and no 
EDTA. As is apparent in these micrographs, after 4 hours in wells not treated with 
EDTA, DCs had internalized many beads and many DCs had internalized >10 beads per 
cell. However, Figure 10C shows beads coated with H-BSA-Man100 in the presence of 
5mM EDTA.  As is apparent from this micrograph DCs had internalized few if any of the 
beads and no cells were seen that had internalized more than two beads per cell.   
 The second method chosen for these experiments was to look at the HTP readout 
of the cells in the presence and absence of 5mM and 10mM EDTA.  Figure 10D shows 
the results of this experiment.  Only DCs treated with adsorbed H-BSA-Man100 
conjugates without EDTA treatment had a statistically significant up-regulation of IMF.   
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Figure 10:  DC response to H-BSA-Man100 conjugates adsorbed onto 1.0µm 
fluorescent polystyrene beads and subsequent IMF in the presence of 10mM or 
5mM EDTA.  DCs phagocytized H-BSA and H-BSA-Man100 coated beads to a 
much greater extent than they did H-BSA-Man100 coated beads in the presence of 
5mM EDTA (A-C).  No fold change in IMF was seen between iDCs and the EDTA 
treated cells.  The unblocked HBSA-Man100 conjugate showed a statistical increase 
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in IMF (D).  N=4 donors. Error bars represent standard error, red line indicates 
mean iDC response, * indicates statistical difference from iDC.  
 
4.3.6 Dendritic Cell IMF is Significantly Influenced by Terminal Glycan 
Structural Motif. 
The models shown in Equation 1a-d all indicate that ligand was not a significant 
factor in either IMF or TMF.  Thus, a study to determine if the optimized conjugates 
indicated from Equation 1a-d were able to distinguish between sugar structures was 
performed.  Six different mannose structures were then conjugated to highly cationized 
BSA in a 100:1 molar ratio.  These conjugates were then adsorbed to the wells of a TCPS 
plate and the DC phenotype was assessed via the HTP methodology after 24 hours.  
Figure 11 shows the results from this study.  Figure 11A shows the glycan structures 
assessed in this study.  An additional control sugar was added for these experiments to 
further validate that glycan presentation from the adsorbed highly cationized BSA did not 
activate DCs.  The monosaccharide N-acetyl-glucosamine was chosen as a control sugar 
because it has no known receptor on DCs.  Figure 11B shows that, as expected, the 
positive control, mDC, and the highly cationized BSA-Man conjugate showed a 
statistical increase in IMF over iDC.  However, Figure 11B also shows that the H-BSA-
Man5-A2 conjugate caused a significant increase in IMF as compared to iDC.  
Interestingly, an α1-3, α1-6 branched structural homolog for Man5-A2, Man5-Br, showed 
no activation of DCs.  Furthermore, an α1-3, α1-6 branched trimannose (Man3-Br) also 
showed no activation of DCs.  
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Figure 11: Assessment of DC phenotype in response to poly-mannose structures.  
The structures tested can be seen in (A).  Here R and R* represent the linker used 
for the glycan.  R= (CH2CH2O)3SH and R*= AEAB-NH2C(CH2)3SH,  The IMF was 
assessed for all adsorbed conjugates and H-BSA-Man and H-BSA-Man5-A had had 
a statistically increased expression over iDC (B).   mDCs also showed a statistical 
increase in IMF.  N=17 donors. Error bars represent standard error, red line 
indicates mean iDC response, * indicates statistical difference from iDC.   
   
 Due to the fact that two different mannose structures were shown to increase the 
IMF a model that could group or characterize these structures and use them to predict the 
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structural relevance of the glycans for DC maturation was desired.  The model shown in 
Equation 2 has the variables density_cat, ligand and donor.  Equation 2 shows density 
modeled as a categorical variable because it was first tested as a continuous variable, as 
in Equation 1a, and found to be significant.  Isoelectric point was not included in this 
model because all conjugates were the highly cationized form of BSA and thus their 
isoelectric points only varied between 9.9 and 10.1.   The ligand variable was divided 
into the subclasses seen in Table 3B.  Glycan structural motifs α1-3, α1-6 terminal 
branched mannose and α1-2 terminal linked glycan structures were grouped together for 
this analysis.  The results from the modeling of Equation 2 can be seen in Table 6.  In 
this model structural variables glucose, mannose, and alpha all had a statistically 
significant effect on DC phenotype.  No density variable had a statistically significant 
influence on phenotype nor did any α1-3, α1-6 branched mannose structure or N-
acetylglucosamine.  Of note is that low and medium density had a negative impact on 
IMF and all ligand classes analyzed had a positive influence on DC phenotype.  Because 
the results from Figure 9 clearly show that no mannose or glucose conjugate had a 
significant effect on TMF, only IMF results were assessed and for this study.   
 The R2 of the model shown in Equation 2 was calculated to determine the 
goodness of fit and the appropriateness of these models in assessing the data.  Equation 2 
had an adjusted R2 of 0.622.  This indicate that approximately 62% of the variance seen 
in the data can be explained by the model used.  These R2 values were seen as fairly good 
for the relatively small sample size used (17 donors) and high variability of primary 
donors. 
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t Value Pr > |t| 
Intercept β1 1.01253 0.04706 21.52 <.0001 
Density High β2 0.09053 0.12926 0.7 0.4852 
Density Med β3 -0.05344 0.16854 -0.32 0.7518 
Density Low β4 -0.17087 0.21251 -0.8 0.4232 
OEG** β5 0 . . . 
Glc β6 0.52008 0.14115 3.68 0.0004 
GlcNac β7 0.135 0.2286 0.59 0.5561 
Man β8 0.47628 0.2124 2.24 0.027 
Alpha β9 0.43799 0.2124 2.06 0.0416 
Branch β10 0.12871 0.15445 0.83 0.4065 
Donors 1-16* β11-26 -0.45111 - 1.07452 0.22732 -1.98 - 4.23 0.0005 
* All donor estimates, standard errors, t values, and probabilities can be seen in the Table A 6 in the 
appendix.  
** OEG conjugates varied linearly with the control due to no difference between cell response to 





4.4.1 Carrier Selection 
From the results shown in Figure 5 bovine serum albumin, and specifically 
cationized BSA, was chosen over cationized streptavidin due to its ability to be 
functionalized with upwards of 37 glycan ligands according to literature.237 Also,  
Oyelaran et al.238 showed that BSA was capable of scaling in density to a physiologically 
relevant density (>20 sugars/protein) to drastically enhance CLR binding.  Additionally, 
many studies have shown that BSA is a non-activating background for which to deliver 
molecules to DCs.239,240 Also of importance from Figure 5 is that the base cBSA protein 
tested with no ligand or with OEG linker attached caused no statistical increase in IMF 
from DCs and in the case of the highly cationized cBSA had a slightly lower (0.021) 
average IMF than did untreated cells..  Furthermore, display of glycans in a relatively 
physiological setting (conjugated to a protein backbone instead of synthetic polymer) was 
seen as advantageous as cells rarely encounter unbound complex glycan structures in 
nature. To date no direct studies have been performed that compare how charge of a 
glycolconjugate alters DC phenotype.  However, historically cationic vaccine conjugates 
have been found to play an important role in increasing the immune response to any 
conjugate.24–28  Thus, it was not seen as surprising that cationized BSA conjugates with 
high ligand densities activated DCs to the greatest extent.   
4.4.2 Conjugate Creation and Validation  
Mass spectra of the conjugates showed that glycan moieties scaled in density with 
increased molar ratios of glycan.  The scaling agrees well with results shown by Oyelaran 
et al.238 However, it was found that OEG conjugates did not appear to scale with 
increased molar ratios.  This, was unexpected as OEG conjugates were created at the 
same time with identical conditions to those of the other glycoconjugates.  It was 
 89 
therefore concluded that the OEG linker mass was small enough that the number of 
functionalizations per BSA were lost in the noise generated by MALDI mass spectra.  
While no direct evidence of this has been shown in the literature, the average standard 
deviation of the mass profile for each of the OEG100 conjugates was 11774 ± 6180 Da.    
With an average standard deviation of over 10kD and a maximum weight of OEG ligands 
reaching approximately 3kDa it would be no surprise that the OEG linker weight could 
be lost in the noise of the mass profile. Figure 12 shows two typical sets of MALDI mass 
profiles for produced glycoconjugates.   
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Figure 12:  MALDI mass spectra of four levels of cationization of glucose and 
mannose glycoconjugates.   
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Figure 6D shows that the range of isoelectric points tested was fairly small 
(approximately two pI units) between low and highly cationized conjugates.  However, 
the pI is the pH at which a particular molecule or surface carries no net electrical charge 
and thus a single unit increase in pI indicates a 10 fold increase in charged moieties per 
conjugate.  Thus, while the difference between low and high is only approximately two 
units this represents 100 times the charge density per conjugate and thus is seen as an 
acceptable range especially when including the non-cationized conjugate as a reference 
which increases the range of pI’s test from pI 4.5 to pI 10.1. 
The ELLAs shown in Figure 7A-C show that the glycoconjugates, when adsorbed to 
TCPS plates, are able to present their ligands in a biologically available manner.  This is 
indicated by the fact that lectins were able to bind to the conjugates when they were 
adsorbed to the wells of a TCPS plate and that the higher density conjugates showed an 
increase in signal.  This was expected as ConA binding has been shown to scale with 
density of glycan presentation.241  Also, because the lectins used are multivalent the 
increased binding trend is most consistent and reproducible with higher glycan density 
conjugates.  This is indicated by clear differences in density being shown with 
glycoconjugates that have more than 6 glycans/BSA.  Also noted in Figure 7A-C is the 
trend of increased signal with increased cationization of adsorbed glycoconjugate.  This 
was unexpected but the natural isoelectric point of ConA is approximately 5.0 and thus 
its negative zeta potential at neutral pH could lead it to non-specifically bind more 
strongly to the cationized conjugates and thus allow for longer and more intimate 
association of the lectins with the glycans presented from these conjugates.  This longer 
and stronger association has been hypothesized to lead to more multivalent interaction 
with the lectins and thus higher overall binding of the lectins to the cationized 
conjugates.242  Also of interest when comparing Figure 7A to Figure 7B is that the signal 
from the less cationized glucose conjugates is much lower than that of the equivalent 
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mannose conjugate.  This is expected as ConA has historically been shown to have a 
lower affinity for glucose as compared to mannose conjugates.243   
Finally, Figure 7D indicates that the sugars presented from the glycoconjugates are 
structurally distinct and biologically identifiable.  This is shown by the affinity of the 
NPA being significantly higher for the mannose glycoconjugates than for the glucose 
glycoconjugates.  Because NPA has been shown in the literature to bind to mannose and 
not glucose glycoconjugates this confirms the specificity of the glycan presentation.244  
This was expected as CLRs have been shown to have high structural specificity in the 
literature and all glycans were closed ring structures that were recognizable by the NPA.  
An inherent limitation of ELLAs is their inability to quantitatively state surface 
densities of ligand.  The measures produced by ELLA are always relative to each other.  
However, a rough estimate of surface density of ligand would be useful for reference to 
future researchers designing novel combination products that include glycans.  Thus, an 
order of magnitude calculation was performed by assuming that the hydrodynamic radius 
obtained when the ζ-potential of each conjugate was measured at pH 7.0 was performed.  
In this estimate the conjugates were spheres with the averaged measured hydrodynamic 
radius of 3.64x10-9m and that the conjugates adsorbed to the surface without deforming 
outside of this radius.  In other words, the conjugates had perfectly circular cross-sections 
on the surface.  Using this assumption and maximum packing, the surface packing factor 
was calculated to be 0.9069.  Glycans were assumed to be uniformly distributed across 
the surface of the conjugate and upon adsorption on average half of the glycans were 
covered by the protein structure adsorbing to the surface of the TCPS dish.  Using these 
assumptions conjugates with 26 glycans/BSA had an average density of approximately 
2.83x105 glycans/µm2.  Using the densities found by Osborne et. al.245 for BSA proteins 
adsorbed per unit area in a polystyrene tube, as measured by 125I-labeled proteins, and an 
average molecular weight of BSA of 66,460 Da, it was found that 3.52E+05 sugars/µm2 
were present on the surface.  This continues with the assumption that conjugates had 26 
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glycans/BSA and that half of these glycans would be covered by the adsorbed protein.  
The calculation of these densities can be seen in Figure A 2 in the appendix, of this 
report.  These two numbers are seen as a low and high estimate for glycan density of the 
“high” density conjugates produced in this study.   
4.4.3 Cell Response to Adsorbed Conjugates 
The results from Figure 9A show that there is a necessity for cationization of the 
carrier in order for DCs to be able to recognize and respond to surface adsorbed 
glycoconjugates. Also, only the highest density of conjugates showed significant 
activation of DCs when the glycoconjugates were cationized so not only is a high 
(~>20glycan/protein) density of glycan needed but also there is a synergistic affect 
between charge and density of display.  The BSA backbone appears to not be required for 
activation as identical carriers with different charges showed no change in DC activation 
at equivalent glycan densities and/or charges. 
Another point of interest for Figure 9 is that the cationized forms of the glucose 
glycoconjugates showed an increase in IMF. The monosaccharide glucose was thought to 
be a negative control because no known receptor on DCs binds single β-D-glucose.236  
However, upon searching the literature it was found that Dectin-1, a CLR expressed on 
DCs, can bind to β-glucan which is an extremely high density, structurally 
heterogeneous, polymer of β-D-glucose.154  Thus, it could be possible that the high 
density β-D-glucose conjugates have enough glucose to marginally engage Dectin-1, and 
thus a slight up-regulation of IMF can be seen for these conjugates.  Most concerning 
from this result is that it leaves the possibility that any glycan could activate DCs when 
presented from the adsorbed H-BSA conjugate.  However, concerns over non-specific 
glycan activation of conjugates were allayed by the results from the open ring conjugates 
shown in Figure 8.  Figure 9B shows the TMF expression level by DCs.  No differences 
between conjugates were seen for TMF.  However, a trend was seen between low glycan 
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density and low cationization levels and increased TMF.  The associations between 
charge and density and TMF were analyzed in the models of this data and discussed more 
in-depth below.   
Due to the inherent variability of formulation of protein glycoconjugates results 
produced by different formulations of conjugates are frequently varied and thus direct 
associations and recapitulation of experimental results is challenging.  Thus, there is an 
advantage to modeling the data so that direct comparisons between different formulations 
and experimental conditions can be made.  To that end, the models shown in Equation 
1a-d were produced.  The validity of using these types of models has been discussed 
previously in this report.  Furthermore, the data collected in this study has historically 
been shown to be approximately normal and the variance of the data remains constant 
across all samples.224   
Table 4A and B show that both isoelectric point and glycan density are significant 
factors in the regulation of IMF.  When comparing the coefficients seen in Table 4B high 
density and high cationization have the largest effect on IMF of any other conjugate 
characterization variable.  Additionally, High density has twice the magnitude of impact 
than does having a high isoelectric value; indicating that density is the most important 
factor for consideration when designing glycoconjugates. Interestingly, the models shown 
in Equation 1a-d all indicate that ligand was not a significant factor in either IMF or 
TMF. This is surprising given that in the ANOVA analysis only the cationized mannose 
conjugates showed a significant increase in IMF over untreated cells.  It was 
hypothesized that this was due to the fact that all conjugates were pooled together for 
these analyses and compared controlling for densities and cationization levels. Thus, two-
way interaction variables between ligand, cationization level, and density were 
introduced to the model (equation not shown).  However, due to the limited number of 
donors capable of being tested the model with these interaction variables could not 
converge and thus was not able to be used.  Thus, the study shown in Equation 2 was 
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performed to remove the variability of isoelectric point and compare glycan structures of 
similar density and charge to each other directly.   
Also of note, is that an inverse correlation between variables was seen between 
IMF and TMF which would be expected as they are measuring inverse relationships 
between DCs (pro-inflammatory versus tolerogenic).  Keeping this in mind, and 
comparing between the two models it can also be noted that the coefficients for all 
variables in the TMF model were lower in magnitude from those of the IMF model 
indicating that they play a smaller roll in modification of the TMF than they do in the 
IMF.  This indicates that optimal factors for modification of TMF might not have been 
assessed in these studies and that more variables and ligands are necessary for a more 
thorough understanding of how to optimally modify DCs toward a tolerogenic 
phenotypic state. 
To help ensure that activation of DCs was occurring through CLRs DCs were 
incubated with the adsorbed high density mannose and glucose conjugates in the presence 
and absence of EDTA.  All CLRs are calcium mediated and thus it has been shown in 
literature that incubating DCs with a calcium chelater, in this case EDTA, can drastically 
impair the function and signaling of a variety of CLRs.176  EDTA is a broad spectrum 
inhibitor and was chosen due to the plethora of CLRs that can bind mannose on DCs.236 
Several of these receptors have no known blocking antibody and others have not had the 
molecular signaling pathway that they signal through elucidated yet. 236 Thus, treating 
DCs with EDTA was seen as the best approach for confirmation of CLR interaction with 
the conjugates.  Figure 10A-C shows internalization of coated 1um fluorescent beads in 
the presence or absence of EDTA.  Phagocytosis was chosen as a readout because the 
CLRs DC-SIGN and mannose receptor (MR), two of the most studied and understood of 
the mannose binding lectins on DCs, are known phagocytic receptors.  Thus, an 
inhibition of phagocytosis of the beads would indicate that these two receptors were 
inhibited.  Figure 10A-C clearly shows this inhibition.  Furthermore, the DC phenotype 
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was assessed in the presence and absence of 10mM and 5mM EDTA and the adsorbed 
conjugates and the IMF was found to not be statistically increased in conjugates when in 
the presence of EDTA.  These two concentrations of EDTA were chosen as common 
concentrations known to inhibit CLR binding in DCs without activating DCs.204,246      
4.4.4 Dendritic Cell Response to Diverse Mannose structures 
One of the glycan structures used had a base GlcNAcβ1-β4GlcNAc motif that was 
modified with AEAB and a thiol.  This structure is distinct from the other glycans which 
are homogenous for mannose and have no fluorescent linker (AEAB) attached to them.  
This seemingly random sugar was chosen because this glycan structure is a common 
motif found in humans from which many other glycan motifs are added.176 The other 
glycans are not commonly found in healthy humans and are instead found Entamoeba.247 
The change in linking chemistry was chosen because the sugar was isolated from a 
protein, RNase B, and not made via synthetic carbohydrate chemistry and thus had to be 
identified in HPLC for purification and isolation.  Carbohydrates modified in this way 
have been used frequently in glycan arrays made by the Consortium for Functional 
Glycomics, one of the largest providers of carbohydrate resources to the glycan 
community, and thus it is seen as unlikely to of caused the difference in cell response 
between it and its structural homolog Man-5-A2.  In support of this conclusion Feinberg 
et. al.248 found that any glycan structure with a terminal α1-α2 man-man linkage showed 
a drastically higher binding affinity for DC-SIGN than did those structures that did not.  
Also, Wattendorf et al.107 showed that for Man3-Br conjugates presented from a non-
fouling PEG backbone produced no change in CD80, CD86, and MHCII from iDCs 
which also agrees with the results herein.  Not only does this confirm the results shown 
here but it also has implication for the Man5-Br structure tested in Figure 11 because this 
structure is two Man3-Br conjugates linked via an α1-α6 linkage.  Thus, the fact that 
glycan structure had a significant impact on IMF was not surprising. The results from the 
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model shown in Equation 2 that indicate that terminal branched structures were not able 
to significantly change DC IMF while man α1- α2man terminal linked conjugates were is 
supported by the literature but has never been shown to be applicable across sugar 
structures before this report.  
A discussion of why the donor variables were kept in all models is necessary as 
these variables were always statistically significant.  First, donors’ response to a 
multitude of ligands for each study was performed and thus the repeated measures of the 
donor needed to be controlled for in the analysis. If we did not do this then underlying 
associations between variables for a given donor would not be accounted for in the 
analysis and thus the beta values calculated would be skewed.  Secondly, models without 
donors included had R2 values below 20% due to the high variability of primary donors.  
Because of the small amount of glycan structures available small sample sizes were 
required when testing all conjugates.  Donors that vary in their response to carbohydrate 
ligands frequently vary by an order of magnitude, though underlying trends remain 
constant.  Thus, without being able to sample a large population inter-donor variability 
must be controlled for in order to see other significant trends.  All tested models showed 
identical trends to those discussed for each model regardless of inclusion of the donor 
variable but the overall fit of the model was poor and thus the donor variable was 
retained in the models. 
The model seen in Equation 2 was the result of an unbiased analysis of structure 
groupings.  All combinations of glycan motifs were tested and models run for each 
combination.  Grouping glycans via terminal linkage of glycan, via α1-3, α1-6 branched 
or α1-2 mannose, showed the highest statistical significance for ligands and also 
produced the greatest R2 value for the model. Furthermore, the resultant glycan groups 
used in Equation 2 yielded the most significant grouping of structures.  Algorithmically 
generated grouping was seen as a strength of the model as the data was used to determine 
the underlying trends and no bias was introduced by the researchers.  The grouping that 
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were determined as significant were then assessed for their physiological implications 
and two instances of the truncated mannose structures were found.   First, the α1-2 
terminal linked mannose structures have been shown to be expressed on the surface of 
Entamoeba.247 Second, the α1-2 mannose terminal mannose structures can be seen in 
class E Thy-1 negative mutant lymphomas.249,250  The Thy-1 negative mutants show an 
inability to produce dolichol-P-mannose and thus cannot effectively modify the block 
transferred N-glycan core structure.250,251  Thus, it is hypothesized that since these 
structures are never found in healthy tissue and only in a pathogen, Entamoeba, or on 
lymphomas, that CLRs have evolved to recognize these structures as DAMPs or PAMPs 
and become activated by them.  Futhermore, that CLRs could recognize these structures 
was not surprising considering the affinity studies that were completed by Feinberg et.al., 
Ratner et.al. and the Consortium for Functional Glycomics open database.211,248,252 In 
these studies a complex lectin specificity for glycans is consistently shown and high 
structural specificity is common among lectins.  For example, the Consortium has shown 
that DC-SIGN is able to distinguish between two isoforms of Man3, one branched α1-3, 
α1-6, the other linear α1-3, α1-2, with high prejudice since version 2.1 of its Mammalian 
Printed Array.  
To our knowledge, modeling ligands based on terminal sugar epitopes and density 
of glycan to predict cellular outputs has not been seen before in the literature.  The 
significance of the structural factors and of density indicates a trend that could be used in 
future studies that attempt to model DC interaction with complex carbohydrate structures.  
Combining inferences made from the models in both Equation 1a-d and Equation 2 it 
could be theorized that permutating a limited number of terminal glycan structural motifs 
across densities could account for the largest impact on DC phenotype.  However, this 
conclusion is seemingly confounded in Table 6 because in this model density is not a 
significant factor.  However, this can be explained by the fact that all conjugates used in 
this study were conjugated at the 100:1 molar ratio.  Thus, the variance that was seen 
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between number of ligands per BSA was much smaller than that of the previous study.  
This lack of variance leads to the density variable being a relatively uninformative 
variable in this model.  However, it was retained in the model so that future researchers 
are able to compare their glycoconjugates to ours regardless of density or formulation 
used.      
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CHAPTER 5  ELUCIDATION OF HOW PRESENTATION 
MODALITY OF GLYCOCONJUGATES ALTERS DENDRITIC 
CELL PHENOTYPE 
5.1 Overview 
Currently the field of glycobiology is focused on assessing the 
immunomodulatory ability of different glycan structures, densities, and molecular 
contexts of presentation.  However, the experiments performed herein test the hypothesis 
that it is also modality of glycan display that can shape DC phenotype.  The study began 
by using the optimized glycoconjugates from Chapter 4 and assessing these conjugates’ 
ability to be bound by recombinant human CLRs.  After confirming that recombinant 
human CLRs could bind to the conjugates the DC response to these conjugates presented 
in three modalities (a range of soluble concentrations, adsorbed to 1 µm polystyrene 
beads, and adsorbed to the wells of a 384 well plate) was performed.  The DC response to 
different modalities of presentation were found to be have differential DC responses 
across each of the conjugates tested.  Thus, a confrimation of whether this difference was 
due to DC apoptosis and/or necrosis was measured in response to each of the conjugate 
modalities to ensure that cell viability was not the cause of the differential response. It 
was found that cell viability was not altered for any of the modalities from that of 
untreated cells, however, cell apoptosis was increased for high amounts of β-glucan.  
Once confirmed that cell response to the conjugates presented in different modalities was 
not due to cell viability, a general linear model was created to determine if differences in 
cell response to different modalities of display were statistically significant. In this model 
β-glucan and mannan were removed to avoid the confounding viability results.  The 
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model showed a difference in DC IMF between modalities and thus confirmation of what 
receptors DCs were using to interact with these conjugates was performed.  Dendritic 
Cell CLRs were blocked with antibodies specific for two likely candidates for 
glycoconjugate interaction and compared to DCs that were isotype control Ab treated or 
treated with non-specific CLR inhibitor EDTA.  These studies showed that DC IMF, in 
response to adsorbed mannose conjugates, was inhibited by antibody blocking and EDTA 
treatment.  Finally, with the knowledge that DCs were using CLRs to interact with the 
adsorbed mannose conjugates an assessment of whether  internalization of the adsorbed 
conjugates was occurring was determined.  It was found that fluorescently modified 
adsorbed conjugates were internalized by DCs, though to a lesser extent than soluble 
conjugates.  Thus, it was concluded that removal of glycoconjugates from adsorbed 
surfaces was occuring but that internalization of conjugates was not sufficient to cause 
cell activation. 
The experiments in this chapter show that modality of display of glycoconjugate 
is significant in determining DC phenotype in response to the conjugates.  The response 
to the mannose conjugates is mediated at least in part by lectins and it is not 
internalization of the conjugates that is causing DC phenotype to change. The exact 
molecular mechanisms for why and how phenotype modulation is occurring were not 
uncovered in this report but future works are discussed to address this shortcoming.   
5.2 Methods 
5.2.1 Glycoconjugate Presentation to Dendritic Cells in Three Modalities 
 For all experiments where glycan conjugates were adsorbed to flat wells a 384 
well tissue culture polystyrene (TCPS) plate was coated with 20µg/ml of the BSA 
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glycoconjugates dissolved in PBS overnight at room temperature.  Then, all the wells 
were washed with complete DC medium five times and blocked for two hours at 37°C 
with 5mg/ml biotin free HSA in 0.1M NaHCO3.  After blocking the plates were then 
washed 5x with complete DC media and 40 µl of cells at 7.5x 105 cells/ml were added to 
each well and allowed to incubate for 24 hours.  DC phenotype was then assessed using 
the HTP methodology discussed in Chapter 4.2.9. 
 For all soluble conjugate deliveries wells of a 384-well plate were pre-coated with 
complete DC medium overnight and then washed and blocked as per the method used 
above for glycan conjugates adsorbed to flat wells.  Glycoconjugates were dissolved in 
complete DC medium at concentrations starting at 100 µg/ml with 1:10 dilutions and 
used to resuspend DCs which were then immediately added to the pre-blocked wells of 
the 384-well plate for 24hours of incubation.  DC phenotype was then assessed using the 
HTP methodology discussed in Chapter 4.2.9. 
 For all experiments where DCs were treated with glycoconjugates adsorbed to 1 
µm beads treatment, wells of the 384-well plate were treated as per the method used 
above for glycan conjugates adsorbed to flat wells.  Polystyrene beads (1 µm; Fisher 
Scientific, Waltham, MA) polystyrene beads were coated with 20µg/ml of the BSA 
glycoconjugates dissolved in PBS overnight at room temperature.  Beads were then 
centrifuged at 10K RCF for 3 minutes, supernatants removed, and beads resuspended in 
complete DC medium with vortexing for dispersion of beads.  This process was repeated 
twice more to wash beads.  Beads were then resuspended to their original volume in 
complete DC medium and added to DCs in the blocked wells of the 384 well plate at 
bead numbers corresponding to 0.2x, 1.0x, 5.0x and 25.0x the surface area of a well and 
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incubated for 24 horus.  DC phenotype was then assessed using the HTP methodology 
discussed in Chapter 4.2.9. 
5.2.2 Assessment of DC Uptake of Fluorescent Glycoconjugates 
 To assess uptake of glycoconjugates from flat-well surfaces to which they had 
been pre-adsorbed as described above or as soluble glycoconjugates, the conjugates were 
fluorescently modified with Alexa-fluor-488-TFP Ester (AF488, Invitrogen according to 
manufacturer’s directions).  Briefly, cationized glycan functionalized glycoconjugates 
were incubated with AF488, 5mg/ml in sterile PBS, at a 10:1 AF488 to protein molar 
ratio (1 hour, room temperature).   After conjugation the glycoconjugates were purified 
using 10KDa molecular weight cut-off Membrane Centrifugal Filter Unit (Millipore) 
using 9 rounds of 1:10 buffer exchanges against distilled, endotoxin free, water and 
stored in the dark.  When delivered to cells in a soluble form all wells were precoated 
with complete DC medium overnight prior to addition of cells or soluble conjugates.  To 
determine internalization of conjugates, cells were harvested onto a filter plate and 
analyzed for fluorescence uptake.  Thus, after 24 hours of incubation with fluorescent 
conjugates cell suspensions were pipetted up and down vigorously 3 times and then 
transferred to a 384 well filter plate (Pall).  Cells were then spun down at 400 RCF for 5 
minutes and the resultant supernatant was removed. While this was occurring adherent 
cells remaining in wells were incubated with non-enzymatic cell dissociation solution 
(CDS; Sigma Aldrich) for 2 minutes and then transferred to the spun down filter plate.   
Cells were then spun down at 400 RCF for 5 minutes and the resultant supernatant was 
removed. In the 384 filter plate, cells were then washed with wash buffer (1.0 wt.% BSA, 
0.1 wt.% TWEEN 20, 1x PBS) one time, fixed with 1% formaldehyde for 30 minutes, 
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washed with PBS, and incubated with 0.1% trypsin (Sigma Aldrich) for 1 minute.  Cells 
were then washed three times with wash buffer, resuspended in wash buffer and 
quantification of fluorescent-glycoconjugate internalization was performed via plate 
reader with fluorescence Excitation/Emission of 488/520. 
5.2.3 Assessment of DC Uptake of Glycoconjugate Coated Fluorescent Microbeads 
in the Presence of Blocking Agents 
All studies where ethylenediaminetetraacetic acid (EDTA) or blocking anti-bodies 
were used to block CLR receptors, cells were treated with either 10mM EDTA, 10 µg/ml 
of mouse anti-human Dentin-1 (clone 259931, R&D Systems), 10 µg/ml of mouse anti-
human DC-SIGN (clone 120507, R&D Systems) or 10 µg/ml of mouse anti-human 
IgG2B (Clone 20116, R&D Systems) for 30 minutes at 37°C before exposure to adsorbed 
glycoconjugates.  Similarly, for the negative control cells were incubated at 4°C for 30 
minutes prior to exposure to the glycoconjugates and then maintained at 4°C for four 
hours in the presence of the coated fluorescent microbeads (1 µm Purple high intensity, 
Exc./Emm. 590 nm/ 630 nm, Sphereotech).  The 4°C treatment is a common non-specific 
inhibitor of DC phagocytosis and thus was seen as a negative control and non-specific 
inhibitor for DC phagocytosis. EDTA is a common inhibitor of CLR activity in DCs 
because it chelates calcium and prevents these calcium dependent receptors from forming 
a functional binding pocket.  However, EDTA also has broad effects on DC behavior.246  
Thus, two blocking antibodies specific for common, well characterized CLRs, Dectin 1 
and DC-SIGN, were chosen to show specific inhibitory ability of DC interaction with 
conjugates.  Cells were then transferred, with media still containing EDTA or antibody 
(where applicable) to the wells with the fluorescent bead adsorbed glycoconjugates in a 
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1:10 cell to bead ratio and the subsequent phagocytosis was assessed after 4hrs.  For 
assessment of phagocytosis cell suspensions were pipetted up and down vigorously 3 
times and then transferred to 1.5ml eppendorf tubes.  Cells were then spun down at 300 
RCF for 10 minutes and the resultant supernatant was removed. Cells were then washed 
with PBS, fixed with 1% formaldehyde for 30 minutes, washed again with PBS, and 
incubated with 0.1% trypsin for 1 minute.  Cells were then washed three times with PBS, 
and quantification of phagocytosis was performed via flow cytometry (BD LSR II Flow 
Cytometer, BD Biosciences). 
5.2.4 Preparation and Assessment of ζ-Potential, Mass and Endotoxin Content of 
Glycoconjugates 
 All mass spectra and ζ-potential measurements were performed in an identical 
manner to that of Chapter 4.  The endotoxin contents of the glycoconjugates was assessed 
in an identical manner to that of Chapter 4.  The endotoxin content of all glycoconjugates 
was determined to be less than 0.2 EU/mL, which is well below the FDA limit of 0.5 
EU/mL.  Furthermore, all mannose conjugates were below the detection limit of the assay 
for endotoxin content. 
5.2.5 Binding Assay of Recombinant Human C-Type Lectin Receptors to 
Adsorbed Glycoconjugates   
 A 384 well tissue culture polystyrene (TCPS) plate was coated with 20µg/ml of 
the glycoconjugates overnight at room temperature.  During this incubation, rhDectin-1 
or rhDC-SIGN-Fc Chimera (R&D Systems) were biotinylated according to 
manufacturer’s direction from Solulink’s ChromaLink™ Biotin Protein Labeling Kit. 
Briefly, biotin-PEG3-bis(arylhydrazine)succinimidyl ester dissolved in 
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dimethylformamide at 5 mg/ml was added to rhDectin-1 or rhDC-SIGN-Fc in a 10:1 
biotin to protein molar ratio and allowed to react for 2hrs at room temperature mixing at 
900 RPM.  Next, proteins were purified via provided Zeba spin columns (Pierce) and 
then diluted to 15 µg/ml with lectin buffer (0.1 mM MgCl2, 0.1mM CaCl2, and 1x PBS) 
(Sigma).  Extent of biotinylation was then confirmed via included standards and UV 
fluorescence at 354nm.   
After the completion of the overnight incubation all wells with glycoconjugates 
were washed and blocked for two hours at 37°C with block solution (1x PBS, 5 mg/ml 
biotin free BSA, 1mM MnCl2, 1mM CaCl2 and 0.1wt% TWEEN20).  After blocking the 
plates were then washed 5 times with the wash solution 3 (0.5mg/ml BSA in 0.1x PBS, 
0.1mM MnCl2, 0.1mM CaCl2, and 0.01wt% TWEEN 20). Next, a 15 µg/ml rhDectin1-
biotin or 15 µg/ml rhDC-SIGN-FC-biotin (diluted in lectin buffer:  1x PBS, 1mM MnCl2, 
and 1mM CaCl2) was incubated with the adsorbed conjugates for three hours at 37°C or 
overnight at 4°C. The plates were then washed 5 times with wash solution 3 and 40µl of a 
streptavidin-HRP (BD Pharmingen) solution diluted 100x with lectin buffer from stock 
was added to each well and allowed to incubate in the well for 1 hour at room 
temperature.   The plate was then washed 5x more with the wash solution 3 and a TMB 
(3,3',5,5'-tetramethylbenzidine-peroxide) substrate (BD Pharminogen) was added and the 
plates were allowed to develop for 10 minutes.  1.0N sulfuric acid was then added to stop 
the reaction and the absorbance at 450nm was determined.   
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5.2.6 Culture and Phenotype Assessment of DCs. 
 Culture and HTP assessment of DC phenotype upon treatment with 
glycoconjugates presented on various modalities of display was identical to that of 
Chapter 4.  The extent of DC maturation was compared to untreated DCs (iDCs) for the 
negative reference control and lipopolysaccharide (LPS) (1 mg/ml; E. coli 055:B5; 
Sigma)-treated DCs (mDCs) for the IMF control, and IL10 and IFNα (R&D Systems) at 
3500 units/ml and 35000 units/ml respectively for the TMF control. 
5.2.7 Viability/Cytotoxicity and Apoptosis Assessment of Glycoconjugates 
 Cytotoxicity associated with glycoconjugate treatment was assessed via live/dead 
staining in an identical manner to that of Chapter 4.  The amount of cell apoptosis was of 
interest due to possibility that cells were impermeable to Ethidium homodimer but still in 
the process of apoptosis.  To assess apoptosis DCs were stained for Annexin V-FITC 
(BD Biosciences) and the extent of binding to phosphatidylserine was measured.  No 
treatments showed a significantly different viability from untreated cells and no treatment 
showed a statistical increase in Annexin V binding except for 100 µg/ml β-glucan which 
showed a statistically significant increase in Annexin V from untreated cells (Data shown 
in Figure 16) Dead controls were freeze-thawed two times prior to placement into wells.   
5.2.8 Statistical Analysis 
 To observe any significant differences between all sample groups in pairs, a 
pairwise repeated measures two-way ANOVA followed by Tukey’s posttest was 
performed using the SAS software (Cary, NC), and the p-value equal to or less than 0.05 
was considered significant.  Significance of general linear statistical model parameters 
discussed in section 5.2.9 of this report and seen in Model 3a and b and Model 4 was 
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determined by T value in reference to referent group discussed in section 5.2.9 of this 
report. 
5.2.9 Statistical Modeling  
Table 7 lists the quantitative parameters that were collected and separates them by 
variable classification: Continuous, categorical/nominal, and binomial.  The 
characterization of the variables Inflammatory Maturation Factor (IMF), Tolerogenic 
Maturation Factor (TMF), ligand attached to carrier, modality of display, and donors can 
be seen in Table 7A and B.  Table 7A contains IMF and TMF continuous variables.  
Table 7B contains the variables:  Ligand, modality, and donor.  There were 20 total 
donors for this analysis.   
Model 3a and b show the general linear models that have IMF (a) or TMF (b) as 
outcome variables and are a function of the ligand conjugated to BSA, modality of 
display, and the donor.  The models in Model 3a and b sought to isolate and compare the 
effect of presentation modality when controlling for ligand and donor variations.  The 
null hypothesis was that modality of presentation did not play a role in IMF or TMF and 
thus that this variable would not have a significant T value when compared to the referent 
group discussed below.  The coding of these variables is shown to denote the reference 
group, always denoted by the coding value of 0.  The reference ligand was none and thus 
its value for this variable is shown as 0 in Table 7B.  Three other classes of ligand were 
analyzed in this model:  oligoethylene glycol linker (OEG), monosaccharide glucose 
(Glc), and monosaccharide mannose (Man).  Similarly, adsorbed glycoconjugates were 
the reference group for the modalities of display and 1µm beads at a surface area ratio of 
1x to that of well adsorbed and 1.0 µg/ml soluble modalities were the other modalities 
compared in the model.  Finally, the variable donor was included in the analysis to 
account for the repeated measures of each donor across conjugates and to help limit the 
large inter-donor variability that is seen with primary donors. 
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IMF = β1 + β2*donor + β3*ligand + β4*modality Model 3a 
TMF = β1 + β2*donor + β3*ligand + β4*modality Model 3b 
The reference donor was chosen at random and because all other factors control for 
donor in their calculation of beta no influence on the calculated coefficients or their 
significance was seen when changing between reference donors.  Thus, the reference 
group was any donor with a conjugate that had no ligand and was adsorbed to the well of 
a plate.  
Table 7A: List of continuous variables and their statistics  
  IMF TMF 
Number of Measures* 96 93 
Mean 0.9705 0.1081 
Standard Dev. 0.5833 0.1414 
Minimum 0.273 -0.107 
Maximum 3.309 0.735 
Skewness 1.552 1.952 
Kurtosis 2.656 5.821 
*Three donors fell below the detection limit of the assay for TMF and were not included in the dataset. 
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Table 7B: List of categorical variables, their coding in the model, and the frequency 
of occurrence. 
Variable Sub Category Code Count 
Ligand 
   
 
None 0 24 
 
OEG 1 24 
 
Glc 2 24 
 
Man 3 24 
Modality
   
 
Adsorbed 0 48 
 
1 um Bead 1 24 
 




   1-20 0-19 96
 
 For the comparative model used the R2 was calculated to determine how well the 
model fits the data.  The R2 value of model was 0.874 and thus the model was seen as a 
reasonably good model for the data.  Furthermore, the IMF data has historically been 
shown to be approximately normal and the variance of the data remains constant across 
all samples thus the linear model used herein is further deemed as a valid analysis 
method.224   
 Model 4 shows a general linear model that has IMF as outcome variables and is a 
function of donor used (donor), ligand linked to BSA (ligand), modality of presentation 
(modality), and the interaction between modality and ligand (ligand*modality). Model 4 
sought to isolate and compare the pairwise comparisons between all pairs of ligand on 
BSA and modality of display of that ligand.  The null hypothesis was that no ligand-
modality combination would be different from each other.  To make this comparison, 
after the ANOVA was performed, all ligand-modality combinations were compared using 
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Tukey’s Post-test.  In this model the reference group was any donor tested with a BSA 
conjugate with no ligand, presented from a well adsorbed modality.  Finally, the variable 
donor was included in the analysis to account for the repeated measures of each donor 
across conjugates and to help limit the large inter-donor variability that is seen with 
primary donors.  The reference donor was chosen at random and because all other factors 
control for donor in their calculation of beta no influence on the calculated coefficients or 
their significance was seen when changing between reference donors. 
 
IMF = β1 + β2*donor + β3*ligand + β4*modality + β5*ligand*modality Model 4 
 
5.3 Results 
5.3.1 Overall Experimental Approach 
 In house produced glycoconjugates were produced as per the methodology used 
in Chapter 4 for the highly cationized high density BSA conjugates.  These conjugates 
were chosen based on the results from that section and because of the historical 
precedence of importance of cationization and high density of glycan for response from 
DCs.  The bioavailability of sugars from adsorbed conjugates was confirmed via a 
binding assay of recombinant human CLRs, Dectin-1 and an Fc-DC-SIGN chimeric 
protein, to adsorbed glycoconjugates.  The primary focus of this study was to assess how 
DC phenotype of presented glycoconjugates was affected by the modality of display: 
adsorbed to a flat well surface, soluble, or adsorbed to a 1 µm PS beads.  The overall 
experimental approach is shown in Figure 13 including glycan modification of the 
maleimide functionalized BSA, cationization of the BSA with an excess of EDA, the 
subsequent adsorption of the glycoconjugates onto plates or microbeads, and finally 
assessment of DC phenotype to either soluble, bead adsorbed, or flat well surface 
adsorbed conjugates.  Analysis of issues of DC interactions with glycoconjugates 
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included examining phenotype for DCs pretreated with blocking antibodies for the CLRs, 
DC-SIGN and Dectin-1, and uptake of fluorescently labeled glycans during DC treatment 
with these reagents. 
  
 
Figure 13:  Diagram of the modification of BSA, adsorption onto well or microbead, 
then culture with DCs as either adsorbed to flat well surface, adsorbed to 
microbead, or soluble modalities. 
 
5.3.2 Characterization of Glycoconjugates 
 The same set of glycans prepared for, characterized and used in the study 
described in Chapter 4 were used again for these studies.  More specifically, Table 8 also 
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shows the calculated isoelectric point (pI), and hydrodynamic radius for each conjugate.  
The mean isoelectric point of each conjugate was approximately equal for all conjugates 
and was close to a pI of 10.  While obtaining the ζ-potential of each conjugate the 
hydrodynamic radius was also measured and can also be seen in Table 8.  Of interest is 
that each of the ligand reacted conjugates was smaller than that of the H-BSA alone.   
Table 8: Molecular properties of the BSA conjugates used in this study. 





H-BSA None 0 10.08 5.12 
H-BSA-OEG100 OEG 4.41 9.85 2.97 
H-BSA-Glc100 Glc 26.2 10.1 3.62 
H-BSA-Man100 Man 23.5 9.63 2.99 
 
5.3.3 Recombinant Human Lectins Are Able to Bind to Flat Well Adsorbed 
Glycoconjugates. 
 To confirm that the adsorbed conjugates had biologically available glycans that 
were able to interact with CLRs on DCs and that the adsorption of these conjugates 
produced relatively consistent presentations of glycans; a binding assay with recombinant 
CLRs was performed on all conjugates adsorbed to the wells of 384 well TCPS plates.  
Unexpectedly, the mean absorbance for the H-BSA-Man100 conjugates with DC-SIGN, 
was higher than was observed for mannan, the positive control.  Figure 14 shows the 
results of this study.  Figure 14A shows the binding of rhDC-SIGN and Figure 14B 
shows the binding of rhDectin-1.  Figure 14B shows little binding of Dectin-1 to any of 
the conjugates other than the positive control. This Positive controls Mannan for DC-
SIGN and β-glucan for the Dectin-1 both showed high binding of DC-SIGN and Dectin-1 
respectively.    No signal above the detection limit of the assay was seen for H-BSA-































































































































Figure 14: Binding assay for glycan recognition by recombinant human CLRs, 
rhDC-SIGN-Fc and rhDectin-1, showed CLR specificity for the conjugates. (A) 
Biotinylated rhDC-SIGN-Fc was incubated with adsorbed conjugates and the 
subsequent mean absorbance for each conjugate was measured.  (B) Shows 
biotinylated rhDectin-1 incubated with adsorbed conjugates.  All signals are 
background subtracted from untreated wells.  N=4 Trials, 3 wells/trial.  “-“ 
indicates below detection limit of the assay. 
 
5.3.4 Dendritic Cell Response to Glycoconjugates was Different Between the Three 
Display Modalities for Both DC IMF and TMF 
Assessment of DC resposnes to glycoconjguates presented in three different 
modalities shows that glycans adsorbed to flat well surfaces support the highest level of 
IMF response (Figure 15E) while presentation of glycoconjugates in the soluble form 
(Figure 15A) resulted in the smallest effect on IMF, both compared to iDCs.  Presentation 
of glycoconjugates adsorbed to 1 µm PS beads resulted in an intermediate level of 
induced IMF expression (Figure 15C) .   Figure 15A and B show the DC response to 
glycoconjugates when adsorbed to 1 µm polystyrene (PS) beads at four different bead 
surface area ratios.  Each ratio represents a multiplicative of the surface area of a well.  
The surface area of a well was chosen as a standard rather than bead number or ratio of 
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beads to cells because it was desired that the results from these studies be directly 
compared to those of the well adsorbed studies shown in Figure 15E and F.  Figure 15A 
shows that when control ligands LPS, mannan, and β-glucan were adsorbed to 1µm beads 
all caused a statistically significant increase in IMF.  LPS showed the highest level of 
activation, with significant increases in IMF at all surface area ratios while mannan and 
β-glucan showed a significant increase in IMF at 25x, and 5x ratios respectively.  No 
other treatments were different from iDC except the positive control (mDC).  However, 
of note is the increased trend in IMF for 5x and 25x surface area ratios for both H-BSA-
Glc100 conjugates and H-BSA-Man100 conjugates.  The trend of increasing IMF with 
increasing surface area ratio was then analyzed using a GLM in which donor and 
treatment were controlled for and surface area ratios were compared.  Using Tukey’s 
Post-test all pairwise comparisons between surface area ratios were performed and Table 
9 shows the results.  Both 5x and 25x surface area ratios were significantly different from 
0.2x and 1.0x.  However, 0.2x and 1.0x were not statstically different from eachother, nor 
were 5x and 25x ratios.  Thus, the trend of increasing IMF with surface area ratio was 
further substantiated using this model.  No significant increase in TMF for any conjugate 
adsorbed to 1 µm polystyrene beads was seen except for the TMF positive control, tDC.  
When TMF was modeled in a GLM with surface area, ligand, and donor as categorical 
predictor variables no surface area ratios reached significance. 
Table 9: Pairwise comparisons between all surface area ratios for DC IMF. 
Surface 
Area Ratio 0.2x 1.0x 5.0x 25.0x 
0.2x 
 




5.0x 0.0002 0.004 
 
0.9928 




Figure 15:  DC Response to glycoconjugates presented in three modalities of display. 
(A), (C), and (E) show the IMF response of DCs to the conjugates and (B), (D), and 
(F) show the TMF response from DCs.  (A) and (B) show the DC response to 
glycoconjugates when adsorbed to 1 µm PS beads at 0.2x, 1.0x, 5.0x and 25.0x the 
surface area of a well.  Bead surface area was scaled by increasing bead number 
until the desired ratio was reached.  (C) and (D) indicate DC response to soluble 
conjugates across five orders of magnitude of concentration.  (E) and (F) show DC 
response to well adsorbed conjugates.  For A-D N=6 donors, E and F N=12 donors. 
Error bars represent standard error, red line indicates mean iDC response, * 
indicates statistical difference from iDC.   
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Figure 15C and D show the DC response to glycoconjugates when delivered in 
five different soluble concentrations.  The concentration of conjugate was varied over 5 
orders of magnitude, from 10 ng/ml to 100 µg/ml.   Figure 15C shows that when control 
ligand β-glucan is delivered to DCs at any concentration between 100 ng/ml to 100 µg/ml 
IMF increases significantly over that of untreated cells.  Interestingly, the 100 µg/ml 
treatment did not cause the highest level of IMF.  This was due to statstically significant 
increases in apoptosis of DCs at this β-glucan concentration as measured by Annexin V-
FITC.  Results of the apoptosis test can be seen in Figure 16.   No other treatments, 
including soluble mannan, at any concentration, were statistically different from 
untreated cells.  No significant increase in TMF for any concentration of soluble 
conjugate was seen.  However, for BSA glycoconjugates as soluble concentration 
increased an increasing trend in TMF is seem.  This trend, when modeled using a general 
linear model, was not found to be statistically significant.  However, β coefficients were 
found to be consistent with visual trends showing that β coefficients for concentration 
were positive when predicting TMF as a function of concentration, BSA conjugate, and 
donor (data not shown because βs did not reach 0.05 significance.). 
Figure 15E and F show the DC response to glycoconjugates when adsorbed to the 
wells of a 384 well TCPS plate.  Figure 15E shows that when control ligands Mannan or 
β-glucan were adsorbed to wells and displayed to DCs, IMF increases significantly over 
that of untreated cells.  The positive IMF control, mDC, was also shown to be statistically 
different from untreated cells.  Interestingly, both adsorbed H-BSA-Glc100 and H-BSA-
Man100 were also significantly increased over untreated cells.  Figure 15F shows that no 
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significant increase in TMF for any adsorbed conjugate was seen except for that of 
positive control tDC.   
 
 
Figure 16: DC apoptosis as measured by Annexin V-FITC Binding.  The average 
fold change over untreated cells is shown.  Positive control (dead) and 100 µg/ml β-
glucan showed a statistical increase in fold change of Annexin V binding.  N=3 
donors. Error bars represent standard error, red line indicates mean iDC response, 
* indicates statistical difference from iDC.   
 
5.3.5 Display Modalities are Significantly Different for DC IMF when Statistically 
Modeled. 
A measure of whether DCs showed an altered phenotype when exposed to 
conjugates displayed in different modalities, when controlling for ligand used and donor, 
was desired.  Thus, two sets of statistical models were created.  The first set of models 
assessed whether DC response to modality of display was different controlling for ligand 
of glycoconjugate and donor and can be seen in Model 3a and b.    The second model 
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assessed which specific conjugates and display modality combinations were statistically 
different for IMF.  This models can be seen in Equation 1.   
The results of Model 3a show that for IMF all modalities are statistically different 
from each other controlling for ligand and donor with all probabilities being lower than 
P<0.0042.  The results of Model 3b showed that for TMF no modalities are statistically 
different from each and that adsorbed and bead adsorbed modalities are co-linear and 
thus can either be combined or one must be excluded from the model for it to converge.  
In both Model 3a and b all variables were treated as categorical variable as seen in Table 
7B and when modeled were divided into their binomial substituents as indicated in the 
methods of this dissertation. A table of the comparison between all modalities and their P 
values can be seen in Table A 7 of the appendix.   
Based off of the results from Model 3a and b a model assessing the interaction 
between ligand and modality was desired to determine which ligand/modality 
combinations were significantly different from each other.  Model 4 showed that 
Adsorbed H-BSA-Man100 was statistically different from soluble delivery of H-BSA-
Man100 and soluble H-BSA-Glc100.  To do compare these ligand/modality pairs Model 
4 creates an interaction variable to determine which specific pairwise comparisons 
between the modality/ligand combinations are different.    No other differences between 
modalities of display were noted from this analysis.  A TMF model using an interaction 
variable was not performed due to the instability of Model 3b. 
5.3.6 Cell Interaction with Glycoconjugates 
5.3.6.1 DC phagocytosis of mannose glycoconjugate coated microbeads is inhibited by 
anti-CLR antibodies 
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 After identifying that display modalities altered DC phenotype an attempt to 
determine which receptors DCs were using to respond to these glycoconjugates was 
performed. An assessment of DC phagocytosis of conjugate coated 1 µm fluorescent 
polystyrene beads was performed. Dendritic cell phagocytosis of the mannose 
glycoconjugate coated beads was significantly inhibited when blocked with antibodies 
specific for lectins DC-SIGN or Dectin-1, 10mM EDTA, or treatment at 4°C as can be 
seen in Figure 17D.  No anti-body or EDTA significance was found for any of the other 
conjugates other than the mannan control (shown in Appendix Figure A 3).  Figure 17 
shows the results from this study.  In Figure 17A-C only the negative control, 4°C treated 
DCs, were statistically different from the isotype control treated cells.  From Figure 17D 
it is clear that EDTA and 4°C treatment of DCs has a larger impact on phagocytosis as 
compared to the antibody treated cells, however no statistical differences can be seen 
between these groups.   Figure 17D thus indicates that for beads coated with H-BSA-
Man100 phagocytosis is mediated through lectin interaction and specifically can be 
inhibited partially by blocking DC-SIGN or Dectin-1.  Phagocytosis of other conjugate 
coated beads is not mediated by lectins as indicated by lack of statistical inhibition via 
EDTA.  The controls uncoated bead, mannan coated beads, and β-glucan coated beads 
can be seen in the Appendix of this report in Figure A 3.  The uncoated bead showed 
similar results to that of H-BSA while mannan was significantly inhibited by the EDTA 
and 4°C.   
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Figure 17: Antibody blocking to confirm receptor specificity. Blocking antibodies 
reduce phagocytosis of beads.  Data is fold change over isotype treated DCs.  N=4 
donors. Error bars represent standard error, red line indicates mean isotype Ab 
treated cells’ internalization of beads fluorescence, * indicates statistical difference 
from isotype Ab treated cells.   
 
5.3.6.2 DCs are internalizing adsorbed conjugates but to a lesser extent than soluble 
conjugates 
 Finally, whether DCs were internalizing conjugates from adsorbed surfaces was 
quantified to determine if cells were capable of removing adsorbed conjugates from the 
surface.  DCs internalized both adsorbed and soluble conjugates as indicated by all 
treatments in Figure 18 having a net positive fluorescence when cultured with 
fluorescently modified BSA conjugates.  From Figure 18 it can be seen that for the 
adsorbed conjugates, as compared to the H-BSA coated wells, more glycoconjugate was 
taken into cells for both the H-BSA-Glc100 and H-BSA-Man100.  The results from 
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Figure 18 were produced from conjugates that were fluorescently modified and adsorbed 
to well surfaces or delivered in a soluble form to DCs for 24 hours.  Two concentrations 
of soluble ligand were chosen to test the hypotheses that 1) DCs were capable of 
internalizing these conjugates and 2) that at a concentration on the same order of 
magnitude as that of adsorbed glycoconjugates a greater fluorescence was seen for 
soluble conjugates than for adsorbed conjugates. All conjugates delivered at 10 µg/ml 
had a fluorescence above the detection limit of the plate reader when set at a gain which 
allowed for resolution of DC/conjugate fluorescence at 1.0 µg/ml and when conjugates 
were adsorbed to wells. Also of note was that adsorbed H-BSA-Man100 conjugates had a 
higher mean net fluorescence than did H-BSA-Glc100, though not to a statistically 
significant amount.  Also, the soluble 1 µg/ml conjugates showed a higher mean net 
fluorescence regardless of ligand used than that of the adsorbed conjugates. Finally, 
adsorbed H-BSA-OEG100 conjugates had a lower mean net fluorescence than did any 
other group.   
 
Figure 18: Quantification of internalized fluorescent adsorbed conjugates.  The 
relative amount of fluorescent glycoconjugates adsorbed to wells or in soluble form 
internalization by DCs after 24 hour incubation.  Net fluorescence measured by 
subtracting signal from DCs treated with non-fluorescent equivalent conjugate.  
N=2 donors. Error bars represent one half range. ! indicates above the maximum 




 In the studies herein we test only two types of sugars, mannose and glucose 
conjugates.  Glucose was chosen because no known CLR on DCs can bind to the 
monosaccharide glucose.  Mannose was chosen because mannose CLRs on DCs are some 
of the most heavily studied and well characterized CLRs.  Additionally, DCs constantly 
encounter mannose glycans in different modalities:  soluble glycoproteins (plasma 
glycoproteins)253, particulate bound glycoproteins (bacterial and viral surfaces)254,255, and 
non-phagocytosable glycoproteins (endothelium and parasites).119,256 The outcome from 
stimulation by each of these modalities ranges from tolerogenic to pro-inflammatory.  
Thus, we hypothesized that DCs will react to each modality in a different fashion even if 
identical glycans are presented.  Finally, the studies from Chapter 4 show that DC IMF 
was increased to an equal amount using the monosaccharide mannose as it was with more 
complex mannose structures.  Thus, single mannose was used in these assays because of 
its availability, relatively inexpensive cost, and for its ability to provide no confounding 
structural indications in the modality comparison.   
 Cellular adhesion or migration were not used in this report as an indicator of DC 
phenotype because these outputs have been shown to be poor indicators of DC 
phenotype.206  Also, the end result of the DC maturation process, whether its pro or anti-
inflammatory, CD4 or CD8 stimulating, etc. is independent of adhesion and thus, 
adhesion was not seen as an ideal reporter for DC, and in general APC, activation.207    
5.4.1 Characterization of Glycoconjugates 
The ELLAs in Figure 14 showed that not only were the H-BSA-Man100 
conjugates capable of being bound by rhDC-SIGN-Fc but also that the Glc conjugates 
were not recognized by rhDC-SIGN-Fc or rhDectin-1.  The magnitude of rhDC-SIGN 
binding to the H-BSA-Man100 conjugates was seen to be greater in magnitude than that 
of mannan, the positive control; however, this difference was not statistically different 
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and thus was seen as a confirmation that ligand density was high enough for these 
conjugates to cause functional binding of rhDC-SIGN-Fc.  Additionally, the higher mean 
fluorescence of the H-BSA-Man100 conjugates from that of wells treated with HBSA, 
HBSA-OEG100, and H-BSA-Glc100 indicate that rhDC-SIGN-Fc was able to bind to the 
glycoconjugates with relatively high specificity.  Therefore, from this the results of the 
rhDC-SIGN-Fc bidnign assay in Figure 14A it was inferred that H-BSA-Man100 
conjugates could be bound by CLRs found on DCs.  The Glc conjugates did not show a 
higher binding affinity for the recombinant Dectin-1 receptor as no signal was above the 
detection limit of the assay.  Because the positive control worked for this ELLA the 
conclusion that the activation seen in Figure 15 was not mediated by Dectin-1 and 
therefore unlikely to of occurred through any lectin mediated process on DCs was made.  
A discussion of what possible receptors could be playing a role is further discussed 
below.   
5.4.2 Cell Response to Glycoconjugates Across Three Modalities 
From Figure 15 it is clear that DC response to identical glycoconjugates displayed 
in different modalities is disparate.  Adsorbed mannan, H-BSA-Man100 and H-BSA-
Glc100 conjugates were all able to increase DC IMF to a statistically relevant amount as 
compared to untreated controls.  However, whe these same glycoconjugates were 
delivered in a soluble form no change in IMF for any of these conjugates was seen.  Also, 
when H-BSA-Glc100 and H-BSA-Man100 were adsorbed onto 1 µm beads and cultured 
with cells a statistical increase in IMF was not seen even for treatments containing 
enough beads for 25 times the surface area of that of well adsorbed conjugates.  From 
Figure 17 and Figure 18 it is clear that DCs are able to recognize and internalize these 
 125 
conjugates when adsorbed to 1 µm beads or delivered at low soluble concentrations.  
Thus, we hypothesize that a different molecular signaling mechanism is involved 
between each of the modalities.  From the raw IMF averages compared between 
modalities for both mannose and glucose conjugates DC activation is highest for well 
adsorbed glycoconjugates and lowest for soluble conjugates even delivered at the 
relatively high concentration of 100µg/ml.  DC activation when exposed to 1 µm beads is 
between these two but a significant trend was seen between surface area and increased 
IMF and thus it is possible that high ligand concentration is needed to activate DCs in this 
modality.  This has been postulated by other researchers and this report further supports 
the assertions made by Dam et al.257 
Of note is that DCs did not respond to soluble mannan at any of the 
concentrations tested.  The negative outcome of the mannan conjugates goes against 
previous studies that showed that mannan was an immune agonist.108,208,209 However, in 
these studies mannan was combined with particulates based on liposomes linked through 
membrane lipids, such as cholesterol108 or palmitoyl-mannan.208 Therefore, it could have 
been the synergistic effect of the lipids and the mannan that led to these activation 
reports.  This implies that the Th1/Th2 cell proliferation that was seen in these studies, 
that were thought to be mediated through mannan, may not represent the result of the 
ligand alone but through the synergistic recognition of the conjugates by TLR4 and 
CLRs.  Indeed, in an elegant study by Wattendorf et al.107 human DCs were cultured with 
phagocytosable polystyrene microbeads functionalized with di-branched PLL-PEG that 
had a man, Man3-Br (α1-3 α1-6), or mannan attached to the end of the PEG branch.  The 
mannan and PLL were passively adsorbed onto the PS beads leaving the mannan and 
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PEG functionalized glycan monomers free in solution instead of being found on the bead 
surface and no DC maturation was found.  This finding further supports our hypothesis 
not only by confirming the findings herein but also by showing the mannan did not 
activate cells when in solution and not “bound” to the bead surface. 
The fact that the DC response to different modalities appears to be different from 
Figure 15 was then confirmed using a general linear model, Model 3a.  Model 3a shows 
that cell response is statistically different between all modalities of display even when 
controlling for ligand and donor variances. Furthermore, all pairwise comparisons 
between modalities of display for Model 3a and b were done using a Bonferroni 
correction for multiple comparisons.  A Bonferroni correction was used for these models 
so as to be more conservative in estimation of significance.  However, the argument 
could be made that the glycan display density on well adsorbed surfaces is much higher 
than that of the soluble or phagocytosable modalities.  Because CLRs are multivalent 
receptors this increased density could be causing the increased activation of the DCs.  
Determining quantitative estimates of glycan surface density presented to cells is 
extremely technically challenging when looking at microbead presentation and virtually 
impossible in solution.  Thus, large ranges in concentration and bead number were tested 
to try to mitigate this concern.  Additionally, the same material is used between the well 
adsorbed and 1 µm bead adsorbed modalities.  Thus, the surface density between these 
two should theoretically be identical as steric hindrance of protein adsorbtion on such 
relatively large beads (1 µm versus a maximum hydrodynamic radius of 5.2 nm) has been 
shown to  not affect protein adsorbtion.258,259   
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Equation 1a used the interaction variable between ligand and modality to assess 
differences between modality/ligand combinations.  The results of the modeling yielded 
that Adsorbed H-BSA-Man100 was statistically different from soluble delivery of H-
BSA-Man100 and soluble H-BSA-Glc100.  In this model, and in Model 3a and b, 
mannan and β-glucan were not included.  This was done so as not to skew the data 
toward showing different modalities as significantly different when using poorly defined 
ligands that clearly showed differences in cell response between modalities.   While the 
result that adsorbed H-BSA-Man100 was different than soluble glycoconjugates was 
anticipated from a cursory comparison of the statistics shown in Figure 15. Confirmation 
that DCs’ IMF was statistically different between the mannose conjugate modalities 
further confirms the hypothesis of this report: that modality of glycan display alters DC 
phenotype; especially when combined with the anti-body blocking data seen in Figure 17.  
Finally, no significance for any ligand or modality, other than the positive control, 
was seen in any of the TMF studies or models.  This was not unexpected as mannose 
conjugates are frequently used as agonists for vaccines and to increase DC recognition 
and uptake of particles.107,260,261  Similarly, no known effect of the monosaccharide 
glucose has been shown on DCs.  Thus, that no treatments or modality claims were 
significant for the tolerogenic reporter was expected.  These data were left in the 
manuscript as validation that such an assessment is possible for DCs using this HTP 
methodology.  This is valuable because CLRs on DCs are also known to be instrumental 
in promoting tolerance and maintaining immune cell homeostasis.2,40,63,262   The 
assessment of tolerogenic phenotypes is especially important for DCs when CLRs are 
ligated because it has been shown that identical CLR stimulation can promote tolerance 
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or pro-inflammatory responses from DC depending on if the bound.1,263,264 Thus, any 
methodology that assesses activation and pro-inflammatory responses from DCs using 
CLRs must also evaluate tolerogenic responses from DCs.   
5.4.3 Cell Interaction with Glycoconjugates 
When combining the cell response data from Figure 15E and the antibody 
blocking data of Figure 17 it is clear that at least some of the DC response is due to lectin 
interaction with the H-BSA-Man100 conjugates.  However, from Figure 17 it is clear that 
the lectins tested do not mediate H-BSA-Glc100 activation of DCs shown in Figure 15E.  
This indicates that the DC response to the H-BSA-Glc100 glycans is independent of 
lectin activation due to the fact that no other lectin known on DCs, other than Dectin-1, 
can bind glucose.42  Thus, another mechanism for DC response to the H-BSA-Glc100 
conjugates must be used for activation of the DCs.  Other groups have shown that 
Complement receptor-3 (CR3), lactosylceramides, and scavenger receptors 265 can all 
bind β-D-glucose and thus it is hypothesized that it is these receptors that are mediating 
the increase in IMF for adsorbed H-BSA-Glc100 conjugates.    
Phagocytosis of beads was chosen as a way to assess DC interaction with any 
form of glycoconjugate for two reasons.  1) Mannose CLRs on DCs are known to be 
phagocytic receptors thus this was a functional reporter. 2) Using the HTP reporter of 
IMF or TMF could not be performed after 24hrs due to activation of cells occurring with 
prolonged incubation of relatively high concentrations of Abs.  All Ab treatments of DCs 
with 10 µg/ml of Ab, including isotype, were found to activate DCs significantly at 
24hrs.  A 2 µg/ml concentration of Ab was attempted but showed no functional blocking 
of the receptors in terms of phagocytosis at 4hrs and no influence of IMF or TMF at 24 
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hours (Data not shown).   IMF and TMF were checked at 4 hours with 10 µg/ml and no 
up-regulation of either was seen for any conjugate.  However, this does not mean that 
DCs were not being activated by these high concentrations of Ab, just that up-regulation 
of surface receptors had not occurred yet.  Thus, isotype antibody control treated DCs 
were chosen as the referent group in these studies to overcome concerns over non-
specific activation and thus phenotype modulation of DCs due to Ab treatment. Finally, 
mannan was not inhibited by either of the lectin blocking antibodies, however this was 
not surprising given that many other CLRs on DCs are capable of binding and 
recognizing mannan, as indicated in Table 1. 
From Figure 18 it can be seen that for the adsorbed conjugates, as compared to the 
H-BSA coated wells, more glycoconjugate was taken into cells for both the H-BSA-
Glc100 and H-BSA-Man100.  This further provides evidence indicating that 
internalization is receptor mediated, especially for H-BSA-Man100 when combined with 
the Ab blocking data shown in Figure 17.  Receptor meditated internalization is further 
supported by the fact that the adsorbed H-BSA-Man100 conjugates had a higher mean 
net fluorescence than did other conjugates, though not to a statistically significant 
amount.  Also of interest from Figure 18 is that adsorbed H-BSA-OEG100 conjugates 
had a lower mean fluorescence than did any other group.  This was expected as PEG 
coated ligands have frequently been reported to in inhibit phagocytosis in the 
literature.266,267  Additionally, when looking at any conjugate’s soluble delivery it is clear 
that DCs are internalizing the soluble conjugates.  Thus, the internalization of conjugates 
from the adsorbed wells must not be the sole process necessary for the increase in DC 
IMF seen in Figure 15.   
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Finally, the soluble 1 µg/ml conjugates showed a higher mean net fluorescence 
than adsorbed conjugates regardless of ligand used. This is significant because an 
approximately equal amount of soluble BSA was delivered as was present on the surface 
of the adsorbed wells.  This calculation came from using the surface density of BSA 
found by Osborne et. al.245 for BSA proteins adsorbed per unit area in a polystyrene tube, 
as measured by 125I-labeled proteins.  Using this calculation, 0.0168 µgs of protein are 
adsorbed to each well surface and thus an equivalent amount of BSA in 40µl of media 
would be needed.  This amounts to 0.438 µg/ml of conjugate being delivered per well.  
Assumptions for this calculation were that BSA had an average molecular weight of 
66,460 Da and that the surface area of the 384 well TCPS plate was 5.6 mm2.  The 1 
µg/ml concentration was chosen over delivering 0.438 µg/ml because a direct comparison 
between the DC internalization of fluorescent conjugates to that of the soluble delivery in 







CHAPTER 6  CONCLUSIONS AND FUTURE DIRECTIONS  
6.1 Conclusions 
This study uncovered a novel mechanism for the alteration of DC phenotype with 
adsorbed glycoconjugates that had not been reported in the literature before.  
Furthermore, this report showed quantitatively for the first time that density had the 
largest impact on DC IMF response and that charge also was a significant factor in DC 
response to adsorbed glycoconjugates.  Additionally, this report showed that factors for 
promotion of IMF were inversely correlated to factors that promoted TMF.  While this 
claim seems to be common sense, to the knowledge of the authors, this is the first time 
this has been shown to be statistically true.  Finally, this report showed that DC response 
to oligomannose structures presented from adsorbed conjugates was different between 
glycan structures.  When these structures were grouped in a model by terminal glycan 
motif it was found that terminal structural motifs played a significant role in the 
prediction of DC IMF.  To date this is the first time that terminal glycan structural motifs 
have been found to correlate to DC phenotype in response to adsorbed glycoconjugates 
across a variety of glycan structures.  Finally, this study showed that general linear 
modeling of DC interaction with adsorbed glycoconjugates produced models that had 
relatively high predictive capabilities, R2 ≈ 0.6 for all models, for a study using primary 
human donors with relatively small sample sizes (N<20).  It is expected that based off of 
these results other labs will incorporate this type of modeling into their analyses of DC 
response to glycoconjugates. 
This report also quantitatively shows for the first time that glycoconjugate 
presentation modality alters DC phenotype.  This is of importance for the glycobiology 
field because it challenges the precepts that glycan structure, density, and context are the 
only factors of importance for recognition and response from DCs.  This paper also helps 
to resolve conflicts in reports from multiple labs showing differential DC profiles in 
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response to similar if not identical ligands delivered in different modalities.  Additionally, 
this study beings to bridge the gap between microarray binding data and functional cell 
responses by highlighting the different phenotypes induced from adsorbed conjugates as 
compared to those in solution or adsorbed onto microparticles.  However, this study 
leaves many questions unanswered that must be investigated in the future.  First, given 
that different modalities of display are capable of producing differential DC phenotypes, 
what molecular signaling mechanism is involved in the differential response?  Possible 
explanations include mechanical interaction, length of time of interaction with CLRs on 
the surface, ability of CLRs to co-localize in a single area for extended periods of time on 
the cell surface, and/or generation of a “frustrated phagocytosis” state in which DCs 
release ROS and MMPs that leads to activation of surrounding DCs. A more in-depth 
discussion of these can be found in the future directions of this chapter. 
Second, for the H-BSA-Glc100 conjugates we hypothesized that the activation 
seen in Figure 15F was not caused by lectin interaction.  However, this was not directly 
proved and anti-body blocking produced inconclusive results.  Thus, cell knockout 
studies should be performed with these adsorbed conjugates to determine if dectin-1 is 
necessary for DC activation by the H-BSA-Glc100 conjugates and if not which receptors 
are necessary for activation (see Albeituni et al. for probably receptor classes.)265  Finally, 
the results from Figure 18 show that adsorbed conjugates are being internalized by DCs.  
Whether this internalization is necessary for DC activation and to what extent the 
internalization of conjugates plays in the phenotype modulation of DCs is an important 
and unanswered question.   A more in-depth discussion of these issues can be found in 
the future directions of this chapter. 
 Overall, the experiments proposed above and discussed in detail in the future 
directions of this chapter are not trivial and will require large amount of glycans and 
reagents.  However, with the use of statistical modeling it was shown in this report that 
important and here-to-fore unknown associations between glycan structure and DC 
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phenotype are capable of being uncovering using statistical modeling with relatively 
small amounts of glycan used (mg quantities).  This report showed the power of 
modeling and from this modeling strong indicators for future carbohydrate presentation 
approaches were uncovered.  Not only was it found that density and charge are both 
significant factors in adsorbed glycoconjugate alteration of DC phenotype but that 
grouping carbohydrate structures by terminal motifs one can create a model that has 
significant structural variables for the modification of DC phenotype. Therefore, it is 
expected that this report will provide a guide for future glycobiologists to analyze their 
data so that different glycan formulations can be compared more easily and so that 
underlying trends in the data can be uncovered.  Also, with the relative robustness of the 
models presented herein, as judged by R2 values, it is considered rational that other 
studies will use multivariate linear modeling of their data to determine the relative 
significance of other molecular factors not considered here (linker charge, length, or 
flexibility or different polymeric carriers, etc.) that are relevant to phenotype modulation 
of DCs via CLRs. 
 In addition to the modeling significance of this work, this dissertation uncovers 
the importance of non-phagocytosable display of glycans to DCs.  This area has generally 
received little attention in the field of glycobiology and it is expected that this report will 
increase its exploration and attention.  Use of glycans for implant coatings or as adjuvants 
for combination products for any other purpose than to increase phagocytosis or targeting 
of APCs is still relatively unexplored.  This dissertation shows that not only are glycans 
able to perform the functions typically associated with glycans but that they can serve as 
immunomodulators in their own right especially when delivered in a modality that DCs 
are able to recognize.  It is expected that with further optimization of molecular factors 
glycoconjugates could be engineered to tune the immune response to any desired 
outcome.  Furthermore, the work shown here begins to demonstrate what molecular 
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factors are of importance for DC recognition of non-phagocytosable glycans which could 
eventually lead to more efficacious clinical therapies.   
6.2 Future Directions 
 While the studies conducted herein took large steps toward the elucidation and 
analysis of pertinent molecular factors and modalities of glycan display for optimal DC 
phenotypic modulation; they do not bridge the gap between basic science and clinical 
therapy.  The field of glycoimmunology, specifically at the cellular and systemic level, is 
still in its infancy.  Many steps are needed to cross the divide between the fundamental 
cellular responses and potent clinical therapies.  This project was seen as building part of 
the foundation necessary to create these therapies and the future directions listed below 
are seen as the next steps that would be necessary to begin to fully understand, optimize, 
and engineer a relevant diagnostic/therapy based on glycoimmunology in the future.  The 
field is still rife with challenges including amount of complex glycan structures able to be 
produced, scale of assays conducted, relevant and accurate controls, and highly 
efficacious and specific blocking agents.  These are fundamental building blocks that 
must be created prior to the field being able to quickly, easily, and accurately assess cell 
responses and are seen as more broad areas of exploration for the field that do not 
necessarily stem from this project but that are important to its continued advancement. 
The immediate future directions of this project can be seen to work in two parallel 
tracks.  Track one is the elucidation and assessment of underlying molecular mechanisms 
for the response discovered in this dissertation.  Track two is the development of a 
synthetic polymeric carrier that recapitulates the results seen in this study for the 
adsorbed conjugates but that has more fine control over density of carbohydrate display, 
charge of carrier, and sugar linker length and motility.  Also, varying simple sugars 
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(disaccharides or less) with the polymer across a range of charges, densities, linker 
lengths, and linker motilities would be advantageous for this track.  
After these two tracks are completed tracks three, four, five and six can be 
performed in concert.  Track three, which was found to be desirable as a result of this 
dissertation, would be to further scale down the HTP assay to a 1536 well plate and print 
glycan arrays within the wells of these plates.  Ideally, the polymers developed in track 2 
would be used here and thus development of a delivery/coating system that delivered the 
polymer from track 2 with reproducible coating densities and glycan presentations would 
be needed for the successful completion of this track.  Additionally, the fundamental 
reporting mechanism of this assay would need to be different than the current HTP assay 
as filter plates are not available in this size and signal to noise ratios of staining 
antibodies at the volumes necessary for 1536 well plate assays are too low.  Track four 
would be to assess the DC response to a diverse set of well-defined sugar structures using 
the polymer developed in track 2.  Here, well defined sugar structures in each class of 
sugar known to bind to CLRs on DCs would be iterated to determine the exact structural 
motifs needed to stimulate DC IMF or TMF.  Essentially, taking the basic sugar 
structures possible in each class of glycan and iterating them over the optimized polymer 
seen from track 2 and modeling these interactions for prediction of DC response to more 
complex structures.  The sensitivity and specificity of predictive models could be 
determined by using the motifs as the training and validation set and then then more 
complex structures as the “test” set.  The fifth track would be a clinical study that would 
isolate and functionalize glycans from the glycoproteins of cancer patients, which are 
known to show aberrant glycosylation, and display these carbohydrates to DCs for use in 
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identification of novel targets for therapeutics and novel detection or screening 
methodologies.  Finally, track six would be to isolate, functionalize, and identify glycans 
from serum glycoproteins that mediate the immune response to implanted materials and 
utilize these glycans in vaccine or combination products. 
6.2.1 Molecular Mechanisms of Dendritic Cell Response to Adsorbed 
Glycoconjugates. 
This dissertation uncovered a previously unknown response of DCs to an 
adsorbed glycoconjugate.  It was shown also shown that cationized conjugates produced 
a much greater response than did non-cationized carriers.  The question then must be 
asked: why is the response to the cationized adsorbed conjugates by DCs so much higher 
than that of the non-cationized conjugates?  The cationization of carriers and its effect on 
immune response has been studied a great deal and an in-depth discussion has been 
performed for other cell types242,268–270 Perhaps the most obvious explanation for these 
data is the fact that cationized proteins tend to adhere better to the slightly anionic cell 
membrane271 However, this has not been shown on DCs and thus a study similar to that 
of the Schalkwilk et. al. could be performed with labeled cationized BSA 
glycoconjugates and DCs to determine if cationized conjugates adhere better to DC 
surfaces. The possibility also exists that cBSA may be recognized more efficiently by 
DCs because of its altered structure. This is more difficult to assess but a study could be 
performed in which a Acrylic acid N-hydroxysuccinimide ester (Sigma) was used to cap 
all the amine groups of the cationized glycoconjugate and look at the subsequent DC 
response.  However, this is seen as a less definitive experiment because by altering the 
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charge of the protein the structure of the protein is altered and thus confounding structural 
changes are introduced.   
While this dissertation uncovered a novel ligand capable of inducing DC 
maturation, how this ligand was able to do so was not uncovered.  What signaling and 
specific receptors are mediating this response?  Aim 2 implicates both DC-SIGN and 
Dectin-1 are important to the DC interaction with the conjugates however,  it does not 
conclusively show that these receptors are necessary for DC IMF up-regulation due to the 
activation caused by the high concentration of Ab necessary for blocking of these 
receptors.  Thus, DCs from DC-SIGN and Dectin-1 knockout mice could be obtained and 
treated with the conjugates to determine the receptors necessary for activation.  DC-SIGN 
KO mice are available through the Consortium for Functional Glycomics and Dectin-1 
KO mice can be generated as per Taylor et al.272  The response to surface adsorbed and 
the conjugates in different modalities should be assessed as DC response was found to 
vary drastically between modalities of display as well.   
Also, given that different modalities of display are capable of producing 
differential DC phenotypes, what molecular signaling mechanism is involved in the 
differential response?  Possible explanations include mechanical interaction, length of 
time of interaction with CLRs on the surface, ability of CLRs to co-localize in a single 
area for extended periods of time on the cell surface, and/or generation of a “frustrated 
phagocytosis” state in which DCs release ROS and MMPs that leads to activation of 
surrounding.  Mechanical testing could be performed by displaying covalently bound 
carbohydrates to DCs from polymers with different rigidities and exploring the 
subsequent DC response.  Substrate rigidity has recently been found to influence T cell 
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activation and proliferation273 and thus it is expected that DC response would also scale 
with these factors and could be assessed in a similar fashion to the O’Connor study.  
Transducing DCs to express fluorescently tagged DC-SIGN and Decint-1 and then 
measuring the length of time of interaction with fluorescently labeled glycoconjugates via 
confocal microscopy could be used to determine the length of time of interaction between 
adsorbed and soluble conjugates.  These same transduced DCs could then be used to look 
at CLR co-localization in response to different modalities of glycoconjugate presentation.  
Finally, measuring ROS and MMPs in solution after exposure of DCs to adsorbed 
conjugates could be performed to determine whether DCs were entering into a 
“frustrated” phagocytic state. 
Of additional interest from these studies is how the cells treated with the adsorbed 
conjugates affect the systemic immune system, i.e. Th1 or Th2 proliferation, cytokine and 
chemokine production, MHC and other costimulatory molecule expression, and 
presentation of co-delivered antigen.  The supernatants from the studies performed in this 
dissertation were saved at -80°C and can be assayed at any time for cytokine and 
chemokine content.  However, due to the large number of groups that could be tested and 
the relatively large variability that has been shown to exist for the profiles in the assays224 
the benefit to performing these assays versus the cost of them was seen as low.  However, 
a smaller study could be done in which the highly cationized conjugates were compared 
across display modalities for a limited number of donors and the subsequent cytokine and 
chemokine profiles assessed.  Additionally, in this reduced study DCs could be stained 
with a variety of anti-bodies for a range of costimulatory molecules and analyzed via 
flow cytometry.   
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For a more functional immune response assessment co-delivery of a model 
antigen, OVA, with the H-BSA-Man100 conjugates could be performed and the 
subsequent proliferation of OTI and OTII T cells could be measured.  This would identify 
whether the high IMF seen in the DCs led to a high Th1 or Th2 response.  Also, the DCs 
could be assessed for epitopes presented on the MHCI and MHCII of these molecules via 
antibodies known to bind to OVA or BSA for an assessment of how well the DCs were 
presenting the co-delivered antigen. 
Also, Aim 2 showed that DCs were being activated by the adsorbed H-BSA-
Glc100 conjugates.  However, in the dectin-1 blocking studies and the ELLAs performed 
in this Aim, no interaction with Dection-1 was shown for these conjugates.  It is known 
that CR3, lactosylceramide and scavenger receptors all can bind glucose and thus a fully 
reductive study blocking each of these receptors and assessing the DC phenotype to the 
adsorbed H-BSA-Glc100 conjugates could be performed.265       
Finally, the results from Aim 2 showed that adsorbed conjugates were being 
internalized by DCs but whether this internalization was necessary for DC activation and 
to what extent the internalization of conjugates plays in the phenotype modulation of DCs 
was not uncovered.  Thus, a study where DCs are treated with the adsorbed conjugates at 
4°C and the subsequent DC phenotype assessed after 24 hours could be performed.  In all 
Ab blocking experiments performed in Aim 2 internalization of coated beads was the 
lowest for DC treated at 4°C thus, internalization and subsequent maturation of well 
adsorbed conjugates should be performed at 4°C to determine extent of maturation of 
DCs when minimal internalization of conjugates is occurring.   
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6.2.2 Development of a Tunable Synthetic Polymeric Carrier for Non-
Phagocytosible Display of Glycans to Dendritic Cells.  
Track two is the assessment of mannose and sialic acid in mono and disaccharide 
form from a polymeric structure.  Functionally, this track will be very similar to that of  
Aim 1 in this dissertation.  However, instead of development of the BSA carrier the 
researcher would develop a polymeric carrier for glycans.  This polymer would need to 
be able to be able to scale in charge, glycan density, glycan linker length, and 
motility/lability of linker.  Several types of polymers are possible but Dr. Ravin Narain of 
the University of Alberta has already developed a library of cationic glycopolymers of 
pre-determined molar masses and narrow polydispersities ranging from 3 to 30 kDa that 
were synthesized using RAFT polymerization techniquess.  Furthermore, using RAFT 
polymerization it is easy to scale the level of cationization to that of virtually any desired 
level using different block copolymers.  This chemistry is standard and well 
characterized.274  Thus, in collaboration with Dr. Narain a library of conjugates scaling in 
glycan density, level of cationization, and in linker length could be produced.   
In this track only two sets of sugars are proposed to be tested: Mannose and sialic 
acid.  Mannose was chosen because the mannose binding CLRs are the most studied and 
well understood DC CLRs.  Additionally, mannose was shown in this dissertation to 
produce a pro-inflammatory response from DCs.  Thus, the results from this dissertation 
could be compared to the results of the RAFT polymers produced in this Track.  Sialic 
acid, was chosen as the other sugar of interest because this sugar is  known to be bound 
by Siglecs which have ITIM motifs.87,100  Ligation of  Siglecs has been shown to induce 
tolerance and apoptosis in DCs275 and thus it is expected that using sialic acid will 
increase the TMF in DCs.  Though no literature has shown that Siglec ligation leads to 
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increased ILT3, Siglecs are sialic-acid-binding immunoglobulin-like lectins and thus are 
in the same receptor super family as ILT-3 and it is therefore seen as likely that these two 
are linked.   
Thus, a polymeric carrier can be optimized for both a pro-inflammatory and anti-
inflammatory DC phenotype using these two glycans.  Optimization for TMF was a 
shortcoming of this dissertation as no combination of properties were found to 
significantly up-regulate TMF; though trends of low density and cationization being 
favorable for TMF was shown in the models.  Furthermore, the properties of the polymer 
can be optimized for each glycan and then applied to other sugar classes in later studies.  
Mono- and disaccharides are recommended for use in this section so as to increase lectin 
affinity for the glycan moieties and to better permutate possible structural motifs found in 
nature.  
6.2.3 High Throughput Development of a Functional Cellular Output in 1536 Well 
Plates for Use with Printed Glycan Arrays.  
 This track of experiments has two main development components that can be 
developed simultaneously.  The first is the printing and validation of glycoconjugates in 
the wells of a 1536 well plate.  For this Track the RAFT polymer developed in Track 2 
would be immobilized in the wells of a 1536 well plate.  Ideally, from Track 2, several 
polymer formulations would be necessary to exploit the range of DC phenotypes desired 
across different sugar structures (from tolerogenic to pro-inflammatory) and thus the 
subsequent characterization of the spotted glycopolymers will need to be performed.  A 
liquid handling system will need to be purchased and ideally the glycopolymers would be 
formed and spotted simultaneously.  The heterogeneity of the spotted conjugates could 
then be assessed via standard MS and SPR methodologies. This process would be similar 
to the process used by Langer et. al. and Bradley et. al.276,277 except using glycopolymers 
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instead of strictly polymeric or hydrogel substituents.  Also, instead of being performed 
on non-welled slides the procedure would have to be optimized for a 1536 well plate. 
 The second is a 1536 well HTP approach that uses DCs and T cells to produce a 
functional output.   HTP approach is necessary to assess functional phenotypic effects of 
glycans for four key reasons.  First, only limited amounts of oligosaccharides (at sub-
µmol levels) can typically be isolated from natural sources when cleaved from proteins or 
lipids and they are highly heterogeneous in structure. 4,177–179  Second, the structural 
diversity of oligosaccharides leads to difficulties in their structural characterization; 
currently, there is a lack of an efficient means of automated assignment and the 
characterization is mainly reliant on expert interpretation by MS analyses.180 Third, the 
biosynthesis of oligosaccharides is not template driven as it is for DNA and proteins, and 
thus the diverse repertoire of oligosaccharides that would be representative of the 
glycoform of a typical glycoprotein is extremely difficult to reproduce by chemical 
synthesis.181–183 Fourth, most carbohydrate-protein interactions are of low affinity, and 
there is a requirement of multivalent presentation of carbohydrate ligands for detection of 
binding in microscale screening analysis.104,105,184 All of these challenges are addressed 
and mitigated by using a carbohydrate microarray as indicated herein. 
While the HTP assay developed in this dissertation is a significant improvement 
over other HTP screening strategies in terms of functional assessment of DC phenotype 
the assay does have several limitations.  First, the assay only assesses three surface 
markers on the DCs.  Many more surface markers show differential expression on DCs in 
response to various challenges and thus the full repertoire of effector functions these DCs 
are capable of producing is not assessed in this assay.  Second, in order to determine the 
cytokine profile a relatively expensive bioplex assay is needed.  While many cytokines 
profiles can be determined using this methodology the expense of performing this assay 
on every well of a HTP assay is prohibitive.  Thirdly, no time course of expression is 
seen in this assay.  This assay uses a static time point analysis and no information about 
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temporality of expression/secretion can be gleaned from it.  Finally, this assay only 
provides a read out for the non-adherent fraction of DCs that have responded to an 
agonist.  The adherent fraction could be substantial if a surface is modified with an 
adhesive ligand.  As many CLRs on DCs are known to be adhesion receptors79,278 the loss 
of this population could result in a biased cell assessment.  Thus, designing a new HTP 
methodology that addresses these shortcomings would have large implications for DC 
response to glycan arrays.   
The new assay must still rely on wells for DC treatment because DCs are loosely 
adherent and thus can migrate to other treatment spots in un-welled arrays.  Additionally, 
DCs also produce large amounts of soluble cytokines and therefore cross-contamination 
of soluble factors between treatment groups is a concern in an un-welled array format.  
This is especially valid if longer time courses of response than a few hours are of interest.  
The smallest welled plate currently commercially available is a 1536 well plate.  The 
advantage of utilizing this format over the 384 well assay is the reduction in reagent use.  
The 384 well screen uses nanomoles of glycan per assay and the 1536 well plate reduces 
the amount of glycan needed into the picomolar range. Furthermore, the scale down to 
the 1536 well plates has the potential to increase the number of ligands tested in a single 
test by a factor of 4.   
Unfortunately, the scale down to a 1536 well plate changes the nature of the assay 
because 1536 well filter plates are not produced.  However, the removal of the filter plate 
is not necessarily a negative aspect of a new assay. The use of filter plates increases the 
complexity of the assay in that more washes and incubation steps are needed and because 
the cell culture is performed in a separate, non-filter plate, well only the non-adherent 
fraction of DCs is assessed in the current protocol.  Thus, elimination of the filter plate 
potentially reduces the complexity of the assay and allows for the assessment of the 
adherent DC population.  A new reporter would be needed for a read out in these plates 
as Ab staining, which is the current reporter mechanism, is not able to be used without a 
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filter plate.  A mixed lymphocyte reaction (MLR) was chosen as the reporter mechanism 
for this assay because T cells can become highly proliferate when exposed to activated 
DCs.  The basic principle of the MLR is that when allogeneic T cells are added to a 
culture of APCs, in this case DCs, the TCR recognizes the MHC, either MHC I or MHC 
II depending on T cell phenotype, of the APC as being foreign and the T cell becomes 
primed to clonally expand.  However, clonal expansion requires more than just 
recognition of a foreign MHC, the T cell must also have its costimulatory molecules 
activated in order to clonally expand.  This can only occur if the APC has been activated.  
Thus, in an MLR clonal expansion of the T cell occurs only when the APC has been 
activated and when the T cell recognizes the MHC presented from the APC as being 
foreign.  Therefore, if one can quantify the amount of T cell expansion as compared to an 
unstimulated control one could assess the activation state of the APC.  When using DCs 
in a MLR there is the added advantage of being able to stimulate CD4+, CD8+, and T 
regulatory (Treg) cells in an antigen independent manner as DCs have a high expression of 
MHC I & II as well as the ability to stimulate Tregs.
279–290  Thus, this new reporter has the 
advantage of directly assessing a complete DC phenotype across multiple activation 
profiles.  T cell expansion is itself an effector function of DCs and thus is an extremely 
applicable reporter.   The new methodology addresses the shortcomings of the previous 
assay in that the surface marker and cytokine profile is indirectly assessed.  The 
proliferation of T cells requires the appropriate regulation of many surface markers and 
the secretion of many cytokines not to mention accurate temporal expression of these 
molecules.  Therefore, if a T cell population expands it could be inferred that the DC has 
become activated and has up and down regulated the expression of the correct surface 
molecules and cytokines.   In summary, the new methodology is able to directly assess an 
effector function of DCs in its reporter unlike any HTP methodology before it, it assess 
the effector function of the entire DC population as it does not require a transfer of cells 
to a filter plate, it can assess 4x as many ligands as the current HTP protocol, it requires 
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5x less reagent to perform, and is cheaper to perform as it does not require expensive 
antibody or bioplex assays for its reporter. 
Two protocols to quantify the amount of T cell proliferation have been considered 
for further development and are outlined below.  Each protocol has its own strengths and 
weaknesses that will be discussed.  
6.2.3.1 T Cell Hybridoma High Throughput Assay 
The first protocol involves the use of an antigen specific T cell hybridoma that has 
been transduced to express a fluorophore.  T cell hybridoma are a combination of a 
healthy antigen specific T cell and a lymphoblast.  Due to the nature of these cells they do 
not proliferate as traditional T cells do and are considered immortal.  Of note is that while 
T  cell hybridoma are lymphomas they express relatively normal signaling and surface 
markers, as compared to T cells lines, for DCs to recognize, signal, and/or activate.291–295 
For this assay the hybridoma could be cultured with primary DCs in the presence of the 
antigen that the T cell is specific for.  The hypothesis is that if the DC is activated then 
the hybridoma will clonally expand more quickly than if the DC is not activated.  
Expansion of the T cell would be measured by fluorescent intensity as compared to the 
intensity of unstimulated wells. Through careful analysis of literature five T cell lines 
have been identified that have correct surface marker expression of T cell signaling 
molecules and do not autologously proliferate excessively, doubling time ≥ 48 hours.  
These cell lines are: Jurkat, Molt-3, Molt-16, CCRF-HSB2, and TALL-104.  Thus, while 
these cell lines are lymphomas they express relatively normal signaling and surface 
markers for DCs to recognize, signal, and/or activate and are seen as good candidates for 
creation of T cell hybridoma.   
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 There are many advantages to using T cell hybridoma.  First, these cells are 
capable of being stably transduced with a fluorescent marker that is constitutively 
expressed.  This fluorescent tagging can be used as a reporter for cell number as the cells 
proliferate.  Therefore, if a DC stimulates the T cell it will begin to clonally expand and, 
if this occurs in a well, the GMFI of that well will increase as compared to the mean 
fluorescence of an unstimulated well.  A second advantage of this method of analysis is 
that it also allows for a time course study to be possible as the fluorescent intensity of the 
well can be taken at multiple time points to determine how fast and to what magnitude 
the cells are proliferating.  A third advantage of using T cell hybridoma is that they 
expedite the high through put nature of the assay.  The cells need only be cultured, 
transduced, and then selected out for their GFP production.  After this process the cells 
can be frozen and then thawed several days before use.  This provides for easy access to 
an almost infinite amount of GFP expressing T cells that are ready without any real 
culture time, reagent expenditure, or in-depth preparation.  The final advantage of using 
hybridoma is that they allow for a similar reaction to be assessed for each culture 
condition and each DC donor.  T cell hybridoma are clones of cells and thus their 
response is very homogeneous and so variability of two donors, one for DCs and one for 
T cells, does not have to be accounted for when performing this assay. 
The use of T cell hybridoma vs. primary cells has its caveats in that the T cells are 
lymphomas and therefore not a completely accurate representation of healthy T cell 
proliferation.  This reduces the ability of the assay to determine actual effector function 
of the DC stimulation which is one of the main strengths of the assay.  However, 
stimulation of T cell proliferation still requires the up and down regulation of many 
surface receptors, intercellular interaction, and secretion of a dearth of cytokines296, 
regardless of if it is a hybridoma or primary cell, and thus is still a much more relevant 
output versus current HTP strategies.   
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6.2.3.2 Primary Allogeneic T cell  High Throughput Assay 
The second protocol involves the use of primary allogeneic T cells.  This protocol 
more closely follows the MLR protocol previously established in this lab. T cells are co-
cultured with DCs from a different donor to determine if the DCs are activated.  This 
protocol involves only measuring an end point replication.  This end point is total 
quantification of DNA present in the well as measured by the fluorescent intensity of the 
DNA of all of the cells in a well stained by Pico-green.  The cell proliferation would be 
assessed by staining with pico-green 5 days after the DCs and T cells have been seeded 
together in the wells. This reporter is chosen because of the previously mentioned 
resistance of primary cells to be stably transduced with a reporter and because even if this 
stable transduction occurs it is in very low prevalence.     
This assay has the advantage of using primary T cells that are healthy and fully 
functional.  However, it has several weaknesses that make this a non-ideal assay in a high 
throughput evaluation.  First, the quantification is an endpoint and thus no time course of 
replication can be easily determined.  Second, the quantification is non-specific.  What 
cells have proliferated and to what extent they have proliferated is unknown, only the 
total DNA concentration per well can be determined.  Thirdly, T cells must be taken from 
a second donor for every experiment.  This not only entails significantly more time and 
work for every donor tested but also introduces another level of variability in the data.  It 
is thought that it is this added variability that has caused confounding results in the 96 
well plate MLR that has been performed in the Babensee lab.   
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6.2.3.3 High Throughput Assay Conclusions 
With either methodology before the final analysis the supernatant of the DC – T 
cell co-culture can be taken and applied to a different well of activated clonally 
expanding GFP expressing T cells.  This assay will be performed to determine if the co-
culture of the cells has created an anti-inflammatory, immunosuppressive 
microenvironment.  This is valuable because two types of tolerance are possible.  One 
type of tolerance is active tolerance in which Tregs are stimulated and clonally expand to 
actively inhibit the inflammatory response.  However, another type of tolerance can be 
seen in the literature that shows the release of anti-inflammatory cytokines that inhibit the 
further activation and maturation of immune cells without causing T cell expansion.  This 
second kind of tolerance is much more common but also difficult to detect with a typical 
MLR.  An additional analysis of the soluble factors must be done in order to determine if 
this is the case.  At the volumes possible in a 1536 well plate soluble factors cannot be 
analyzed.  Thus, this further culture with activated T cells will allow for the 
determination of this second type of tolerance.  There are technical concerns for this 
methodology because of the small volume of liquid in each well of a 1536 well plate, 
≤10µl.  These are valid concerns and cell count assays should be done initially on the 
supernatants to determine if it is possible to remove them without significant 
simultaneous cellular uptake.  After validation a liquid handling robot would be needed to 
perform this expiration of supernatants and so it is expected that after optimization this 
will significantly reduce the variability of the removal.   
 149 
6.2.4 Assessment and Modeling of the DC response to a Diverse Set of 
Incremental, Well-Defined, Sugar Structures.  
 In this dissertation it was shown that glycan structure and specifically terminal 
structural motif of glucan is a significant predictor of DC phenotype.  Additionally, 
microarray studies have repeatedly shown drastically altered affinity for different glycan 
structures from the same lectin.211   However, the analysis conducted in Aim 1 of the 
dissertation was not a thorough and mechanistic study of glycan structure versus cell 
function.  Additionally, not enough glycan structures were able to be tested to create a 
validation and test set for the models created.  Thus, a future proposal for this Track 
would be to assess DC phenotype to a diverse set of incremental, well defined, sugar 
structures presented from the polymer surface optimized in Track 2.  From the study 
conducted in Aim 1 it was found that α1-α2 linked terminal glycan structures were 
associated with IMF and α1-α3, α1-α6 branched mannose structures were not.  However, 
this grouping left out single α1-α3 mannose linkages as well as combinations of the 
above motifs.  Therefore, a complete understanding of which components of the glycan 
structures affect DC phenotype is unknown.  Figure 19 shows the oligomannose 
structures that could be tested to quantitatively prove which structural motifs were 
necessary for DC activation.   
 With the glycan structures proposed in Figure 19 a predictive model could be 
created using the general linear model technique used in Aims 1 and 2 of this report.  The 
model would be similar to that shown in Equation 2 of Aim 1 of this dissertation, just 
with more structural ligands.  The hypotheses would be the same for this model as for the 
model shown in Equation 2.   
 The difference between the proposed model and the model shown in Equation 2 
would be that the proposed model has a fully reductive set of terminal glycan motifs and 
that the purpose of these  experiments would be to validate the model against more 
complex glycan structures and against another donor “test” pool.  With this setup one set 
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of donors could be used to create the proposed model, the output for which would be DC 
IMF and be obtained from the HTP assay developed in this dissertation.  In this model 
DC IMF would be modeled as a function of glycan terminal motif.  Iterative models 
could be created including each level of mannose from below Man2-X, Man3-X, etc. and 
its predictive ability could be measured against that of a second “test” set of donors.  
Additionally, these models could then be used to predict the DC phenotype to the more 
complex sugar structures shown in Figure 19.  This could originally be performed with 
the same set of donors to determine which motifs are predictive of DC phenotype and 
then applied to the DC response of a “test” set of donors to these high mannose 
structures.  The predicted values would be compared to the actual values via least squares 
regression and the models compared based upon their relative R2 values.  Glycans from 
Figure 19 could be produced in house or purchased from LuCella Biosciences. However, 
it is recommended that the glycan be produced in house via the solid state glycan 
synthesis perfected by Ratner et. al.297 due to the prohibitive cost of producing a large 
array of glycan structures.  
 In addition to the scientific value of the modeling and DC response above the DC 
response to complex mannose structures and an understanding of which structures 
modulate DC phenotype to the greatest extent could be applied to vaccine adjuvants, 
combination product formulation, and for coating for implants.  Additionally, several of 
the structures from Figure 19 are known glycan structures of pathogens such as 
Entamoeba247 and could be used to develop a vaccine for these parasites. 
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Figure 19: Mannose glycan structures for training, validation, and test set analysis. 
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 After proving that this methodology is valid for the test set and for prediction of 
phenotype of DCs in response to more complex structures this methodology could then 
be applied to another set of sugars.  Glycan classes of possible interest include the Lewis 
glycan structures and human Blood antigens, (lacto-N-tetraose ) LNT based strucutres, 
sialyl derivitized structures known to bind Siglecs, and Core 1-4 structures.   A fully 
reductive study could be done for each of these sets of sugars in an identical fashion to 
that of the polymannose described in detail herein.  Each of these classes is of interest for 
different reasons: knowledge of the blood antigens and Lewis structures could provide 
novel mechanisms for adjuvants for vaccines or combination products or for immune 
avoidance for implanted materials/scaffolds.  The LN based structures are commonly 
found in breast milk298 and as antibody targets for Schistosoma mansoni infection.299  
Sialyl derivatized structures are targets for siglecs which have broad immune regulatory 
ability from cell adhesion to inhibiting immune cell activation via ITIMs.87 Finally, Core 
1-4 structures are found on a variety of mucins and mammalian glycoproteins and have 
been shown to have broad antigenic capabilities.176    
 Finally, the cost of producing the sugars suggested for further research would be 
prohibitive for a fully reductive study on each sugar class.  However, the Consortium for 
Functional Glycomics has a large library of glycans that are readily available in quantities 
that would be well suited to the HTP polymeric assessment of DC phenotype.  Currently, 
the Consortium makes 85 sugar structures available in 1 or 5 mg quantities which would 
be enough to produce the optimized sugar/polymer conjugates.  These sugars span the 
Lewis and blood antigens, LN based structures, and contain many sialyl functionalized 
structures.     Table 10 shows the list of all available structures from the consortium.  
With the structures provided by the Consortium it would be possible to easily model the 




Table 10:  List of sugars available from the Consortium for Functional Glycomics. 
No. Consortium 
Compound # 






1 M5 GlcNAcb-Sp GN 1 or 5 mg 
2 D11 Galb1-3GalNAca-Thr TF 1 mg 
3 D8 Galb1-3GlcNAcb-Sp Lec 1 or 5 mg 
4 D9 Galb1-4Glcb-Sp Lac, L 1 mg 
5 D10 Galb1-4GlcNAcb-Sp LacNAc, LN 1 mg 
6 D14 Neu5Aca2-6GalNAca-Thr STn 1 mg 
7 Tr116 Fuca1-2Galb1-3GlcNAcb-Sp H-type1 1 or 5 mg 
8 Tr120 Fuca1-2Galb1-4Glcb-Sp 2'FL 1 or 5 mg 
9 Tr117 Fuca1-2Galb1-4GlcNAcb-Sp H-type2 1 or 5 mg 
10 Tr260 Gala1-3Galb1-3GlcNAcb-Sp Gala3-type1 1 mg 
11 Tr59 Gala1-3Galb1-4Glcb-Sp Galili-tri 1 or 5 mg 
12 Tr60 Gala1-3Galb1-4GlcNAcb-Sp B2-tri 1 mg 
13 Tr61 Gala1-4Galb1-4Glcb-Sp Pk 1 or 5 mg 
14 Tr62 Gala1-4Galb1-4GlcNAcb-Sp P1 tri 1 or 5 mg 
15 Tr57 Galb1-3[Fuca1-4]GlcNAcb-Sp LeA 1 or 5 mg 
16 Tr38 Galb1-3[Neu5Aca2-6]GalNAca-Thr 6'STF 1 or 5 mg 
17 Tr58 Galb1-4[Fuca1-3]GlcNAcb-Sp Lex 1 or 5 mg 
18 Tr307 GlcNAcb1-3Galb1-3GlcNAcb-Sp 3'GN type1 1 mg 
19 Tr55 GlcNAcb1-3Galb1-4GlcNAcb-Sp GNLN 1 or 5 mg 
20 Tr54 GlcNAcb1-3Galb1-4Glcb-Sp LNT-2 1 or 5 mg 
21 Tr48 KDNa2-3Galb1-3GlcNAcb-Sp 3'-KDNLec 1 or 5 mg 
22 Tr47 KDNa2-3Galb1-4GlcNAcb-Sp 3'KDNLN 1 or 5 mg 
23 Tr34 Neu5Aca2-3Galb1-3GlcNAcb-Sp 3'SLec 1 or 5 mg 
24 Tr113 Neu5Aca2-3Galb1-4Glc GM3 (no 
spacer) 
1 or 5 mg 
25 Tr32 Neu5Aca2-3Galb1-4Glcb-Sp GM3 1 or 5 mg 
26 Tr33 Neu5Aca2-3Galb1-4GlcNAcb-Sp 3'SLN 1 or 5 mg 
27 Tr35 Neu5Aca2-6Galb1-4Glcb-Sp 6'SL 1 or 5 mg 
28 Tr36 Neu5Aca2-6Galb1-4GlcNAcb-Sp 6'SLN 1 mg 
29 Tr269 Neu5Aca2-6GalNAcb1-4GlcNAcb-
Sp 
6'SLDN 1 or 5 mg 
30 Tr323 Neu5Ac(9Ac)a2-3Galb1-3GlcNAcb-
Sp 
9OAc3'Slec 1 mg 
31 Tr322 Neu5Ac(9Ac)a2-3Galb1-4GlcNAcb-
Sp 
9OAc3'SLN 1 mg 
32 Tr41 Neu5Gca2-3Galb1-3GlcNAcb-Sp 3'SLec (Gc) 1 mg 
33 Tr39 Neu5Gca2-3Galb1-4Glcb-Sp 3'SL (Gc) 1 mg 
34 Tr40 Neu5Gca2-3Galb1-4GlcNAcb-Sp 3'SLN (Gc) 1 mg 
35 Tr43 Neu5Gca2-6Galb1-4GlcNAcb-Sp 6'SLN (Gc) 1 mg 
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Table 10 Continued   
36 Te134 Fuca1-2(Galb1-4GlcNAcb1-3)2b-Sp H2 1 or 5 mg 
37 Te118 Fuca1-2Galb1-4[Fuca1-3]GlcNAcb-
Sp 








Ley-Di-Lex 1 mg 
40 Te135 Fuca1-2(Galb1-4GlcNAcb1-3)3b -
Sp 
H3 1 mg 
41 Te258 Gala1-3[Fuca1-2]Galb1-3GlcNAcb-
Sp 
B tetra type 1 1 mg 
42 Te262 Gala1-3[Fuca1-2]Galb1-4[Fuca1-
3]GlcNAcb-Sp 
2'F-B type 2 1 mg 
43 Te225 Gala1-3[Fuca1-2]Galb1-4Glcb-Sp B tetra L 1 mg 
44 Te223 Gala1-3[Fuca1-2]Galb1-4GlcNAcb-
Sp 
B tetra type 2 1 mg 
45 Te221 Gala1-3Galb1-4[Fuca1-3]GlcNAcb-
Sp 
Gala3Lex 1 mg 
46 Te327 Gala1-4Galb1-4GlcNAcb1-3Galb1-
4Glcb-Sp 
P1 penta 1 mg 
47 Te287 Galb1-3[Fuca1-4]GlcNAcb1-
3Galb1-4[Fuca1-3]GlcNAcb-Sp 
LeALex 1 mg 
48 Te318 Galb1-3[Fuca1-4]GlcNAcb1-
3Galb1-3[Fuca1-4]GlcNAcb-Sp 
Di-LeA 1 mg 
49 Te286 Galb1-3GlcNacb1-3Galb1-4[Fuca1-
3]GlcNac-bSp 
Lec-LeX 1 mg 
50 Te302 Galb1-3GalNAcb1-3Gala1-4Galb1-
4GlcNAcb-Sp 
P1 penta 1 mg 
51 Te271 Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb-Sp 
LNT 1 mg 
52 Te316 Galb1-3GlcNAcb1-3Galb1-
3GlcNAcb-Sp 
Di-Lec 1 mg 
53 Te101 (Galb1-4[Fuca1-3]GlcNAcb1-3)2b-
Sp 
Di-Lex 1 mg 
54 Te102 (Galb1-4[Fuca1-3]GlcNAcb1-3)3b-
Sp 
Tri-Lex 1 mg 
55 Te319 Galb1-4[Fuca1-3]GlcNAcb1-
3Galb1-3[Fuca1-4]GlcNAcb-Sp 
Lex-LeA 1 mg 
56 Te98 (Galb1-4GlcNAcb1-3)2b-Sp Di-LN 1 or 5 mg 
57 Te100 (Galb1-4GlcNAcb1-3)3b-Sp Tri-LN 1 or 5 mg 
58 Te72 Galb1-4GlcNAcb1-3Galb1-4Glcb-
Sp 
LNnT 1 or 5 mg 
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Table 10 Continued   
59 Te259 GalNAca1-3[Fuca1-2]Galb1-
3GlcNAcb-Sp 
A tetra type 1 1 mg 
60 Te261 GalNAca1-3[Fuca1-2]Galb1-
4[Fuca1-3]GlcNAcb-Sp 
2'F-A type 2 1 mg 
61 Te224 GalNAca1-3[Fuca1-2]Galb1-4Glcb-
Sp 
A tetra L 1 or 5 mg 
62 Te222 GalNAca1-3[Fuca1-2]Galb1-
4GlcNAcb-Sp 
A tetra type 2 1 mg 
63 Te289 GalNAcb1-3Gala1-4Galb1-
4GlcNAcb-Sp 
P1 tetra 1 mg 
64 Te99 GlcNAcb1-3(Galb1-4GlcNAcb1-
3)2b-Sp 
3'GN-Di-LN 1 mg 
65 Te325 Neu5Aca2-3(Galb1-3[Fuca1-
4]GlcNAcb1-3)2b-Sp 




3'SLeA-LeX 1 mg 
67 Te291 Neu5Aca2-3Galb1-3GalNAcb1-
3Gala1-4Galb1-4Glcb-Sp 
SSEA-4 1 mg 
68 Te321 Neu5Aca2-3Galb1-3GlcNAcb1-
3Galb1-3GlcNAcb-Sp 
3'S-Di-Lec 1 mg 
69 Te288 Neu5Aca2-3Galb1-3GlcNAcb1-
3Galb1-4GlcNAcb-Sp 
3'SLecLN 1 mg 
70 Te75 Neu5Aca2-3[Galb1-3GalNAcb1-
4]Galb1-4Glcb-Sp 
GM1 1 mg 
71 Te64 Neu5Aca2-3Galb1-4[Fuca1-
3]GlcNAcb-Sp 
3'SLex 1 or 5 mg 
72 Te140 Neu5Aca2-3(Galb1-4[Fuca1-
3]GlcNAcb1-3)2b-Sp 
3'S-Di-Lex 1 mg 
73 Te175 Neu5Aca2-3[Galb1-4GlcNAcb1-
3)2b-Sp 
3'S-Di-LN 1 or 5 mg 
74 Te192 Neu5Aca2-3[Galb1-4GlcNAcb1-
3)3b-Sp 
3'STri-LN 1 mg 
75 Te320 Neu5Aca2-3Galb1-4GlcNAcb1-
3Galb1-3GlcNAcb-Sp 
3'SLN-Lec 1 mg 
76 Te74 Neu5Aca2-3[GalNAcb1-4]Galb1-
4Glcb-Sp 
GM2 1 mg 
77 Te201 Neu5Aca2-3[GalNAcb1-4]Galb1-
4GlcNAcb-Sp 
CT/Sda 1 mg 
78 Te303 Neu5Aca2-3[Neu5Aca2-3Galb1-
3GalNAcb1-4]Galb1-4Glcb-Sp 
GD1a 1 mg 
79 Te176 Neu5Aca2-6[Galb1-4GlcNAcb1-
3)2b-Sp 
6'S-Di-LN 1 or 5 mg 
80 Te324 Neu5Aca2-6Galb1-4GlcNAcb1-
3Galb1-3GlcNAcb-Sp 
6SLN-Lec 1 mg 
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81 Te78 Neu5Aca2-8Neu5Aca2-
3[GalNAcb1-4]Galb1-4Glcb-Sp 
GD2 1 mg 
82 Te79 Neu5Aca2-8Neu5Aca2-3Galb1-
4Glcb-Sp 
GD3 1 or 5 mg 
83 Te97 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-
3Galb1-4Glcb-Sp 
GT3 1 mg 
84 Te119 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-
3[GalNAcb1-4]Galb1-4Glcb-Sp 




GQ2 1 mg 
 
6.2.5 Isolation, Functionalization, and Identification of Serum and Pathologic 
Glycan Motifs from Cancer Patients for Use in Identification of Novel 
Targets for Therapeutics and/or Detection/Screening Methodologies. 
 Track five and six can be performed while the models and testing of the 
consortium glycans is being performed.  These tracks will be discussed in concert due to 
their similarity and structure and ultimate goals.  For these tracks endogenous glycans 
from the plasma of healthy human donors and that of cancer patients, here pancreatic 
cancer patients, could be tested. It is important to note that many cancers have shown 
aberrant glycosylation and that pancreatic cancer was chosen as a model here due to its 
low survival rates and clinical ties with Dr. John Kauh from Emory University of my 
Committee.  More in-depth discussion of pancreatic cancer and other cancer’s 
glycosylation is discussed below.   
 The first hypothesis is that glycans from the plasma of healthy donors will 
differentially modulate DC phenotype.  This hypothesis stems from the idea that 
glycoprotein adsorption to a biomaterial can modulate DC phenotype via the glycan 
moieties of the glycoproteins found in plasma.  Also implicit to this step is the hypothesis 
that glycans presented in a non-physiological milieu will be able to modulate DC 
phenotype.  After this assessment is completed the DC response to glycans from the 
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plasma of patients with pancreatic cancer should be determined and compared to that of 
healthy patients.  The inherent hypothesis here is that the principle constituents of plasma 
glycans from pancreatic cancer patients can modulate DC phenotype differentially as 
compared to plasma glycans from healthy donors.  After obtaining DC response to both 
healthy donor and pancreatic cancer patient glycans the structure of glycans that show 
promising results would be determined for use in vaccine development and biomarker 
identification. 
6.2.6 Endogenous Glycans 
6.2.6.1.1 Isolate the glycans from plasma proteins of healthy donors and sort them by 
molecular weight. 
 Plasma glycans from a pool of healthy donors (Approximately 30 donors) would 
be isolated and sorted by molecular weight.  A discussion of the sample size will be 
performed later in this discussion.  The outcome of these experiments would be an array 
of glycan fractions, that each contains a milieu of glycans of similar molecular weight.  In 
order to easily separate and quantify glycans that have been cleaved from glycoproteins a 
fluorescent linker is necessary.210 Cummings et. al. have developed a simple chemistry 
that will non-specifically functionalize free reducing glycans with a fluorescent linker 
that can be easily functionalized with N-hydroxy succinimide (NHS) chemistry. 
 There is precedent in the literature to isolate differentially-glycosylated proteins 
from the milieu of plasma proteins of cancer patients via their carbohydrate motifs.300–302  
Also, glycans isolated from plasma glycoproteins have been successfully obtained, 
isolated, and characterized before.300,302  Thus, this track is seen as a novel combination 
of these two techniques.  In order to obtain glycans from plasma the plasma proteins must 
first be digested, and N- and O-linked glycans separated from the proteins. This step is 
necessary as separation of the glycan from their protein carriers is necessary to isolate the 
effects of the differential glycosylation from the effects of the protein carrier.  A simple 
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size exclusion separation of the glycans was chosen based on its speed and simplicity.  
Further chromagraphic separation techniques should be used in later steps to isolate and 
purify glycans more thoroughly if they show a functional DC response when cultured for 
24hrs with DCs.   
6.2.6.1.2 Identify glycan fractions of interest from donors that show a functional 
phenotypic effect from the immobilize glycans using a HTP format. 
 The objective is to identify glycan fractions that cause mature pro-inflammatory 
DC phenotype or an immunosuppressive/tolerogenic DC phenotype upon contact with 
surface-immobilized glycans.  The initial size exclusion sorting of glycans will yield a 
heterogeneous mix of glycans at each molecular weight separation, but as glycans are 
almost never seen in an isolated form in nature and are always presented from the 
heterogeneous glycocalyx around cells it is thought that separation in this fashion will 
still be able to elicit responses from DCs.  This novel approach was chosen because it 
allows for a significantly reduced amount of processing of the glycans and because unlike 
contemporary HTP methods presented in the literature this will allow for assessment of 
functional immunological outcomes prior to structural identification and characterization 
of glycans of interest.  
 Many oligosaccharides have different structures but identical molecular weights 
due to the chemical composition of each carbohydrate being identical/similar. For 
instance, mannose, glucose, galactose, and altrose all have identical molecular weights 
but are bound by drastically different lectins.  All of these structures also have alpha and 
beta confirmers that have identical molecular weights but that differ in binding 
specificity.  This functionally means that at any given size range for the glycan fractions 
isolated by size, many different glycan structures could be present.  Thus, if a well is 
shown to modulate DC phenotype many different sugar structures would be present in the 
well.  Therefore, several rounds of separation and isolation should be performed in order 
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to reduce the number of glycans in each fraction down to almost single structures after 
the initial DC response assay.  Initially, the size sorted glycans can be assessed using the 
polymeric carriers from Track 2 and the HTP method used in this dissertation or from 
Track three of the future work.  Wells showing a DC response using these methodologies 
can then be further sorted using reverse phase and normal phase high pressure liquid 
chromatography.  The constituents will then be immobilized in a well again and DC 
phenotype assessed.   
6.2.7 Aberrant Endogenous Glycans 
 Differential activation of the DCs between the two patient groups is expected due 
to reports in literature that glycans from onco-glycoproteins have shown 
immunomodulatory effects on DCs.18,301,303 Current methods for relevant glycan 
identification center around the hypothesis that in order to be a therapeutically relevant 
glycan it must be relatively high in abundance AND that in order to be in high abundance 
this structure must therefore be on highly prevalent proteins.  This has been shown 
numerous times in the literature by the analysis of the elevated proteins in a given cancer 
and then the subsequent analysis of the glycoform of the protein.  However, unlike 
proteins and DNA which are template driven processes glycosylation is regulated by a set 
of glycosyltransferases and in general time spent in the Endoplasmic Reticulum and 
Golgi apparatus (also for select O-glycans time spent in the cytoplasm).  This time is not 
as rigidly regulated as transcription or translation and thus a diverse glycoform is often 
seen on a single protein originating from a single cell.  The other key facet of this 
processes is that a single set of post translational proteins, the glycosyltransferases, are 
responsible for glycosylation of all proteins and lipids304.  Therefore, if a 
glycosyltransferase activity is altered or has an altered expression due to abnormal 
oncogene regulation not just one protein or type of protein is altered but all proteins that 
would undergo post translational modification by that glycosyltransferase are altered in a 
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similar fashion.  Thus, a glycan structure could in theory, be highly prevalent and have a 
high biological significance and only be present on low prevalence proteins.  This is 
possible because while the low prevalence proteins may individually be rare their 
aggregate occurrence accounts for a significant portion of the protein found in blood.  
Therefore, a protein independent analysis of glycan structures is needed in order to 
determine which structures are prevalent and which have biological significance 
regardless of protein carrier. 
 Based on the plasma protein content, blood would be collected from healthy 
human donors or from patients with pancreatic cancer (in collaboration with Dr. John 
Kauh, Winship Cancer Center, Emory University); objective is 30 donors per group.  
Plasma is composed of ~75mg/ml of protein and if one were to obtain 600 ml of plasma 
from a pool of 30 random donors approximately 45 grams of protein would be isolated.  
Approximately half of this protein is human serum albumin (HSA) which is a non-
glycosylated protein in healthy patients.305  Thus, from 600 ml of plasma one would 
obtain approximately 22.5 grams of glycoprotein.  A general estimate for glycan weight 
of glycoproteins is that ~10% of the molecular weight is carbohydrates and thus we 
should obtain about 2.25 grams of carbohydrates.  Currently it is thought that plasma is 
composed of approximately 3020 proteins.306  Knowing that the lowest concentration of 
the 60 most abundant proteins in plasma is 50mg/L307 and assuming that all the 
glycoproteins that have a relative abundance of at least 1000 times lower than this 
concentration are desirable because they are abundant enough to contribute significantly 
to the glycan pool (50ug/L or a 1:1,500,000 molecular weight prevalence ) it can be 
calculated that approximately 20.0 nmol of the least abundant sugar from 600 ml of 
plasma would be collected.  As one would need a minimum of 10nmol of glycan to 
perform our study 600 ml of blood is seen as a sufficient quantity of blood to isolate the 
glycans of interest that are at the lowest relevant concentration while allowing for 
decreases in glycan pool due to conjugation efficiencies and incomplete reactions. 
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 The isolation, separation, cell response, and identification process would be 
identical to that discussed for endogenous glycan study.  To conserve time and resources 
the healthy donors in this study would be the patients from the endogenous glycan work 
and would be chosen to be age, gender, and race matched to the pancreatic cancer 
patients.  The key difference between the endogenous and aberrant endogenous glycan 
study is that for the aberrant glycan study a differential activation profile from that seen 
in the endogenous glycan work would be the output.  Thus, instead of looking for any 
activation of the DCs (as in the endogenous glycan work) only wells containing fractions 
of identical mass range showing activation of DCs that show no response in the healthy 
donors would be analyzed in in the exogenous glycan work.  This comparison is possible 
because wells would be sorted in both healthy and pancreatic cancer patients using the 
same size exclusion column methodology.  Care should be taken to sort identical mass 
ranges into identical wells for comparison.  While it will not be known if the exact 
glycans are identical in between the two wells it will confirm that all glycans at X size 
range for each sample are represented and thus if there is a difference in DC response 
between the two it is due to some difference in either glycan constituents or concentration 
between the two sets of donors.  In either case this would be interesting and identifiable 
with further analysis. 
6.2.8 Experimental Design 
6.2.8.1 Endogenous Glycans 
 The blood can be obtained from primary donors, treated with 10 mmol/dL308 of 
Disodium Ethylenediaminetetraacetic acid, EDTA, spun down at 1000g for 10 minutes 
and the plasma supernatant collected and collectively pooled from 30 donors.  While 
these donors are being obtained the plasma would be stored at -80°C. Once all patients’ 
plasma has been obtained the plasma would be lyophilized.  The resulting lyophilized 
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protein powder would then be dissolved in denaturing buffer, at a concentration of 
20mg/ml and heat to a boil for 10 minutes.  Lyophilize this denatured solution.  
 For N glycan isolation dissolve the lyophilized plasma in a 0.1% (w/v) RapiGest 
solution (Waters Inc.) add Pronase (Sigma) in sufficient quantity to digest all protein 
overnight at 37°C.  After an overnight incubation freeze and lyophilize the solution again.  
Dissolve in fresh RapiGest solution and add an equal amount of pronase to that which 
was added previously.  After another overnight run an SDS-PAGE gel to determine if all 
digestion has occurred.  If not, repeat the above steps until all protein has been 
completely digested.  After this digestion has occurred and the resulting solution 
lyophilized take the resulting powder and dissolve and then add PNGase F (Sigma).  
Initially add 1500 units of PNGase F per ml of solution and incubate for 48 hours.  
Repeat this process for 8 days.  Boil the solution for 5 minutes to inactivate the PNGase F 
and pass the slurry through a 2g C18 Sep-Pak cartridge.  Collect the flow through.  Wash 
the column with methanol to collect the protein trapped in the cartridge.  Collect this 
methanol flow through as well and dry this solution under vacuum.  Take the initial flow 
through and apply to a carbograph coloumn.  Elute the glycan off of the column.  This 
fraction should contain all N-linked glycans from the plasma.   
 To isolate the remaining O-linked glycans use the methanol flow through that was 
previously obtained from the Sep-Pak cartridge.  Resuspend the vacuum dried volume in 
water and then freeze and lyophilize.  Make a 28vol% ammonium hydroxide solution 
saturated with ammonium carbonate (28AHAC).  Add glycoprotein to the 28AHAC to a 
concentration of 1mg/ml.  Add additional ammonium carbonate to the solution, 
~10mg/ml and heat the solution at 60ºC for 96hrs.  Remove the ammonium hydroxide 
and ammonium carbonate by repeated evaporation of water using vacuum centrifugation.  
Add 0.5M boric acid to powder and heat the solution to 37ºC for 90mins.  Remove boric 
acid by adding methanol and passing nitrogen over solution until dry.  Add a 50% boric 
acid solution and spin the resultant suspension down at 10000g.  Collect the supernatant 
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and dry under vacuum centrifugation and then resuspend in H2O.  Finally, purify the 
glycans collected using the cerograph column method expounded upon above.  The 
above protocols were developed by Song et al.210. 
 The above N-linked and O-linked glycans are not to be combined as identification 
of the glycans later becomes much simpler if the linkage of the glycan is known.  The 
above procedure would be performed for a pool of 30 healthy donors.  After isolation the 
two glycan solutions would be non-specifically functionalize with a fluorescent linker as 
shown by Song et al.210  Briefly, the fluorescent linker 2-amino-N-(2-amino-ethyl)-
benzamide (AEAB) is added in a 10:1 molar excess of glycan.  Dimethyl sulfoxide 
(DMSO) and sodium cyanoborohydride is added and this solution is allowed to incubate 
at 65ºC for 4 hours.  After the reaction with AEAB the glycans would be separated non-
specifically using a size exclusion column (SEC) and HPLC.  The polyacrylamide P4 
SEC columns provided by Bio-Rad are known to separate oligosaccharides differing by 
only one sugar, a pentasaccharide vs. a hexasaccharide, and thus these columns would be 
used for the separation of the above sugar solutions.  Forty-six fractions would be 
collected for each set of glycans.  Thus, 46 fractions of N-linked glycans and 46 fractions 
of O-linked glycans, for a total of 92 glycan fractions, would be collected.  92 fractions 
were chosen so that fractions could be spotted in quadruplicate wells of a 384 well plate 
using the HTP methodology used in this dissertation while still allowing for control wells 
to be used in the same plate. 
 The glycans would then be immobilized in a 384 well or 1536 well plate 
(whichever HTP methodology has been developed) via the optimized synthetic carrier 
developed in Track 2. The resultant DC response to the glycans can be assessed via the 
HTP method used in this dissertation or via the HTP methodology seen in Track 3 if it 
has been developed.  The glycans from the wells showing a DC response, either pro or 
anti-inflammatory, will then be further separated.     
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 The immobilization strategy for the 384-well plate would be to add ten microliters 
of each of the 92 N- or O-linked glycan fractions in triplicate into the Disuccinimidyl 
tartrate (DST) functionalized wells at a concentration of 100uM.  The glycans would be 
allowed to conjugate to the NHS functionalized surface overnight. A fourth well will also 
be functionalized with each glycan fraction for use as an isotype control well to ensure 
that the glycan that is immobilized in the well does not randomly increase binding of the 
labeling antibodies that would be used later.  In the 1536-well assay 1.5 microliter of 
each of the 92 N- or O-linked glycans fractions would be added to the plate in duplicate.  
Two additional wells would be functionalized for the later addition of DCs with no 
transduced T cells to ensure that any increase in signal found in the wells later is due only 
to the proliferative ability of the T cells.   
 After the first round of separation and cell response the wells showing positive 
response from the DCs will undergo reverse phase and normal phase HPLC separation. 
After the glycans have been separated using 3D-HPLC they will then be immobilized 
again in a 384 well microtiter plate and DC response to the isolated glycans would be 
assessed.  Glycans that show an immunomodulatory effect will then be identified via 
matrix assisted laser desorption/ionization mass spectrometry (MALDI) and 
exoglycosidase array digestion.  The information from these analysis techniques, mass 
and glycan constituents respectively, along with whether the glycans are N-linked or O-
linked provides glycobiologists with enough information to accurately determine what 
the structure of the sugar is.210  This information can then be used by synthetic chemists 
to replicate relevant and interesting glycans for further study and also by physicians and 
screening facilities to help identify cancer markers for pancreatic cancer. 
6.2.8.2 Aberrant Endogenous Glycans from Pancreatic Cancer Patients 
 The exact experimental design seen in the endogenous glycan work would be 
used again for this section.  Blood from patients who have a stage I or II pancreatic tumor 
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that is still resectable and is static would be collected.  This group offers the dual benefit 
of being able to identify glycans that are of immunological interest and that can be used 
as early tumor biomarkers to identify pancreatic cancer in its early stages.  Thus, by 
isolating the glycans/glycoproteins earlier in tumor development they will necessarily be 
at a lower concentration and thus if they are still able to elicit an immunomodulatory 
effect on the DCs at this lower concentration they are more likely to be an efficacious 
target for therapy.  This fact coupled with the fact that the glycans could have a dual use 
as a novel biomarker outweighs the potential therapeutic benefit of obtaining blood from 
late stage patients.  
 
One of five outcomes is anticipated when comparing the two carbohydrate activation 
profiles:   
1) A differential profile is seen on a feasible number of wells for further study but 
the onco-glycan group causes less stimulation of DCs than does the healthy 
glycan group 
2) A differential profile is seen on a feasible amount of wells for further study but 
the healthy glycan group causes less stimulation of DCs than does the onco-
glycan group 
3) No DC response difference between the two groups but an activation profile is 
seen in a feasible number of wells 
4) Too many wells show activation of DCs to make further isolation and purification 
feasible. 
5) No wells show activation of DCs to any significant level. 
 The term feasible is relative but here refers to any amount of wells over 10 
positive “hits” as judged by the fold change parameter over iDC.  Ten hits was chosen as 
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the threshold for feasibility as this is ~10% of the total glycans tested and any number 
higher than this begins to defeat the advantage of using a HTP methodology. Outcome 
one or two provides an interesting result as these wells can be further separated and 
characterized to better determine the cell response to smaller sets of glycans and to 
determine these glycan’s structures.  Outcome three could also be interesting as DC 
phenotype modulation to glycans immobilized in an array format has not been shown 
before and thus the information from this outcome could be used to further direct cancer 
vaccine and biomaterial research in the future. Outcome four could be mitigated by 
altering our initial criterion of a hit to be more selective, such as above two standard 
deviations of the inactivated signal or not statistically different from DCs treated with 
LPS.  Finally, outcome five could also prove interesting as there are many reports in 
literature of glycans produced by tumors having immunomodulatory effects on DCs 
18,301,303 and thus the fact that they do not modulate DC phenotype when immobilized on 
a surface could be used to further direct cancer therapy development in the future.   
 Outcomes four and five are seen as unlikely because DC activation in many wells 
would indicate that the glycans across a wide range of molecular weights obtained from 
plasma are capable of activating myeloid derived DCs or that glycans immobilized on a 
surface are unable to modulate DC phenotype.  The former seems unlikely as DCs 
encounter these glycans in tissue and blood constantly and thus to avoid autoimmunity 
would need to have a high level of tolerance to the majority of them regardless of 
presentation strategy.  The latter seems unlikely because DC phenotype has been shown 
to be modulated by glycans in the literature previously. 18,301,303 
 The aberrant endogenous study is meant to test the hypothesis that a differential 
DC phenotypic profile is capable of being produced from the glycoform of pancreatic 
cancer patients as compared to that of the profile produced by healthy donors.  This track 
is not meant to be an in-depth analysis of the immune response to tumor glycans.  As 
such additional controls and more in-depth analysis of glycans from these patients is not 
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proposed.  However, for future studies, tissue samples of the tumor and healthy 
pancreatic tissue would be collected from the patients who undergo resection.  Also, 
blood before tumor resection and 6-8 weeks after tumor removal could be collected as 
blood after tumor resection could serve as an excellent control for the patients.  In 
addition, common controls for pancreatic cancer patients in studies similar to these 
include pancreatitis patients and diabetic patients as people with pancreatic cancer often 
share these comorbidities and thus the differential response seen between healthy donors 





A.1. Supplemental to Elucidation and Optimization of Pertinent Molecular 

































Figure A 1:  Enzyme linked lectin assay detection of biotinylated glycans with a 
range of sizes [mono-saccharide (mannose) to an 11 sugar oligo-saccharide (Man9) 
immobilized on a SA-coated TCPS 96-well plate to determine the concentration of 
glycan that needed to be delivered per well to saturate the SA binding sites.  
Generally, 4000 pmol of biotinylated glycan needed to be delivered per well in order 













t Value Pr > |t| 
Intercept β1 0.50603 0.05453 9.28 <.0001 
Isoelectric Point β2 0.03965 0.00592 6.7 <.0001 
Ligand OEG β3 -0.03324 0.04325 -0.77 0.4425 
Ligand Glc β4 -0.0041 0.04718 -0.09 0.9308 
Ligand Man β 5 0.06817 0.04623 1.47 0.141 
Density β6 0.01382 0.00152 9.07 <.0001 
Donor β7 -0.59434 0.05966 -9.96 <.0001 
Donor β8 -0.11864 0.05966 -1.99 0.0473 
Donor Β9 0.01207 0.05966 0.2 0.8398 
Donor β10 -0.33773 0.05966 -5.66 <.0001 
Donor β11 -0.57418 0.05966 -9.62 <.0001 
Donor β12 -0.24482 0.05966 -4.1 <.0001 
Donor β13 -0.14216 0.05966 -2.38 0.0176 
Donor β14 -0.24173 0.05966 -4.05 <.0001 
Donor β15 -0.42702 0.05966 -7.16 <.0001 
Donor β16 0.66049 0.05966 11.07 <.0001 
Donor β17 -0.35118 0.05966 -5.89 <.0001 
Donor β18 -0.38287 0.05966 -6.42 <.0001 
 







t Value Pr > |t| 
Intercept β1 0.92276 0.01557 59.27 <.0001 
Isoelectric High β2 0.17195 0.03355 5.12 <.0001 
Isoelectric Med. β3 0.15722 0.03243 4.85 <.0001 
Isoelectric Low β4 -0.00784 0.04854 -0.16 0.8718 
Ligand OEG β 5 -0.0042 0.04426 -0.09 0.9245 
Ligand Glc β6 0.0145 0.04791 0.3 0.7622 
Ligand Man β7 0.06549 0.04656 1.41 0.1602 
Density β8 0.38133 0.03736 10.21 <.0001 
Density Β9 0.09719 0.03118 3.12 0.0019 
Density β10 0 . . . 
Donor β11 -0.59434 0.05818 -10.21 <.0001 
Donor β12 -0.11864 0.05818 -2.04 0.042 
Donor β13 0.01207 0.05818 0.21 0.8358 
Donor β14 -0.33773 0.05818 -5.8 <.0001 
Donor β15 -0.57418 0.05818 -9.87 <.0001 
Donor β16 -0.24482 0.05818 -4.21 <.0001 
Donor β17 -0.14216 0.05818 -2.44 0.0149 
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Table A 2 Continued   
Donor β18 -0.24173 0.05818 -4.15 <.0001 
Donor β19 -0.42702 0.05818 -7.34 <.0001 
Donor Β20 0.66049 0.05818 11.35 <.0001 
Donor Β21 -0.35118 0.05818 -6.04 <.0001 
Donor Β22 -0.38287 0.05818 -6.58 <.0001 
 
Table A 3: Parameter estimates for model 1c using continuous isoelectric point and 






t Value Pr > |t| 
Intercept β1 0.16929 0.01871 9.05 <.0001 
Isoelectric Point β2 -0.00474 0.00203 -2.34 0.0199 
Ligand OEG β3 0.00301 0.01484 0.2 0.8395 
Ligand Glc β4 -0.03615 0.01618 -2.23 0.0259 
Ligand Man β 5 -0.03053 0.01586 -1.92 0.0548 
Density β6 -0.00209 0.000522 -4.01 <.0001 
Donor* β7-18 -0.12619 - 0.21436 0.02036 -6.17 - 10.47 <.0001 
* All donor estimates, standard errors, t values, and probabilities can be seen in the Table A 4 in 
the appendix. 
 






t Value Pr > |t| 
Intercept β1 0.16929 0.01871 9.05 <.0001 
Isoelectric Point β2 -0.00474 0.00203 -2.34 0.0199 
Ligand OEG β3 0.00301 0.01484 0.2 0.8395 
Ligand Glc β4 -0.03615 0.01618 -2.23 0.0259 
Ligand Man β 5 -0.03053 0.01586 -1.92 0.0548 
Density β6 -0.00209 0.00052 -4.01 <.0001 
Donor β7 0.10193 0.02047 4.98 <.0001 
Donor β8 0.20634 0.02047 10.08 <.0001 
Donor Β9 0.21436 0.02047 10.47 <.0001 
Donor β10 -0.12619 0.02047 -6.17 <.0001 
Donor β11 -0.01768 0.02047 -0.86 0.388 
Donor β12 -0.02878 0.02047 -1.41 0.1603 
Donor β13 0.07103 0.02047 3.47 0.0006 
Donor β14 -0.03678 0.02047 -1.8 0.0729 
Donor β15 0.03078 0.02047 1.5 0.1332 
Donor β16 -0.02929 0.02047 -1.43 0.1531 
Donor β17 -0.01219 0.02047 -0.6 0.5517 
Donor β18 0.05221 0.02047 2.55 0.011 
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t Value Pr > |t| 
Intercept β1 0.12018 0.00543 22.15 <.0001 
Isoelectric High β2 -0.02412 0.01169 -2.06 0.0397 
Isoelectric Med. β3 -0.0002072 0.0113 -0.02 0.9854 
Isoelectric Low β4 0.03534 0.01692 2.09 0.0372 
Ligand OEG β 5 0.00662 0.01543 0.43 0.6681 
Ligand Glc β6 -0.0291 0.0167 -1.74 0.0819 
Ligand Man β7 -0.02491 0.01623 -1.54 0.1253 
Density β8 -0.06402 0.01302 -4.92 <.0001 
Density Β9 -0.02769 0.01087 -2.55 0.0111 
Density β10 0 . . . 
Donor β11 0.10193 0.02028 5.03 <.0001 
Donor β12 0.20634 0.02028 10.18 <.0001 
Donor β13 0.21436 0.02028 10.57 <.0001 
Donor β14 -0.12619 0.02028 -6.22 <.0001 
Donor β15 -0.01768 0.02028 -0.87 0.3836 
Donor β16 -0.02878 0.02028 -1.42 0.1564 
Donor β17 0.07103 0.02028 3.5 0.0005 
Donor β18 -0.03678 0.02028 -1.81 0.0703 
Donor β19 0.03078 0.02028 1.52 0.1297 
Donor Β20 -0.02929 0.02028 -1.44 0.1493 
Donor Β21 -0.01219 0.02028 -0.6 0.548 
Donor Β22 0.05221 0.02028 2.57 0.0103 
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t Value Pr > |t| 
Intercept β1 1.01253 0.04706 21.52 <.0001 
Density High β2 0.09053 0.12926 0.7 0.4852 
Density Med. β3 -0.0534 0.16854 -0.32 0.7518 
Density Low β4 -0.1709 0.21251 -0.8 0.4232 
OEG β5 0 . . . 
Ligand Glc β 5 0.52008 0.14115 3.68 0.0004 
Ligand Man β6 0.47628 0.2124 2.24 0.027 
Ligand GlcNAc β7 0.135 0.2286 0.59 0.5561 
Ligand Alpha β8 0.43799 0.2124 2.06 0.0416 
Ligand Branch β9 0.12871 0.15445 0.83 0.4065 
Donor β10 -0.4511 0.22732 -1.98 0.0498 
Donor β11 -0.3717 0.22732 -1.63 0.105 
Donor β12 -0.2281 0.22732 -1 0.3179 
Donor β13 -0.3564 0.22732 -1.57 0.1199 
Donor β14 -0.4134 0.22732 -1.82 0.0718 
Donor β15 -0.3026 0.22732 -1.33 0.186 
Donor β16 -0.0399 0.22732 -0.18 0.8609 
Donor β17 0.81132 0.22732 3.57 0.0005 
Donor β18 -0.2714 0.22732 -1.19 0.2351 
Donor β19 0.4375 0.22732 1.92 0.057 
Donor β20 1.07452 0.25388 4.23 <.0001 
Donor β21 -0.1844 0.25388 -0.73 0.4693 
Donor β22 0.20063 0.25388 0.79 0.4312 
Donor β23 0.98387 0.26648 3.69 0.0004 
Donor β24 0.17857 0.26648 0.67 0.5042 
Donor β25 0.55334 0.26648 2.08 0.0403 
 
 
Method 1:   
R1 = mean hydrodynamic radius of all conjugates = 3.64*10
-9 m 
PF = Optimal Packing factor for a circle = 0.9069 
SU =  Unit Surface area= 1 µm
2 = 1.0*10-12 m2 
LM = Mean Glycans/BSA = 26 
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LM2 = Mean Displayed Glycans = LM/2 = 13 
Surface area footprint of a circle =  
Ligands Displayed Per Unit Surface Area = 
 
Method 2:   
W1 = Weight of BSA/Weight of Polystyrene:  (0.0171 g BSA)/(gram of PS) 
D = Density of Polystyrene= 1.05 g/cm3 = 1050000 g/m3 
R2 = Radius of Polystyrene Bead = 5.0*10
-7 m 
WBSA = 66463 g/mol 
SU=  Unit Surface area= 1 µm
2 = 1.0*10-12 
SU =  Unit Surface area= 1 µm
2 = 1.0*10-12 m2 
NA = Avagadro’s Number = 6.02214*10
23 
Surface Area of a Sphere =  
Volume of a Sphere =  
Carbohydrates/um2 = 
 
Figure A 2: Estimation of glycan density.  Estimates calculated from the average 
measured hydrodynamic radius of the conjugates (Method 1).  Estimates calculated 
from the average number of BSA proteins per unit area of polystyrene as measured 
by Osborne et. al.245 (Method 2).    
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A.2. Supplemental to the Elucidation of How Presentation Modality of 
Glycoconjugates Alters Dendritic Cell Phenotype 
Table A 7:  ANOVA table comparing all modalities of display.  Significance of 
comparison was determined using a Bonferroni correction to allow for a more 
conservative estimate of error.  Thus, an α < 0.0167 was used as the determinant of 
the level of statistical significance. 
  1 µg/ml Soluble 1 µm Bead Well Adsorbed 
1 µg/ml Soluble   <0.0001 0.0042 
1 µm Bead <0.0001   <0.0001 
Well Adsorbed 0.0042 <0.0001   
 
 
Figure A 3:  Phagocytosis of 1 µm PS, mannan, or β-glucan coated fluorescent beads 
by DCs when exposed to blocking antibodies, EDTA, or 4°C. 
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A.3. Modification of High Throughput Assay for Assessment of Tolerogenic DC 
Phenotype 
A.3.1. Overview 
 A HTP approach is necessary to assess functional phenotypic effects of complex 
carbohydrates obtained from natural sources on DC phenotype for four key reasons.  
First, glycan structures from natural sources are typically only available in sub-µmol 
levels and they are highly heterogeneous in structure.4,177–179  Second, there is a lack of an 
efficient means of automated assignment and structural characterization of glycans from 
these sources.180 Third, the biosynthesis of oligosaccharides is inherently heterogenous 
even between cells from the same cell line and thus developing a repertoire of 
oligosaccharides that would be representative of the glycoform of a typical glycoprotein 
is extremely difficult to reproduce by chemical synthesis.181–183 Fourth, most 
carbohydrate-protein interactions are multivalent; thus, dense carbohydrate displays are 
necessary for detection of cellular interaction in screening analyses.104,105,184 The 
combination of dense coating and low prevalence yields testing apparatuses that must 
have small presentation surfaces for cell interaction.   Furthermore, when assessing the 
DC phenotype in response to glycoconjugates it is necessary to determine both pro-
inflammatory and tolerogenic DC phenotypes as ligation of CLRs has been shown to 
have both pro- and anti- inflammatory phenotypic modulation, as can be seen in Table 1.  
Thus, a surface marker associated with a tolerogenic DC phenotype was desired.  After 
reviewing the literature it was found that ILT3 was an excellent indicator of tolerogenic 
DC phenotype.312–314 However, the current HTP assay does not assess tolerogenic 
phenotype in any way other than via analysis of cytokines.  Due to its screening reporter 
(CD86/DC-SIGN fold change) being biased toward pro-inflammatory DC responses it is 
possible that treatments that induce a tolerogenic DC phenotype could not be assessed for 
cytokine profile and thus, missed as important modulators of DC phenotype. 
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 To mitigate these concerns the HTP DC phenotype assessment assay originally 
developed by the Babensee lab was scaled down to a 384 well plate from a 96 well plate.  
To accomplish this the assay was first validated in a similar way to that of the original 
HTP assay.  The 96 well HTP assay was originally validated using clinically relevant 
biomaterials PLGA and agarose.  Of these materials only PLGA showed a statistically 
significant increase in CD86/DC-SIGN fold change over that of iDC.  Additionally, the 
magnitude of the DC response to PLGA was at an intermediate level between that of 
iDCs and mDCs.  Thus, for the HTP assay iDCs, mDCs, and PLGA treated DCs were 
tested for their CD86/DC-SIGN fold change in both 96 well plates and 384 well plates.  
Next, the addition of a tolerogenic reporter, ILT3/CD86 (TMF) was developed and 
validated via flow cytometry.  Finally, the addition of cell disassociation solution (CDS) 
and effect of seeded cell number was assessed to determine if these factors needed to be 
varied to obtain more consistent results from the IMF and TMF assays in 384 wells.   
 It was found that 96 and 384 well assays produced results that were not 
statistically different from each other and showed identical trends in DC response to 
PLGA and LPS.  Then TMF was found to be an excellent reporter for tolerogenic DC 
phenotype and that the HTP assay produced equivalent results to that of flow cytometry.  
Finally, it was found that for treatments where DCs were found to adsorb to plates more 
readily, LPS, use of CDS produced higher signals with lower variance than did the 
conventional HTP methodology.  Additionally, it was found that seeding cells at 7.5x105 
cells/ml produced higher signals, particularly for the TMF, as compared to the 
conventional culture method.   
 The addition of a tolerogenic reporter to the HTP assay was seen as a significant 
improvement of the assay, increasing its ability to effectively screen ligands that induce 
both pro-inflammatory and tolerogenic phenotypes is an important step in functional 
assessment of DCs.  Additionally, the scale down to 384 wells was seen as significant for 
reagents where quantities of ligand are precious.  For glycans, and in particular complex 
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glycan structures, this is unilaterally the case and thus the scale down to 384 wells made 
this dissertation possible.  On average, the scale down to 384 wells reduced the quantity 
of reagents needed by 5x while maintaining the number cells used for four times the 
number of treatments.  
A.3.2. Methods 
A.3.2.1. Original 96 well High Throughput Dendritic Cell Phenotype Methodology 
 Differentially-treated and reference control DCs were harvested after 24 h for 
analysis using an HTP method previously described.224  Briefly, all treated DCs and 
controls were transferred via multi-channel pipette to a black 96-well filter plate (Pall 
Life Sciences), and the supernatants were immediately collected into a 96-well plate 
through the filters by stacking the filter plate on top of the collection plate and 
centrifuging at 300 RCF for 4 min.  To the retained cells 150 µl of 0.05% formaldehyde 
solution was added and the cells were allowed to fix for 40 minutes at room temperature 
while being shaken at 600 RPM. The formaldehyde solution was then removed via 
centrifugation at 400 RCF for 4 minutes.  The cells retained in the wells were assessed 
for phenotype by immunostaining using antibodies anti-CD86-PE (Clone BU63; Ancell) 
and anti- DC-SIGN-FITC (Clone 120507; R & D Systems). IgG1-PE (clone MOPC31C; 
Ancell) and IgG2B-FITC (clone 133303; R&D Systems) isotype-stained DCs were used 
for background fluorescence subtraction in separate treatment for control wells. CD86 is 
a costimulatory molecule that is up-regulated upon pro-inflammatory DC maturation,224 
DC-SIGN is an endocytic receptor that is slightly down-regulated upon pro-inflammatory 
maturation.224 After 40 minutes of staining the cells were washed three times. The 
fluorescent intensity for each well was measured at the emission/excitation wavelengths 
for each fluorophore 535/590 PE and 485/535 FITC.  The geometric mean fluorescent 
intensities (gMFIs) were then calculated with a Tecan Infinite F500 microplate reader, 
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and the ratio of respective gMFIs were determined as CD86/DC-SIGN, a cell number 
independent metric.    
A.3.2.2. Initial 384 well High Throughput Dendritic Cell Phenotype Methodology 
 Prior  to the addition of the ILT3 reporter and CDS solution DCs were assessed 
for their phenotype with an identical methodology to that of the 96 well plate described 
above but in a 384-well TCPS plate and 384-well filter plate.  All volumes used in this 
assay were ¼ those used in the 96 well plate assay. 
A.3.2.3. Comparison of  96 well high throughput to 384-well high throughput 
Methodologies 
Primary human DCs were cultured as per 4.2.7.  On day 5 after isolation DCs for 
experiments where the 96 well and 384 well methodologies were compared DCs were 
transferred to wells that had a PLGA film already in them and allowed to incubate in the 
presence of the PLGA film for 24 hours.  LPS was also added to mDC wells at each plate 
as outlined in Chapter 4.  The resultant DC phenotype was assessed via the 
methodologies described in A.3.2.1 and A.3.2.2.   
A.3.2.4. Preparation of PLGA films 
 PLGA (molar ratio = 75:25, inherent viscosity = 0.70 dl/g in trichloromethane, 
MW = 100,000 Da; Birmingham Polymers, Birmingham, AL) films were prepared by 
solvent casting without a porogen as previously reported.224   Briefly, PLGA was 
dissolved 20% w/v in dichloromethane overnight at room temperature and poured into a 
50 mm Teflon dish (Cole-Parmer, Vernon Hills, IL) in a chemical fume hood. After 
evaporation of the solvent and drying to form films (48–72 h), the PLGA films were 
punched to fit into the wells of a 384- or 96-well plate, followed by three washing steps 
using endotoxin-free water (Cambrex, East Rutherford, NJ) and UV sterilization for 30 
min on each side in the tissue culture hood before iDCs were plated on them. 
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A.3.2.5. Addition of CDS and optimization of cell count.  
 An identical assessment and culture methodology to that described in Chapter 
4.2.9 was performed for these studies except that DCs were resuspended at 5.0x105, 
7.5x105, or 1.5x106 cells/ml and then placed in wells.  For wells where IL10 was added 
3500 units/ml of human IL10 was added.   
A.3.2.6. Flow cytometric analysis and validation of  ILT3 expression for 
tolerogenic DCs.  
 To show that the 384 well HTP methodology produced similar results to the of 
flow cytometry DCs were placed in treatment wells with 8 replicates for flow cytometry 
and four replicates for the HTP methodology.  After 24 hours of treatments the levels of 
surface marker expression were monitored by flow cytometry per the methods described 
previously224  and compared to the controls. Briefly, the cells were collected by 
centrifugation at 1100 rpm for 10 min, resuspended in 0.1% BSA and 2 mM EDTA in 
PBS, pH 7.2 (cell-staining buffer), and stained with fluorescently labeled antibodies 
discussed earlier.  The cells were stained for 1 h at 4°C and analyzed using a BD LSR 
flow cytometer (Beckton Dickinson, San Jose, CA). Data analysis was performed using 
FlowJo (Tree Star, Ashland, OR) based on the differential shift of histograms compared 
to the controls unless otherwise indicated. The IMF and TMF values were determined by 
dividing the geometric mean fluorescence intensities (gMFIs) of anti-CD86-PE by that of 
anti-DC-SIGN-FITC or anti-ILT3-AF647 by that of anti-CD86-PE.  ILT3/CD86 was 
chosen as the tolerance reporter due to the fact that LPS, and all other activating ligands 
tested in this dissertation, also showed a large increase in ILT3 expression.  This is 
typical of healthy DCs as they have been shown to up regulate immune dampening 
receptors when highly activated so that sepsis does not occur.  However, these activated 
cells also dramatically up-regulated CD86 and CD80 and tDCs and those cells treated by 
IL10 showed no increase in expression of these receptors.  Thus, for tolerogenic DCs 
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CD86 became the normalizing agent of cell number per well and provided a stronger 
signal to noise ratio than ILT3 expression alone or that of ILT3 divided by DC-SIGN due 
to CD86 expression being strongly correlated to inflammatory activation and anti-
correlated to tolerance of DCs.   
A.3.3. Results 
A.3.3.1. Validation of a 384-Well HTP Methodology Against that of the 96-Well 
HTP Methodology 
Using the scaled down 384 well high throughput methodology discussed in 
Chapter 4.2.9 it was found that no difference between the 96 well and 384 well plate 
assays were found.  Figure A 4 shows the results of this study.  It was shown that both 
LPS treatment (mDC) and PLGA treatement of DCs caused a statistical increase in fold 
change of CD86/DCSIGN in either the 96-well or the 384-well assay.  Furthermore, an 
ANOVA was run comparing all groups and it was found that no differences were 
significant between treatments run in 96 well plate versus the identical treatment in a 384 

























































Figure A 4:  The fold change in CD86/DCSIGN in a 384 well and 96 well plate was 
measured in response to LPS (mDC) and PLGA plate simultaneous. Mean of iDC 
normalized data shown.  Error bars indicate standard error, N=8 independent 
donors, * represents statistical significance from iDC α<0.05. 
 
A.3.3.2. Development of a Tolerogenic Reporter  
A.3.3.2.1. Cell Number and Cell Disassociation Solution Optimization 
 Dendritic cell IMF and TMF expression can be seen at three cell concentrations 
and with or without CDS washing for all controls in Figure A 5.  Identical profiles for 
IMF can be seen at the classic cell concentration (5.0E5 cells/ml) as with 7.5E5 cells/ml.  
Additionally, while not statistically significant CDS treated wells generally had higher 
mean IMFs than did cells not rinsed with CDS.  Additionally, the variance of IMF was 
seen to be lower for CDS washed cells.  While IMF trends remained similar for all 
treatments at 5.0E5 and 7.5E5 cell/ml concentrations, a higher and more consistent TMF 
signal was shown for cells seeded at 7.5E5 cells/ml.  Also of note was that cells treated 
with IL10 only were expected to have a lower TMF than tDC but a higher TMF than 
iDC.  Using 7.5E5 cells/ml clearly showed this trend and thus 7.5E5 cells/ml with 
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washing with CDS were chosen as the ideal culture and processing steps for the 384-well 
HTP assay. 
 
Figure A 5:  Dendritic cell response to controls at three different cell seeding 
concentrations and when rinsed with CDS. Mean of two independent donors is 
shown.  Error bars represent half range. 
 183 
A.3.3.2.2. Validation of Tolerogenic Reporter 
 Once optimized, the tolerogenic reporter needed to be validated against flow 
cytometry to ensure consistency with an industry standard.  Identical trends between flow 
cytometry and the HTP assay were seen.   Figure A 6 shows the results from this study.  
In all graphs significance of positive controls were identical between assay types.  
Additionally, it was found that for TMF, the assay was able to measure an increase in 
TMF for IL10 treated cells that was smaller than that of tDC but greater than that of 
carriers and iDCs.  Additionally, concerns of spectral overlap between reporting 
fluorophores were allayed by the fact that signal intensity and ratios of expression were  
similar in magnitude to that which was historically measured using the HTP technique 









































































































































Figure A 6:  Validation of HTP assay using ILT3 as a reporter for tolerogenic DCs. 
(A,B) Measure IMF via plate reader (A) and flow cytometry (B).  (B,D) Measure 
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TMF via plate reader (C) and flow cytometry (D).  IMF was measured 
simultaneously to TMF to ensure no confounding of the original reporters occurred.  
Data is mean expression ratio not normalized by iDC.  Error bars indicate standard 
error, N=7 independent donors for (A,C) and N=3 independent donros for (B,D), * 
represents statistical significance from iDC α<0.05. 
 
A.3.4. Discussion and Conclusions 
A.3.4.1. Validation of a 384-Well HTP Methodology Against that of the 96-Well 
HTP Methodology 
 To validate the HTP methology two requirements were set, 1) that the sensitivity 
of the assay was not diminished. 2) That the DC response to treatments that have been 
shown to historically activate cells in the 96-well HTP assay be statistically similar in the 
384-well assay.  An ANOVA showing identical statistical significance between mDC and 
PLGA treatments as compared to iDCs for both the 96-well and 384 well plates proved 
the first claim. However, a more rigorous ANOVA was performed in which all data from 
both 384 and 96 well plates was combined and compared.  This comparison showed that 
there was no difference between identical treatments between assay types.  Thus, with the 
information from these ANOVAs it was concluded that there was no significant 
difference between the assays.   
A.3.4.2. Development of a Tolerogenic Reporter  
A tolerogenic reporter was seen as critical for assessment of DC phenotype to 
glycans due to the plethora of CLRs on DCs that have been shown to induce a tolerogenic 
phenotype, as seen in Table 1.  Thus, an antibody staining for ILT3, a tolerogenic cell 
surface marker on DCs, was added to the assay.  However, it was found that ILT3 was 
not expressed to as great of an extent on DC cell membranes as that of CD86 or DCSIGN 
as indicated by the relatively high gain of the plate reader when measuring stained cells 
(data not shown).  Thus, the number of cells per well was increased to try to increase the 
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signal produced by the stained cells.  As expected , cells seeded at 7.5E5 cells/ml showed 
a dramatic increase in TMF signal intensity and a decrease in variability as compared to 
the 5.0E5 cells/ml treatments.  Cells seeded at 1.5E6 cells/ml were found to clog fliter 
plates and provide inconsistent signals as indicated by the large error bars in many of 
their treatments in Figure A 5. 
 Additionally, because many CLRs on DCs are adhesion receptors ensuring that 
adherent DCs were being measured in the HTP assay was seen as important.  Thus, a 
washing step was added to the classic HTP procedure in which DCs were treated with 
CDS and then transferred to the filter plate and spun down.   Figure A 5 shows that cells 
washed with CDS appeared to provide a higher signal to noise ratio with lower variance 
in signal than their unwashed analogs.  Additionally, wells were visualized before and 
after washing with CDS and it was visually confirmed that virtually all cells were being 
removed form wells after washing with CDS while many cells remained prior to CDS 
wash.  Finally, it was desired that no difference in the profile between that of the old 
lower cell concentration and the new higher cell concentration be seen.  Thus IMF and 
TMF trends between the concentrations were visually compared and found to be 
qualtitatively similar.   
A more rigorous comparison of IMF and TMF activation between assays was 
desired than the qualitative comparison performed in Figure A 5.  Thus, cell response in 
the optimized 384-well HTP protocol were compared to the industry standard flow 
cytometry.  It wsa found that identical IMF and TMF trends were seen between that of 
flow cytometry and the 384-well HTP assay.  Additionally, the magnitude of the response 
between these two was similar and response trends were identical between 
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methodologies.  Flow cytometry showed a higher sensitivity to ILT3 staining than did the 
plate reader as indicated by the magnitude of the signal shown in Figure A 6C and D.  
However, the fold change of TMF over that of iDC was not statistically different between 
the two assays and thus the differences were not seen as significant.   
In conclusion these studies show that the new HTP assay performs similarly to the 
previous assay while adding a tolerogenic reporter, allowing for assessment of adherent 
DCs, using 5x less reagent for surface modification, and assessing 4x as many treatment 
with the same volume of cells as the old assay.  Assessment of tolerogenic DC phenotype 
is critical for future glycan work as CLRs have been shown to induce tolerogenic DC 
phenotypes repeatedly in literature.18,84,264,315  Thus, the development of this assay is seen 
as pivital to continuing glycan research in the DC field.  In addition to the studies 
performed here all studies performed in this dissertation were completed with the 384-
well HTP assay; further verifying its  applicability to glycan systems and its ability to 
assess DC phenotype across display modalities which has not been shown in the literature 
to date.   
A.4. Development of Zero Length Fluorescent Linker for Carbohydrate 
Immobilization on Well and Bead Surfaces 
A.4.1.  Overview  
 Currently, isolating glycans from natural sources involves cleaving the glycan 
from the protein, functionalizing it with a fluorescent linker and then separating different 
glycan structures via HPLC.  This method was shown in detail in the first Aim of this 
dissertation for the Man5-Br conjugate.  Other chemistries have been used by other labs 
but the process essentially remains consistent.316,317 This fluorescent modification serves 
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two purposes, first it makes glycan identification and isolation simple from an often 
complex milieu of glycans.  The other is for quantifying the amount of glycan 
immobilized on a surface after functionalization to validate the glycan has been 
immobilized.  The value of this was highlighted in 4.4.2 of this dissertation.  Briefly, it is 
almost impossible to determine the density of glycan presentation from a surface 
quantitatively without that glycan being fluorescent or radio labeled to allow for 
quantification.  However, the chemical moiety which the carbohydrate is attached 
drastically alters the binding affinity of carbohydrate binding proteins.223  Briefly, it has 
been shown that reduction of the inherent level of flexibility of the linker had a favorable 
impact on cell binding especially for cells displaying a high CLR density, and the 
structure of the carrier can modulate inhibitory potency when comparing different 
lectins.223    This not only shows that lectin affinity can be modulated via linker properties 
but it also shows that different lectins have a differential ideal molecular signature that is 
optimal for maximum glycan binding.  Thus, the smaller and more labile a glycan linker 
can be made so that the carrier it is linked to can exhibit the optimal properties necessary 
for glycan display the better.  A more detailed discussion of the influence of linker 
chemistry can be seen in section 3.5.2 of this report. 
 With this in mind the purpose of this project was to create a small linker whose 
attachment could still be quantified.  Instead of linking a large fluorophore to the glycan, 
a smaller, less intrusive linker will be attached to the glycan; this linker will be used to 
attach the glycan to a surface.  The surface that it links to would be fluorescently 
modified and ideally, the linker would substitute for the fluorophore, leaving a covalent 
link between the glycan and the surface and the fluorescent linker in solution to be 
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washed away.  To accomplish this we chose a substitution reaction in which a fluorescent 
moiety (dansyl chloride (DsCl)) was substituted for an azidomethyl modified glycan.  To 
accomplish this optimization of a DsCl coating was first performed on 1.5 and 45 µm 
silica beads.  Then an azide modified fluorophore was used to substitute off the DsCl 
moiety and the effect of concentration of the fluorophore was measured.  After that 
azidoethyl modified lactose was used as a model glycan to show that substitution of the 
DsCl group could occur with Glycan.  Finally, stability of the structure in PBS was tested 
over a 48 hour period to ensure that the substitution was permanent in buffers commonly 
used by cells.  It was found that both 1.5 and 45 µm amine modified silica beads could be 
modified with DsCl at a 5000:1 DsCl to Amine ratio and that fluorescence from these 
beads scaled linearly with bead number.  Then it was found that the substitution reaction 
between azide modified Alexa Fluor 594 (AF594), and the DsCl beads occurred and 
could be easily quantified in a plate reader.  Next, a concentration dependent reduction in 
fluorescence was shown between azide-glycans and DsCl beads.  Finally, it was show 
that beads modified with the AF594 did not show a statistical decrease in fluorescence 
over the course of 48 hours in PBS but that background fluorescence from DsCl was 
almost completely abrogated.   From these graphs we conclude that the chemical 
mechanism proposed by Suenaga et.al.318 can be used for glycan substitution and that 
modification with glycan is capable of reducing fluorescence in such a way so as to be 
quantifiable.  Future work to be done includes, ELLAs with the glycan modified beads 
and co-culture of beads with DCs to determine if DCs can recognize and respond to 
glycans reacted with this chemistry.   
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A.4.2. Methods 
A.4.2.1. Conjugation of Lactic Acid to Amine Coated Silica Microbeads 
First, amine coated silica microbeads (1.5 µm or 45 µm; Microspheres-
Nanospheres) were aliquoted into a 15 ml polypropylene centrifuge tube and spun down 
at 2000 RCF for 5 minutes.  The supernatant was removed and beads were resuspended 
in dichloromethane (DCM).  Beads were then added to a 100 mM stock of lactic acid 
(Sigma) dissolved in DCM, in an equal volume ratio.  Next, the bead/lactic acid solution 
was mixed with an equal volume of 2 mg/ml 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) dissolved in water.   The solution was allowed 
to react for 2 hours at room temperature.  Finally, beads were spun down at 2000 RCF for 
5 minutes, supernatants removed, and washed with DCM three times.   
A.4.2.2. Dansylation of Lactic Acid Functionalized Microbeads 
Lactic acid functionalized microbeads suspended in DCM were then 
functionalized with 5-(dimethylamino)naphthaline-1-sulfonyl chloride (Dansyl chloride, 
DsCl).  Beads were added in a 1:1 volume ratio to 130mM DsCl dissolved in DCM.  For 
experiments where optimization of DsCl concentration was performed beads were 
dissolved in a 1:1 volume ratio with twice the indicated concentration of DsCl.  Tubes 
were then sealed with aluminum plate sealers (VWR) and covered from light.  The 
reaction was allowed to run for 72 hours at room temperature while shaking at 600 RPM.  
Finally, beads were spun down at 2000 RCF for 5 minutes, supernatants removed, and 
washed with DCM three times.   
For studies where bead number was varied and fluorescence of DsCl beads was 
measured, DsCl modified and unmodified beads were aliquoted into wells of a silica 
coated polypropylene Plate+ 384 well plate (SUN-SRi) and fluorescence was measured at 
excitation/emission 340 nm/535 nm using a Tecan Plate Reader (Tecan, Switzerland).  
 190 
All measures in each well were performed twice with 1 second of shaking at 1000 RPM 
between each measurement and then averaged for the mean fluorescent intensity of each 
well.   
A.4.2.3. Azide Substitution of Dansylated Microbeads 
 Dansyl chloride functionalized microbeads suspended in DCM were then 
functionalized with azide linked moieties.  First, beads were spun down at 2000 RCF for 
5 minutes, supernatants removed, and washed with dimethylformamide (DMF) three 
times.  Beads were added in a 1:1 volume ratio to 20mM sodium azide dissolved in DMF.  
For experiments where Alexa Fluor 594 (AF) substitution was used beads were added to 
a 600 µM stock solution dissolved in DMF in a 1:1 volume ratio. For experiments where 
optimization of lactose-azide (Lac-N3) concentration was performed beads were 
dissolved in a 1:1 volume ratio with twice the indicated concentration of Lac-N3. Tubes 
were then sealed with aluminum plate sealers (VWR) and covered from light.  The tube 
was then heated to 70°C in a water bath and allowed to react for 1 hour.  Finally, beads 
were spun down at 2000 RCF for 5 minutes, supernatants removed, and washed with 
DCM three times.  Figure A 7 shows a schematic of this overall process. 
 For studies where bead fluorescence of was measured, modified beads were 
aliquoted into wells of a Plate+ 384 well plate and fluorescence was measured at 
excitation/emission 340 nm/535 nm and 590 nm/ 635 nm by the Tecan Plate Reader.  All 
measures in each well were performed twice with 1 second of shaking at 1000 RPM 






Figure A 7:  Overview of chemistry for functionalization of amine beads via AF594 
or Lac-N3.  
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A.4.2.4. Stability of Azide-Linked Moiety on DsCl Modified Microbeads  
Fluorescence from unmodified, DsCl functionalized, and AF functionalized beads 
was measured by placing beads into wells of  a Plate+ 384 well plate and fluorescence 
was measured at excitation/emission 340 nm/535 nm and 590 nm/ 635 nm by the Tecan 
Plate Reader.  To measure fluorescence of beads in different buffers beads were spun 
down at 2000 RCF for 5 minutes, supernatants removed, and washed with one of three 
buffers: DCM, PBS, or media (RPMI-1640 (Invitrogen) supplemented with 10% heat 
inactivated fetal bovine serum (Cellgro MediaTech) and 100 U/ml 
penicillin/streptomycin (Cellgro MediaTech)), three times. Then fluorescence was 
measured at excitation/emission 340 nm/535 nm and 590 nm/ 635 nm for each well at 0, 
12, 24, or 48 hours after final buffer exchange.  All wells were sealed with an aluminum 
plate sealer between measures to ensure no loss of buffer.  All measures in each well 
were performed twice with 1 second of shaking at 1000 RPM between each measurement 
and then averaged for the mean fluorescent intensity of each well.   
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A.4.3. Results  
A.4.3.1. Dansyl Chloride Saturates Binding Sites on Microbeads at a 65mM 
Concentration. 
The desired amount of DsCl necessary to saturate binding sites on the amine 
functionalized microbeads was determined.  It was found that DsCl at a concentration of 
65mM saturated binding sites of beads as indicated by fluorescence of beads in wells not 
increasing significantly above this concentration.  Figure A 8 shows the results of this 
experiment.  Interestingly 1.5 µm beads appeared to saturate binding sites at a lower 
concentration that that of the 45 µm beads.   
 
Figure A 8:  Fluorescent intensity of 45 µm and 1.5 µm amine coated silica beads as 
a function of DsCl concentration.  All data is background subtracted from 
unmodified beads.  Error bars represent standard deviation of three wells. 
 
Whether the fluorescence of the beads after functionalization with DsCl scaled 
linearly with bead number was tested next.  This was of concern because beads were not 
optically clear and thus at high bead centrations occlusion of fluorescence could occur 
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from beads.  It was found that for both 45 µm and 1.5 µm beads fluorescence scaled 
linearly over the range of bead concentrations tested (100 to 15 x103 and 5x103 to 9x108 
respectively.   Figure A 9 shows the fluorescence versus number of beads.  Linear trend 
lines using least squares regression were added to each graph and the subsequent R2 of 
the fit from the data was calculated.  The R2 for the 45 µm beads was found to be 0.9795 
and The R2 for the1.5µm beads was found to be 0.9876.  Both of these R2 values were 




A.4.3.2. Dansyl Chloride Fluorescence  on Amine Modified Beads Scales Linearly 
with Bead Number 
Finally, whether the DsCl group could be replaced by sodium azide as reported in 
Suenaga et.al. was confirmed via plate reader.  It was found that in the presence of 10mM 
sodium azide fluorescence from DsCl beads returned to that of background. Figure A 10 
shows the results from this study for 1.5 µm beads.  Identical results were found for 45 
µm beads (data not shown). 
Figure A 9: Fluorescence of beads versus number of beads functionalized. (A) 45 µm
bead fluorescence and (B) 1 µm bead fluorescence as a function of bead number.   
Linear trend lines are added to each graph in black. 
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Figure A 10:  Fluorescence at 535nm for unfunctionalized, DsCl modified, and DsCl 
modified with 10mM sodium azide beads.  All data was background subtracted 
from unmodified beads.  Error bars represent standard deviation, N=3 wells. 
A.4.3.3. Azide Functionalized Fluorophores substitute Dansyl Chloride Groups 
From Beads 
While Suenaga et.al. showed that DsCl fluorescence on microbeads decreased 
dramatically with the addition of sodium azide no other proof of functionalization was 
made.  Thus, it was desired to show quantitatively that the fluorescence decrease in the 
DsCl functionalized beads was occurring via a substitution reaction with the azide.  It 
was found that Alexa Fluor F594-azide (AF) reacted DsCl functionalized beads 
dramatically reduced their fluorescence, below that of background unfunctionalized 
beads, at the DsCl emission wavelength (535 nm).  Additionally, AF reacted beads were 
found to dramatically increase their fluorescence at the AF emission wavelength (635 
nm) over that of unfunctionalized beads.  To determine this AF was incubated with DsCl 
functionalized beads and the resultant fluorescence at 535 nm (DsCl) and 635 nm 
(AF594) was measured as a function of time in a plate reader.  Figure A 11 shows the 
results of three independent formulations of 1.5 µm beads.  Similar results were found for 
45 µm beads (data not shown).  All plotted fluorescences were background subtracted 
from unfunctionalized beads. 
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Figure A 11:  Mean fluorescence of AF594 reacted DsCl modified beads as a 
function of time.  The average fluorescence at the emission of AF594 (635nm) and 
DsCl (535nm) was plotted as a function of time.  Error bars represent standard 
error of three independent formulations of beads.   
 
 Fluorescent images of AF reacted beads were taken at both 535 nm and 635 nm to 
qualitatively show that fluorescence decreased for AF reacted beads.  It is clear from the 
pictures shown in Figure A 12 that AF reacted beads had a significant decrease in DsCl 
fluorescence and a significant increase in AF fluorescence.  Figure A 12A and B were 
unfunctionalized beads that showed a very low fluorescence at both wavelengths.  Figure 
A 12C and D were DsCl modified beads and had an expectedly high fluorescence at 535 
and almost no fluorescence above background at 635.  Figure A 12E and F were DsCl 
beads that had been reacted with AF.  These beads showed a relatively low fluorescence 
at 535 but a very high fluorescence at 635.  Interestingly, some fluorescence remained in 




Figure A 12: Fluorescent micrograph of functionalized beads. Fluorescence of (A,B) 
unmodified beads, (C,D) DsCl modified beads, and (E,F) AF reacted DsCl beads 
was viewed at 535nm and 635nm.   
 
A.4.3.4. Azide Functionalized Glycans Reduce Dansyl Chloride Fluorescence in a 
Concentration Dependent Manner 
Now that the fluorescence studies had shown that beads were being modified with 
azide linked ligands the concentration of glycan necessary to abrogate DsCl fluorescence 
was determined.  It was found that at 45 mM Lac-N3 was able to attenuate DsCl 
fluorescence to that of background.  Additionally, it was seen that as Lac-N3 
concentration increased the mean fluorescence at each bead concentration decreased.  
Figure A 13 shows the results from the 1.5 µm bead study.  Similar results were seen for 
45 µm beads (data not shown). 
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Figure A 13:  Fluorescence of beads at multiple Lac-N3 concentrations was plotted 
against bead number for 1.5 µm beads.  Fluorescence was background subtracted 
from sodium azide treated DsCl beads.  Error bars represent standard error of 3 
independent formulations for 1.0 µm beads. 
 
A.4.3.5. Functionalized Microbeads are Stable in Physiological Solutions 
Finally, whether the azide substituted ligand was covalently bound and could stay 
attached in physiological media or was only adsorbed to the surface was determined.  It 
was found that beads reacted with AF and suspended in PBS showed almost no 
attenuation of signal as compared to AF reacted beads in DCM that had been sealed for 
the 48 hours.  Furthermore, fluorescence at 535 nm from AF reacted DsCl Beads in PBS 
decreased to background levels after only 12 hours.  Figure A 14 shows the results from 
this study.  Figure A 14A shows the fluorescent intensity of DsCl and AF reacted DsCl 
beads at 635 nm when beads were suspended in DCM, PBS, or media.  Figure A 14B 
shows the fluorescent intensity of DsCl and AF reacted DsCl beads at 535 nm when 
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beads were suspended in DCM, PBS, or media.  Interestingly, AF reacted beads in media 
showed a very high background fluorescence and thus when background subtracted 
results appear to not be consistent with the PBS data.  
 
Figure A 14:  Mean fluorescence of DsCl and AF modified DsCl 1.5 µm beads was 
determined when beads were suspended in DCM, PBS or media at 635 nm (A) and 
535 nm (B).  Mean of three wells is plotted; error bars represent standard deviation.   
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A.4.4. Discussion and Conclusions  
A glycan presentation chemistry that could quantify the amount of glycan 
immobilized on a surface without having to have a large fluorescent moiety attached to 
the linker was desired due to the known influence that linkers play in CLR recognition of 
glycans.223 Thus, a subtractive methodology was developed in which a fluorescent 
surface was functionalized with an azide modified ligand.  This functionalization 
removed the fluorescent moiety from the surface, thereby allowing for the assessment of 
functionalization via a decrease is surface fluorescence.  An azide was chosen because 
the library of glycans available from the Consortium for Functional Glycomics have 
azido linkers attached to them and thus a seamless integration with this library was 
desired.   
In the experiments below large 45 µm beads and phagocytosable beads were both 
functionalized and tested.  The reason for this was twofold: 1) this dissertation has 
highlighted the importance of modality of display in how DCs respond to glycans and 
thus a display chemistry that can quantify glycan immobilization on two modalities was 
seen as important and significant. 2)  The chemistries used herein are not conducive to 
well plates as both DCM and DMF dissolve polystyrene and if left to incubate in 
polypropylene will eventually degrade the polypropylene.  Thus, functionalization of 
TCPS wells or other cheap, readily available, cell culture surfaces cannot be performed 
with this chemistry and therefore cell response to flat well presented glycans cannot be 
easily obtained using this chemistry.  Because this dissertation highlights the importance 
of this display modality an alternative display methodology was desired.  Therefore, 
developing a chemistry that was able to be functionalize a large bead in a reaction vessel 
that would not be dissolved by DMF or DCM was developed.  A large bead was chosen 
because we hypothesize that DCs would “see” and respond to glycans presented from a 
large non-phagocytosable bead in the same way as that of a flat well surface. Indeed 
preliminary work with DCs showed that 50 µm bead display of adsorbed glycans showed 
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an identical trend in DC phenotype.  The results of this study can be seen in Figure A 15 
below.    
 
Figure A 15:  DC response to conjugates adsorbed to flat wells or adsorbed to 50 µm 
PS beads.  Error bars represent standard error.  N=12 for adsorbed conjugates and 
N= 8 for 50 µm bead studies. 
 
To accomplish this goal, the first step was to develop a fluorescent coating 
chemistry that could be substituted by an azide and optimize that reaction to obtain 
maximum fluorescence.  A mechanism proposed by Suenaga et.al.318 was found but this 
paper did not test the chemistry quantitatively or when azide what linked to other 
moieties such as glycans.  Thus, we recapitulated the study performed by Suenaga 
et.al.318 using quantitative fluorescence assessment and optimized the reaction elucidated 
by them for our purposes.  It was found that 65mM DsCl saturated fluorescence on the 
DsCl beads for both 1.5 µm and 45 µm beads.  The 1.5 µm beads saturated at a lower 
concentration of DsCl than did the 50 µm beads.  This was hypothesized to be due to 
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poor mixing of the larger beads in the reaction vessel due to their increased size and thus 
increased settling time at the bottom of the wells.  The 1.5 µm beads stayed in suspension 
for a long period of time and thus their functionalized could more readily occur.   
Next, a validation of bead number versus fluorescence was needed to ensure that 
functionalized beads were not optically clear and thus at high bead concentrations 
occlusion of fluorescence could occur from other beads in solution.  Additionally, auto-
fluorescence measures could be of concern in a plate reader due to neighboring bead 
stimulation.  It was found that this was not occurring and that fluorescence was linearly 
related to bead number for both 1.5 µm beads and 45 µm beads.   
Following the validation of bead fluorescence reduction of DsCl fluorescence on 
bead surfaces by sodium azide was determined.  The mechanism and work proposed by 
Suenaga et.al.318 showed that this would occur however, a quantitative fluorescence 
measure was desired as none was given in their report.  It was found that 30mM sodium 
azide abrogated all fluorescence as reported.  
Next, proof of substitution of azide groups when connected to another ligand for 
that of DsCl groups was desired.  For the reaction performed in Figure A 11 as AF 
fluorescence increased DsCl fluorescence decreased as expected.  This trend was seen as 
consistent as three separate independently functionalized bead lots were measured and 
shown in Figure A 11.  Further confirmation of this substitution was provided visually 
with images taken of the beads with a fluorescent microscope.  Interestingly, while the 
plate reader shows a lower than background fluorescence for beads functionalized with 
AF fluorescent microscopy pictures show that some DsCl fluorescence remained.  It is 
thought that this discrepancy was due to the relative insensitivity of the plate reader as 
compared to fluorescent microscope and thus this difference was not seen as significant.   
After confirmation that azide substitution of DsCl groups could occur with a 
ligand attached to the azide an azide modified carbohydrate, lac-N3, was tested for 
concentration dependence of DsCl fluorescence.  A relatively high concentration of 
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glycan, 45mM, was needed to abrogate DsCL fluorescence to that of background at all 
bead concentrations.  Ideally, micro- to nano-molar concentrations of glycan would be 
needed to functionalize surfaces as these are the quantities able to be obtained from 
natural ligand sources.  Thus, in future work for this aim it is proposed that more work be 
done to optimize this reaction for more efficient substitution of glycan azide.  Factors 
such as temperature and incubation time can be varied, (temperature increased and 
incubation time increased) to get higher ligand substitutions at lower concentrations.   
Finally, stability of azide reacted beads in physiological solutions was measured 
to ensure that reacted beads would be able to display glycans to cells.  Stability of linked 
fluorophores over the course of two days was measured as 48 hours is twice as long as is 
typically measured in the HTP assays used in this dissertation.  It was found that beads 
retained their fluorescence in PBS and that background fluorescence from DsCL 
decreased in incubations with PBS.  The loss of DsCl fluorescence was expected as the 
DsCl can be reacted with water via a hydration reaction and removed from the surface.  
The stability of the AF indicates that reacted moieties were covalently bound to the beads 
and that they were not hydrolyzed form the surface significantly over the course of 48 
hours.  However, beads incubated in media were found to have a high background that 
overshadowed bead fluorescence.  This was hypothesized to be due to the fact that bead 
fluorescence was measured in the presence of media and thus it is thought that if beads 
were removed and washed and then measured for fluorescence that results would be 
identical to that shown in the PBS.  This experiment is also proposed for future work of 
this aim.   
In conclusion, the work shown here constitutes a promising avenue for 
quantification of glycan immobilization on surfaces without using large and/or inflexible 
linkers.  This immobilization strategy still has several key experiments before it can be 
seen as ready for use with the HTP assay.  First, optimizing reaction temperatures and 
times with glycan azides to decrease the concentration of glycan-azide necessary to 
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saturate binding sites available is necessary for functional use with available glycan 
sources.  Second, an actual quantification of glycan immobilized on the surface versus 
the fluorescence loss by DsCl must be performed.  This could be easily done using a 
standard curve of amine modified DsCl and radiolabeled glycans.  Third, proving that 
glycans are still on bead surfaces after incubation in PBS or media must be confirmed by 
performing ELLAs on immobilized surfaces.  Fourth, confirmation that azide ligands are 
stable in media needs to be confirmed.  Fifth, DC response to azide modified glycans 
immobilized on these surfaces must be performed in order to confirm that the chemistry 
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